Datasets:

chuyin0321

/

news-stocks

like 1

COF

If you've got this card in your wallet, there's no need to wait for boarding time in a noisy terminal.Continue reading

TheStreet.com

Get a first look at the glitziest new cardholder lounge at D.C. airport

https://finance.yahoo.com/m/c2dc04f2-280f-3a15-9847-c62a7fe75df4/get-a-first-look-at-the.html

c2dc04f2-280f-3a15-9847-c62a7fe75df4

COF

Americans are saving hundreds of dollars in reduced overdraft fees. Find out how to pay zero overdraft fees.Continue reading

Motley Fool

Good News: You May Be Saving $150 Without Realizing It

https://finance.yahoo.com/m/c2116ec1-ea69-391f-8977-03f752af6b6c/good-news-you-may-be-saving.html

c2116ec1-ea69-391f-8977-03f752af6b6c

COKE

Coca-Cola Consolidated, Inc.Second quarter of 2023 net sales increased 9% versus the second quarter of 2022.Gross profit in the second quarter of 2023 was $672 million, an increase of 22% versus the second quarter of 2022. Gross margin in the second quarter of 2023 improved by 410 basis points(a) to 38.6%.Income from operations for the first half of 2023 was $440 million, up $161 million, or 58%, versus the first half of 2022. Operating margin for the first half of 2023 was 13.3% as compared to 9.3% for the first half of 2022, an increase of 400 basis points.Key Results  Second Quarter   First Half  (in millions)  2023   2022  Change  2023   2022  ChangeStandard physical case volume(1)  92.6   96.4  (4.0)%  175.0   181.5  (3.6)%Net sales $1,738.8  $1,595.2  9.0% $3,310.5  $2,999.6  10.4%Gross profit $671.6  $550.7  22.0% $1,295.7  $1,058.2  22.4%Gross margin  38.6%  34.5%    39.1%  35.3%  Income from operations $233.7  $147.3  58.6% $439.7  $278.3  58.0%Operating margin  13.4%  9.2%    13.3%  9.3%               Beverage Sales Second Quarter   First Half  (in millions)  2023   2022  Change  2023   2022  ChangeSparkling bottle/can $1,004.4  $879.9  14.1% $1,918.7  $1,655.9  15.9%Still bottle/can $573.6  $539.6  6.3% $1,082.9  $1,006.8  7.6%(1)   A standard physical case is a volume metric used to standardize differing package configurations in order to measure delivered cases on an equivalent basis.Story continuesSecond Quarter and First Half 2023 ReviewCHARLOTTE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Coca‑Cola Consolidated, Inc. (NASDAQ: COKE) today reported operating results for the second quarter ended June 30, 2023 and the first half of fiscal 2023.“The strong business momentum we attained early this year continued in the second quarter as we posted another quarter of very strong profit growth and achieved a record high operating margin of 13.4%,” said J. Frank Harrison, III, Chairman and Chief Executive Officer. “Our results are a testament to the strength of our brands and the dedication of our people as we navigate the current retail environment and the ever-evolving preferences of our consumers. I believe the plans we have in place for the second half will enable us to build on our first-half success, further strengthen our field operations and drive continued consumer engagement with our brands.”Net sales increased 9% to $1.74 billion in the second quarter of 2023 and increased 10% to $3.31 billion in the first half of 2023. The increase in net sales was driven primarily by price increases taken across our product portfolio over the last year.Standard physical case volume declined 4.0% in the second quarter of 2023 and declined 3.6% in the first half of 2023. Sparkling category volume decreased 2.1% during the second quarter; however, our Sparkling portfolio continues to perform well versus historical price elasticities typically associated with higher pricing. Sales in Immediate Consumption continue to perform well, outpacing sales of take-home packages. Still volume declined 8.9% during the second quarter as the overall sports drinks category slowed considerably. Other Still categories such as energy and enhanced water continue to perform well with Monster and smartwater both achieving solid growth in the quarter.Gross profit in the second quarter of 2023 was $671.6 million, an increase of $120.9 million, or 22%, while gross margin improved 410 basis points to 38.6%. The improvement in gross profit resulted primarily from higher prices for our products and a moderation of prices for certain commodities. Gross profit in the first half of 2023 was $1.30 billion, an increase of $237.4 million, or 22%. The Company continues to expect pricing growth to slow in the second half of 2023 as we hurdle 2022 price increases.“Our strong second quarter results reinforce the success we are having with our retail partners in commercializing our local marketing plans and providing our consumers with a variety of affordable packages,” said Dave Katz, President and Chief Operating Officer. “This is a very dynamic period as we see consumers shifting between retail channels, especially within supermarkets, Club and Value stores. As overall volume slowed in the second quarter, we have proactively engaged with our retail partners to help drive consumer traffic and transaction growth for the balance of this year.”Selling, delivery and administrative (“SD&A”) expenses in the second quarter of 2023 increased $34.5 million, or 9%. SD&A expenses as a percentage of net sales decreased 10 basis points to 25.2% in the second quarter of 2023. The increase in SD&A expenses related primarily to an increase in labor costs, resulting from certain compensation and benefits adjustments made in the prior year to retain and reward our teammates in a challenging labor environment. In addition, broad inflationary increases across a number of SD&A categories pushed expenses higher during the quarter. SD&A expenses in the first half of 2023 increased $76.0 million, or 10%. SD&A expenses as a percentage of net sales in the first half of 2023 decreased 10 basis points to 25.9% as compared to the first half of 2022. We expect the rate of increase to slow in the second half of this year as we hurdle labor adjustments made in late 2022.Income from operations in the second quarter of 2023 was $233.7 million, compared to $147.3 million in the second quarter of 2022, an increase of 59%. On an adjusted(b) basis, income from operations in the second quarter of 2023 increased 47% as compared to the second quarter of 2022. Operating margin for the second quarter of 2023 was 13.4% as compared to 9.2% in the second quarter of 2022, an increase of 420 basis points.Net income in the second quarter of 2023 was $122.3 million, compared to $99.6 million in the second quarter of 2022, an improvement of $22.8 million. On an adjusted(b) basis, net income in the second quarter of 2023 was $172.8 million, compared to $112.2 million in the second quarter of 2022, an increase of $60.6 million.Second quarter net income was adversely impacted by routine, non-cash fair value adjustments to our acquisition related contingent consideration liability, driven by changes in the discount rate and future cash flow projections used to compute the fair value of the liability. Second quarter net income was also adversely impacted by the partial settlement of our primary pension plan, which resulted in a non-cash charge of $39.8 million. In the third quarter of 2023, the Company expects to record an additional non-cash charge of approximately $79 million related to the remaining settlement of the primary pension plan.Income tax expense for the second quarter of 2023 was $42.4 million, compared to $34.4 million in the second quarter of 2022, resulting in an effective income tax rate of approximately 26% for both periods. For the second quarter of 2023, basic net income per share was $13.05 and adjusted(b) basic net income per share was $18.43.Cash flows provided by operations for first half 2023 were $383.3 million, compared to $243.5 million for first half 2022. Cash flows from operations reflected our strong operating performance and the timing of certain working capital payments and receipts during the second quarter. In the first half of 2023, we invested $92.9 million in capital expenditures as we continue to optimize our supply chain and invest for the future growth of small bottle PET packages and mini cans. In fiscal year 2023, we expect our capital expenditures to be between $250 million and $300 million.(a)All comparisons are to the corresponding period in the prior year unless specified otherwise.(b)The discussion of the operating results for the second quarter ended June 30, 2023 and the first half of fiscal 2023 includes selected non-GAAP financial information, such as “adjusted” results. The schedules in this news release reconcile such non-GAAP financial measures to the most directly comparable GAAP financial measures.CONTACTS:  Josh Gelinas (Media) Scott Anthony (Investors)Vice President, Communications Executive Vice President & Chief Financial Officer(704) 807-3703 (704) [email protected] [email protected]   A PDF accompanying this release is available at: http://ml.globenewswire.com/Resource/Download/b58d7ce8-9221-46bf-9fa4-16942fe4485dAbout Coca-Cola Consolidated, Inc.Coca‑Cola Consolidated is the largest Coca‑Cola bottler in the United States. Our Purpose is to honor God in all we do, to serve others, to pursue excellence and to grow profitably. For over 121 years, we have been deeply committed to the consumers, customers and communities we serve and passionate about the broad portfolio of beverages and services we offer. We make, sell and distribute beverages of The Coca‑Cola Company and other partner companies in more than 300 brands and flavors across 14 states and the District of Columbia, to approximately 60 million consumers.Headquartered in Charlotte, N.C., Coca‑Cola Consolidated is traded on The Nasdaq Global Select Market under the symbol “COKE”. More information about the Company is available at www.cokeconsolidated.com. Follow Coca‑Cola Consolidated on Facebook, Twitter, Instagram and LinkedIn.Cautionary Note Regarding Forward-Looking StatementsCertain statements contained in this news release are “forward-looking statements” that involve risks and uncertainties which we expect will or may occur in the future and may impact our business, financial condition and results of operations. The words “anticipate,” “believe,” “expect,” “intend,” “project,” “may,” “will,” “should,” “could” and similar expressions are intended to identify those forward-looking statements. These forward-looking statements reflect the Company’s best judgment based on current information, and, although we base these statements on circumstances that we believe to be reasonable when made, there can be no assurance that future events will not affect the accuracy of such forward-looking information. As such, the forward-looking statements are not guarantees of future performance, and actual results may vary materially from the projected results and expectations discussed in this news release. Factors that might cause the Company’s actual results to differ materially from those anticipated in forward-looking statements include, but are not limited to: increased costs (including due to inflation), disruption of supply or unavailability or shortages of raw materials, fuel and other supplies; the reliance on purchased finished products from external sources; changes in public and consumer perception and preferences, including concerns related to product safety and sustainability, artificial ingredients, brand reputation and obesity; the inability to attract and retain front-line employees in a tight labor market; changes in government regulations related to nonalcoholic beverages, including regulations related to obesity, public health, artificial ingredients and product safety and sustainability; decreases from historic levels of marketing funding support provided to us by The Coca‑Cola Company and other beverage companies; material changes in the performance requirements for marketing funding support or our inability to meet such requirements; decreases from historic levels of advertising, marketing and product innovation spending by The Coca‑Cola Company and other beverage companies, or advertising campaigns that are negatively perceived by the public; any failure of the several Coca‑Cola system governance entities of which we are a participant to function efficiently or on our best behalf and any failure or delay of ours to receive anticipated benefits from these governance entities; provisions in our beverage distribution and manufacturing agreements with The Coca‑Cola Company that could delay or prevent a change in control of us or a sale of our Coca‑Cola distribution or manufacturing businesses; the concentration of our capital stock ownership; our inability to meet requirements under our beverage distribution and manufacturing agreements; changes in the inputs used to calculate our acquisition related contingent consideration liability; technology failures or cyberattacks on our technology systems or our effective response to technology failures or cyberattacks on our customers’, suppliers’ or other third parties’ technology systems; unfavorable changes in the general economy; changes in our top customer relationships and marketing strategies; lower than expected net pricing of our products resulting from continued and increased customer and competitor consolidations and marketplace competition; the effect of changes in our level of debt, borrowing costs and credit ratings on our access to capital and credit markets, operating flexibility and ability to obtain additional financing to fund future needs; the failure to attract, train and retain qualified employees while controlling labor costs, and other labor issues; the failure to maintain productive relationships with our employees covered by collective bargaining agreements, including failing to renegotiate collective bargaining agreements; changes in accounting standards; our use of estimates and assumptions; changes in tax laws, disagreements with tax authorities or additional tax liabilities; changes in legal contingencies; natural disasters, changing weather patterns and unfavorable weather; climate change or legislative or regulatory responses to such change; and the impact of the COVID-19 pandemic, any variants of the virus and any other similar pandemic or public health situation. These and other factors are discussed in the Company’s regulatory filings with the United States Securities and Exchange Commission, including those in “Item 1A. Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. The forward-looking statements contained in this news release speak only as of this date, and the Company does not assume any obligation to update them, except as may be required by applicable law.  FINANCIAL STATEMENTSCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)  Second Quarter First Half(in thousands, except per share data)  2023  2022  2023  2022Net sales $1,738,832 $1,595,215 $3,310,474 $2,999,573Cost of sales  1,067,255  1,044,556  2,014,791  1,941,338Gross profit  671,577  550,659  1,295,683  1,058,235Selling, delivery and administrative expenses  437,907  403,366  855,959  779,957Income from operations  233,670  147,293  439,724  278,278Interest expense, net  1,353  7,146  4,282  14,845Pension plan settlement expense  39,777  —  39,777  —Other expense, net  27,788  6,199  71,711  2,920Income before taxes  164,752  133,948  323,954  260,513Income tax expense  42,433  34,386  83,508  67,561Net income $122,319 $99,562 $240,446 $192,952         Basic net income per share:        Common Stock $13.05 $10.62 $25.65 $20.58Weighted average number of Common Stock shares outstanding  8,369  8,369  8,369  7,863         Class B Common Stock $13.05 $10.62 $25.65 $20.62Weighted average number of Class B Common Stock shares outstanding  1,005  1,005  1,005  1,511         Diluted net income per share:        Common Stock $13.02 $10.59 $25.59 $20.53Weighted average number of Common Stock shares outstanding – assuming dilution  9,396  9,399  9,396  9,399         Class B Common Stock $13.01 $10.59 $25.51 $20.56Weighted average number of Class B Common Stock shares outstanding – assuming dilution  1,027  1,030  1,027  1,536   FINANCIAL STATEMENTSCONDENSED CONSOLIDATED BALANCE SHEETS(UNAUDITED)(in thousands) June 30, 2023 December 31, 2022ASSETS    Current Assets:    Cash and cash equivalents $430,172 $197,648Trade accounts receivable, net  586,104  515,928Other accounts receivable  113,229  90,417Inventories  333,874  347,545Prepaid expenses and other current assets  84,634  94,263Total current assets  1,548,013  1,245,801Property, plant and equipment, net  1,176,339  1,183,730Right-of-use assets - operating leases  128,759  140,588Leased property under financing leases, net  5,608  6,431Other assets  132,017  115,892Goodwill  165,903  165,903Other identifiable intangible assets, net  837,898  851,200Total assets $3,994,537 $3,709,545     LIABILITIES AND EQUITY    Current Liabilities:    Current portion of obligations under operating leases $26,440 $27,635Current portion of obligations under financing leases  2,393  2,303Dividends payable  —  32,808Accounts payable and accrued expenses  863,149  842,410Total current liabilities  891,982  905,156Deferred income taxes  151,630  150,222Pension and postretirement benefit obligations and other liabilities  857,426  813,680Noncurrent portion of obligations under operating leases  108,500  118,763Noncurrent portion of obligations under financing leases  6,299  7,519Long-term debt  598,992  598,817Total liabilities  2,614,829  2,594,157     Equity:    Stockholders’ equity  1,379,708  1,115,388Total liabilities and equity $3,994,537 $3,709,545   FINANCIAL STATEMENTSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)  First Half(in thousands)  2023   2022 Cash Flows from Operating Activities:    Net income $240,446  $192,952 Depreciation expense, amortization of intangible assets and deferred proceeds, net  87,185   85,852 Fair value adjustment of acquisition related contingent consideration  67,174   (1,436)Pension plan settlement expense  39,777   — Deferred income taxes  (7,848)  11,189 Change in current assets and current liabilities  (41,957)  (59,004)Change in noncurrent assets and noncurrent liabilities  (6,061)  12,151 Other  4,622   1,831 Net cash provided by operating activities $383,338  $243,535      Cash Flows from Investing Activities:    Additions to property, plant and equipment $(92,893) $(145,182)Acquisition of distribution rights  —   (30,149)Other  (5,766)  3,717 Net cash used in investing activities $(98,659) $(171,614)     Cash Flows from Financing Activities:    Cash dividends paid $(37,495) $(4,687)Payments of acquisition related contingent consideration  (13,376)  (18,710)Other  (1,284)  (2,035)Net cash used in financing activities $(52,155) $(25,432)     Net increase in cash during period $232,524  $46,489 Cash at beginning of period  197,648   142,314 Cash at end of period $430,172  $188,803    NON-GAAP FINANCIAL MEASURES(c) The following tables reconcile reported results (GAAP) to adjusted results (non-GAAP): Second Quarter 2023(in thousands, except per share data) Gross profit SD&Aexpenses Income from operations Incomebefore taxes Net income  Basic netincome pershareReported results (GAAP) $671,577 $437,907  $233,670 $164,752 $122,319 $13.05Fair value adjustment of acquisition related contingent consideration  —  —   —  25,520  19,214  2.05Fair value adjustments for commodity derivative instruments  1,097  (224)  1,321  1,321  994  0.10Supply chain optimization  474  —   474  474  357  0.04Pension plan settlement expense  —  —   —  39,777  29,948  3.19Total reconciling items  1,571  (224)  1,795  67,092  50,513  5.38Adjusted results (non-GAAP) $673,148 $437,683  $235,465 $231,844 $172,832 $18.43                    Adjusted % Change vs. Second Quarter 2022  19.3% 8.2%  47.1%                             Second Quarter 2022(in thousands, except per share data) Gross profit SD&Aexpenses Income fromoperations Incomebefore taxes Net income  Basic netincome pershareReported results (GAAP) $550,659 $403,366  $147,293 $133,948 $99,562 $10.62Fair value adjustment of acquisition related contingent consideration  —  —   —  4,021  3,028  0.32Fair value adjustments for commodity derivative instruments  13,663  998   12,665  12,665  9,536  1.02Supply chain optimization  84  (33)  117  117  88  0.01Total reconciling items  13,747  965   12,782  16,803  12,652  1.35Adjusted results (non-GAAP) $564,406 $404,331  $160,075 $150,751 $112,214 $11.97 First Half 2023(in thousands, except per share data) Gross profit SD&Aexpenses Income fromoperations  Incomebefore taxes  Net income   Basic netincome pershareReported results (GAAP) $1,295,683 $855,959  $439,724  $323,954  $240,446  $25.65 Fair value adjustment of acquisition related contingent consideration  —  —   —   67,174   50,575   5.40 Fair value adjustments for commodity derivative instruments  1,492  (2,914)  4,406   4,406   3,317   0.35 Supply chain optimization  823  —   823   823   620   0.07 Pension plan settlement expense  —  —   —   39,777   29,948   3.19 Total reconciling items  2,315  (2,914)  5,229   112,180   84,460   9.01 Adjusted results (non-GAAP) $1,297,998 $853,045  $444,953  $436,134  $324,906  $34.66                         Adjusted % Change vs. First Half 2022  21.9% 8.4%  60.4%                                     First Half 2022(in thousands, except per share data) Gross profit SD&Aexpenses Income fromoperations Incomebefore taxes Net income  Basic netincome pershareReported results (GAAP) $1,058,235 $779,957  $278,278  $260,513  $192,952  $20.58 Fair value adjustment of acquisition related contingent consideration  —  —   —   (1,436)  (1,081)  (0.12)Fair value adjustments for commodity derivative instruments  6,169  7,223   (1,054)  (1,054)  (794)  (0.08)Supply chain optimization  89  (72)  161   161   121   0.01 Total reconciling items  6,258  7,151   (893)  (2,329)  (1,754)  (0.19)Adjusted results (non-GAAP) $1,064,493 $787,108  $277,385  $258,184  $191,198  $20.39 (c)The Company reports its financial results in accordance with accounting principles generally accepted in the United States (“GAAP”). However, management believes that certain non-GAAP financial measures provide users of the financial statements with additional, meaningful financial information that should be considered, in addition to the measures reported in accordance with GAAP, when assessing the Company’s ongoing performance. Management also uses these non-GAAP financial measures in making financial, operating and planning decisions and in evaluating the Company’s performance. Non-GAAP financial measures should be viewed in addition to, and not as an alternative for, the Company’s reported results prepared in accordance with GAAP. The Company’s non-GAAP financial information does not represent a comprehensive basis of accounting.

GlobeNewswire

Coca-Cola Consolidated Reports Second Quarter and First Half 2023 Results

https://finance.yahoo.com/news/coca-cola-consolidated-reports-second-201000632.html

6692b97b-db5c-37f1-bb42-645d9124b38b

COKE

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return. With that in mind, the ROCE of Coca-Cola Consolidated (NASDAQ:COKE) looks great, so lets see what the trend can tell us.Understanding Return On Capital Employed (ROCE)For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. Analysts use this formula to calculate it for Coca-Cola Consolidated:Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)0.26 = US$797m ÷ (US$4.0b - US$892m) (Based on the trailing twelve months to June 2023).Therefore, Coca-Cola Consolidated has an ROCE of 26%. That's a fantastic return and not only that, it outpaces the average of 16% earned by companies in a similar industry. See our latest analysis for Coca-Cola Consolidated roceWhile the past is not representative of the future, it can be helpful to know how a company has performed historically, which is why we have this chart above. If you want to delve into the historical earnings, revenue and cash flow of Coca-Cola Consolidated, check out these free graphs here.What Can We Tell From Coca-Cola Consolidated's ROCE Trend?Investors would be pleased with what's happening at Coca-Cola Consolidated. Over the last five years, returns on capital employed have risen substantially to 26%. The company is effectively making more money per dollar of capital used, and it's worth noting that the amount of capital has increased too, by 28%. The increasing returns on a growing amount of capital is common amongst multi-baggers and that's why we're impressed.Story continuesThe Bottom Line On Coca-Cola Consolidated's ROCETo sum it up, Coca-Cola Consolidated has proven it can reinvest in the business and generate higher returns on that capital employed, which is terrific. And a remarkable 331% total return over the last five years tells us that investors are expecting more good things to come in the future. So given the stock has proven it has promising trends, it's worth researching the company further to see if these trends are likely to persist.Before jumping to any conclusions though, we need to know what value we're getting for the current share price. That's where you can check out our FREE intrinsic value estimation that compares the share price and estimated value.Coca-Cola Consolidated is not the only stock earning high returns. If you'd like to see more, check out our free list of companies earning high returns on equity with solid fundamentals.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

We Think Coca-Cola Consolidated (NASDAQ:COKE) Might Have The DNA Of A Multi-Bagger

https://finance.yahoo.com/news/think-coca-cola-consolidated-nasdaq-130644639.html

8cd45ae0-6c46-3961-be2c-10a51f5f2313

COLD

Welltower Inc. WELL owns a well-diversified portfolio of healthcare real estate assets in major, high-growth markets of the United States, Canada and the United Kingdom. The rebound in the senior housing industry, portfolio-repositioning efforts and a healthy balance sheet position the company well for growth. However, competition and high interest rates make us apprehensive.The company’s seniors housing operating (SHO) portfolio segment is witnessing occupancy gains on the back of healthy move-in activity in the wake of the pandemic. Notably, in the second quarter of 2023, the SHO portfolio average same-store occupancy expanded 190 basis points (bps) year over year.With senior citizens’ healthcare expenditure expected to rise in the coming years and favorable demand-supply fundamentals in its markets, Welltower’s SHO portfolio remains well-poised to prosper. Per the company's July Business Update, management anticipates year-over-year occupancy growth of 230 bps for the SHO portfolio in 2023.Welltower usually leases its healthcare facilities under "triple net" leases, where the tenant pays all taxes, insurance and maintenance for the properties in addition to rent. Also, its long-term tie-ups with experienced healthcare management companies or operators insulate it from short-term market swings. These factors are likely to aid in generating stable revenues.Restructuring initiatives over the recent years have enabled the company to attract top-class operators, while its dispositions have helped improve the quality of its cash flows.In the second quarter of 2023, WELL entered into definitive agreements to dissolve its existing joint venture with Revera across the United States, the United Kingdom and Canada during the April-June quarter. Through this, it will acquire the remaining interests in 110 properties from Revera. WELL will simultaneously divest interests in 31 properties to Revera.Its capital-recycling efforts to finance near-term investment and development opportunities highlight its prudent capital management practices and bode well for long-term growth. Also, a robust balance sheet position, with available liquidity of $6.7 billion as of Jul 28, 2023, and a well-laddered debt maturity schedule support its growth endeavors.Analysts seem bullish on this Zacks Rank #2 (Buy) company. The Zacks Consensus Estimate for its current-year funds from operations (FFO) per share has been raised marginally over the past month to $3.53.The company’s shares have gained 11.4% in the past three months compared with the industry’s growth of 3%.Story continuesZacks Investment ResearchImage Source: Zacks Investment ResearchNonetheless, Welltower faces competition from national and local healthcare operators, which limits its power to significantly raise its top line and ink deals at attractive rates. Also, tenant concentration in the company’s triple-net portfolio is concerning.High interest rates are likely to increase borrowing costs, affecting the company’s ability to purchase or develop real estate.Other Stocks to ConsiderSome other top-ranked stocks from the REIT sector are SBA Communications SBAC, Americold Realty Trust COLD and Omega Healthcare Investors OHI, each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.The Zacks Consensus Estimate for SBA Communications’ current-year FFO per share has moved marginally northward over the past week to $12.88.The Zacks Consensus Estimate for Americold Realty Trust’s ongoing year’s FFO per share has been raised 2.5% upward over the past month to $1.24.The Zacks Consensus Estimate for Omega Healthcare’s ongoing year’s FFO per share has been raised marginally upward over the past month to $2.83.Note: Anything related to earnings presented in this write-up represents funds from operations (FFO) — a widely used metric to gauge the performance of REITs.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportSBA Communications Corporation (SBAC) : Free Stock Analysis ReportOmega Healthcare Investors, Inc. (OHI) : Free Stock Analysis ReportAmericold Realty Trust Inc. (COLD) : Free Stock Analysis ReportWelltower Inc. (WELL) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Here's Why You Should Add Welltower (WELL) to Your Portfolio

https://finance.yahoo.com/news/heres-why-add-welltower-well-151900028.html

b8236a7a-4ba3-37bb-bb32-7b411af83936

COLD

Americold Realty TrustATLANTA, GA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Americold Realty Trust, Inc. (NYSE: COLD) (the “Company”), a global leader in temperature-controlled logistics real estate and value-added services focused on the ownership, operation, acquisition and development of temperature-controlled warehouses, today announced that its Board of Directors has declared a dividend of $0.22 per share for the third quarter of 2023, payable to holders of the Company’s common stock. The dividend will be payable in cash on October 13, 2023 to stockholders of record at the close of business on September 29, 2023.About Americold Realty Trust, Inc. Americold is a global leader in temperature-controlled logistics real estate and value- added services. Focused on the ownership, operation, acquisition, and development of temperature-controlled warehouses, Americold owns and/or operates 242 temperature-controlled warehouses, with approximately 1.5 billion refrigerated cubic feet of storage, in North America, Europe, Asia-Pacific, and South America. Americold’s facilities are an integral component of the supply chain connecting food producers, processors, distributors, and retailers to consumers.Contacts:Americold Realty Trust, Inc.Investor RelationsTelephone: 678-459-1959Email: [email protected]

GlobeNewswire

Americold Realty Trust, Inc. Declares Third Quarter 2023 Dividend

https://finance.yahoo.com/news/americold-realty-trust-inc-declares-110000753.html

8b2c2a9e-1a9f-3aac-b501-791db16d5422

COLL

Collegium Pharmaceutical, Inc.STOUGHTON, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted New Patient Population exclusivity for Nucynta®, an immediate release formulation of tapentadol. This grant extends the period of U.S. exclusivity for Nucynta from June 27, 2025 to July 3, 2026.The exclusivity determination is based on data from pediatric trials which were submitted in response to the FDA's Pediatric Written Request to evaluate the use of Nucynta as a treatment for pain in pediatric patients aged 6 years and older.Nucynta is currently approved in the U.S. for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults and pediatric patients aged 6 years and older with a body weight of at least 40kg.“We believe that this grant of additional exclusivity recognizes the importance of Nucynta in the treatment of acute, severe pain,” said Thomas Smith, M.D., Collegium’s Chief Medical Officer. “We remain committed to the Nucynta Franchise, including through continued pursuit of a pediatric extension which would extend exclusivity of the entire Nucynta Franchise an additional six months, to December 2025 for Nucynta ER and January 2027 for Nucynta.”About Collegium Pharmaceutical, Inc.Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.NUCYNTA® (tapentadol) INDICATIONS AND USAGENUCYNTA® (tapentadol) tablets are:A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage short term (acute) pain in adults and children 6 years of age and older who weigh at least 88 pounds (40 kg), when other pain treatments such as non-opioid pain medicines do not treat your pain well enough or you cannot tolerate them.An opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed, you are at risk for opioid addiction, abuse, and misuse that can lead to death.Story continuesIMPORTANT SAFETY INFORMATION ABOUT NUCYNTA TABLETSWARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF NUCYNTA TABLETSAddiction, Abuse, and MisuseBecause the use of NUCYNTA tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess regularly for the development of these behaviors and conditions.Life-Threatening Respiratory DepressionSerious, life-threatening, or fatal respiratory depression may occur with use of NUCYNTA tablets, especially during initiation of NUCYNTA tablets or following a dose increase. To reduce the risk of respiratory depression, proper dosing and titration of NUCYNTA tablets are essential.Accidental IngestionAccidental ingestion of even one dose of NUCYNTA tablets, especially by children, can result in a fatal overdose of tapentadol.Risks From Concomitant Use With Benzodiazepines or Other CNS DepressantsConcomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of NUCYNTA tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.Neonatal Opioid Withdrawal SyndromeIf opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of Neonatal Opioid Withdrawal Syndrome which may be life threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery.Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription.Important information about NUCYNTA tablets:Get emergency help or call 911 right away if you take too much NUCYNTA (overdose) tablets. When you first start taking NUCYNTA tablets, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for the emergency treatment of an opioid overdose.Taking NUCYNTA tablets with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.Never give anyone else your NUCYNTA tablets. They could die from taking it. Selling or giving away NUCYNTA tablets is against the law.Store NUCYNTA tablets securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.Do not take NUCYNTA tablets if you have:severe asthma, trouble breathing, or other lung problems.a bowel blockage or have narrowing of the stomach or intestines.Before taking NUCYNTA tablets, tell your healthcare provider if you have a history of:head injury, seizuresproblems urinatingabuse of street or prescription drugs, alcohol addiction, opioid overdose or mental health problemsliver, kidney, thyroid problemspancreas or gallbladder problemsTell your healthcare provider if you:notice your pain getting worse. If your pain gets worse after you take NUCYNTA tablets, do not take more NUCYNTA tablets without first talking to your healthcare provider. Tell your healthcare provider if the pain that you have increases, if you feel more sensitive to pain, or if you have new pain after taking NUCYNTA tablets.are pregnant or planning to become pregnant. Use of NUCYNTA tablets for an extended period of time during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated.are breastfeeding. NUCYNTA tablets pass into breast milk and may harm your baby.are living in a household where there are small children or someone who has abused street or prescription drugs.are taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking NUCYNTA tablets with certain other medicines can cause serious side effects that could lead to death.When taking NUCYNTA tablets:Do not change your dose. Take NUCYNTA tablets exactly as prescribed by your healthcare provider.Use the lowest dose possible for the shortest time needed.For acute (short-term) pain, you may only need to take NUCYNTA tablets for a few days. You may have some NUCYNTA tablets left over that you did not use. See disposal information at the bottom of this section for directions on how to safely throw away (dispose of) your unused NUCYNTA tablets.Take your prescribed dose every 4-6 hours, at the same time every day. Do not take more than your prescribed dose. If you miss a dose, take your next dose at your usual time.Call your healthcare provider if the dose you are taking does not control your pain.If you have been taking NUCYNTA tablets regularly, do not stop taking NUCYNTA tablets without talking to your healthcare provider.Dispose of expired, unwanted, or unused NUCYNTA Tablets by promptly flushing down the toilet, if a drug take-back option is not readily available. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.While taking NUCYNTA tablets, DO NOT:Drive or operate heavy machinery, until you know how NUCYNTA tablets affect you. NUCYNTA tablets can make you sleepy, dizzy, or lightheaded.Drink alcohol or use prescription or over-the-counter medicines that contain alcohol. Using products containing alcohol during treatment with NUCYNTA tablets may cause you to overdose and die.The possible side effects of NUCYNTA tablets:constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe.Get emergency medical help or call 911 right away if you have:trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion.These are not all of the possible side effects of NUCYNTA tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information, go to dailymed.nlm.nih.gov.See full Prescribing Information, including Boxed Warning on Addiction, Abuse and Misuse and other serious risks, and the Medication Guide accompanying this piece or at Nucynta.com/IRpi. Speak to your healthcare provider if you have questions about Nucynta.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “forecasts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements related to our pursuit of a pediatric extension of exclusivity for the Nucynta franchise. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations, including the risks described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.Investor Contact:Christopher James, M.D.Vice President, Investor [email protected] Contact:Marissa SamuelsVice President, Corporate Communications [email protected]

GlobeNewswire

Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026

https://finance.yahoo.com/news/collegium-announces-extension-nucynta-regulatory-120000406.html

8687eb04-91d6-360e-96ea-b737fcf600e5

COLL

Collegium Pharmaceutical, Inc.STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that 10 poster presentations highlighting data regarding its diversified pain portfolio will be presented at PAINWeek Conference 2023, being held in Las Vegas, NV from September 5–8, 2023.“Collegium is dedicated to responsible pain management and leading with science. We are pleased to present 10 posters with new real-world data at PAINWeek 2023 that underscore the clinical and population health impact of our portfolio and provide significant insights for healthcare decision makers who treat people experiencing pain,” said Thomas Smith, M.D., Chief Medical Officer of Collegium. “We welcome opportunities to share clinical and real-world data with the medical community as part of our commitment to improving the lives of people living with serious medical conditions.”The following poster presentations will also be available on the PAINWeek Conference 2023 website on Wednesday, September 6, 2023, from 3:30 – 4:30 p.m. PT and on Thursday, September 7, 2023, from 3:30 – 5:30 p.m. PT.Poster Presentations: Poster Title:Healthcare Cost and Resource Use in Chronic Low Back Pain Patients Treated with Belbuca® and Buprenorphine Transdermal Patches: A Retrospective US Commercial Claims AnalysisAuthors:Vladimir Zah, Filip Stanicic, Todd Kunkel, Djurdja Vukicevic, Dimitrije Grbic  Poster Title:Treatment Characteristics of Chronic Low Back Pain Patients Treated with Belbuca® and Buprenorphine Transdermal Patches: A Retrospective US Commercial Claims AnalysisAuthors:Vladimir Zah, Filip Stanicic, Todd Kunkel, Djurdja Vukicevic, Dimitrije Grbic  Poster Title:Safety and Tolerability of Buprenorphine and Oral Schedule II Opioid Treatment in Chronic Low Back Pain Patients: A Retrospective US Commercial Claims AnalysisAuthors:Vladimir Zah, Filip Stanicic, Todd Kunkel, Djurdja Vukicevic, Dimitrije Grbic  Poster Title:Healthcare Costs Associated with Rates of Prescription Opioid Misuse/AbuseAuthors:Jody L. Green, Taryn Dailey-Govoni, Suzanne K. Vosburg  Poster Title:Sustained Risk Reduction of Severe Clinical Outcomes Following Misuse/Abuse of XTAMPZA® ER as Compared to Other Prescription OpioidsAuthors:Jody L. Green, Taryn Dailey-Govoni, Suzanne K. Vosburg  Poster Title:Differences in the Severity of Medical Outcomes of Exposures Reported to Poison Centers Involving XTAMPZA® ER and Other Opioid AnalgesicsAuthors:Brooke Kritikos, Stevan Severtson, Joshua C. Black, Heather Olsen, Janetta Iwanicki, Richard C. Dart  Poster Title:Real-world Impact of Abuse-Deterrent Formulation of XTAMPZA® ER in the Context of Behaviors Around Tampering with XTAMPZA® ER and Other Opioid ProductsAuthors:Evelyn Fox, Jennifer S. Jewell, Joshua C. Black, Matthew S. Ellis, Heather Olsen, Hannah L. Burkett, Janetta Iwanicki, Richard C. Dart  Poster Title:Use of Causal Framework to Evaluate Effect of Abuse Deterrent Properties of XTAMPZA® ER on Opioid Tampering in a Post-Market SettingAuthors:Karilynn M. Rockhill, Hannah L. Burkett, Richard C. Dart, Joshua C. Black  Poster Title:Changes in Oxycodone Misuse and Abuse Trends Across COVID-19: A Look BackAuthors:Jennifer S. Jewell, Karilynn M. Rockhill, Joshua C. Black, Hannah L. Burkett, Matthew S. Ellis, Sabrina Kaplan, Richard C. Dart  Poster Title:Association Between Per Capita Prescribing and Abuse of Tapentadol and Other Opioids Among Individuals Entering Treatment For Opioid Use DisordersAuthors:Megan Healy, Stevan Severtson, Annika Czizik, Matthew S. Ellis, Joshua C. Black, Heather Olsen, Janetta Iwanicki, Richard C. DartFor more information on PAINWeek Conference 2023, visit: https://www.painweek.org/.Story continuesXtampza® ER (oxycodone) extended-release capsules, CII, Nucynta® ER (tapentadol) extended-release tablets, CII, and Nucynta® (tapentadol) tablets, CII, can be abused or misused, and carry a risk of addiction. These products are intended for use only in appropriate pain patients and only when other treatment alternatives are inadequate. Use of Xtampza® ER, Nucynta® ER and Nucynta® can result in serious, life-threatening or fatal respiratory depression, even when used exactly as prescribed. See Important Safety Information, including Boxed Warning on addiction, abuse, and misuse and other serious risks regarding each of these three products at the end of this press release.About Collegium Pharmaceutical, Inc.Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.INDICATIONS AND USAGEXtampza® ER (oxycodone) is:A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain severe enough to require daily, around-the-clock, long-term treatment with an opioid when other pain treatments, such as non-opioid pain medicines or immediate-release opioid medicines, do not treat your pain well enough or you cannot tolerate them.A long-acting (extended-release) opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed by your healthcare provider, you are at risk for opioid addiction, abuse, and misuse that can lead to death.Not for use to treat pain that is not around-the-clock.IMPORTANT SAFETY INFORMATION ABOUT XTAMPZA ERWARNING: ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTSAddiction, Abuse, and MisuseXtampza ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing Xtampza ER and monitor all patients regularly for the development of these behaviors or conditions.Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a REMS for these products. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged tocomplete a REMS-compliant education program,counsel patients and/or their caregivers, with every prescription, on safe use, serious risks, storage, and disposal of these products,emphasize to patients and their caregivers the importance of reading the Medication Guide every time it is provided by their pharmacist, andconsider other tools to improve patient, household, and community safety.Life-Threatening Respiratory DepressionSerious, life-threatening, or fatal respiratory depression may occur with use of Xtampza ER. Monitor for respiratory depression, especially during initiation of Xtampza ER or following a dose increase.Accidental IngestionAccidental ingestion of even one dose of Xtampza ER, especially by children, can result in a fatal overdose of oxycodone.Neonatal Opioid Withdrawal SyndromeProlonged use of Xtampza ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.Cytochrome P450 3A4 InteractionThe concomitant use of Xtampza ER with all cytochrome P450 3A4 inhibitors may result in an increase in oxycodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in oxycodone plasma concentration. Monitor patients receiving Xtampza ER and any CYP3A4 inhibitor or inducer.Risks From Concomitant Use With Benzodiazepines or Other CNS DepressantsConcomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.Reserve concomitant prescribing of Xtampza ER and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.Limit dosages and durations to the minimum required.Follow patients for signs and symptoms of respiratory depression and sedation.Important information about Xtampza ER:Get emergency help or call 911 right away if you take too much Xtampza ER (overdose). When you first start taking Xtampza ER, when your dose is changed, or if you take too much (overdose), serious life-threatening breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for the emergency treatment of an overdose.Taking Xtampza ER with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.Never give anyone else your Xtampza ER. They could die from taking it. Selling or giving away Xtampza ER is against the law.Store Xtampza ER securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.Do not take Xtampza ER if you have:severe asthma, trouble breathing, or other lung problems.a bowel blockage, or have narrowing of the stomach or intestines.Before taking Xtampza ER, tell your healthcare provider if you have a history of:head injury, seizuresliver, kidney, thyroid problemsproblems urinatingpancreas or gallbladder problemsabuse of street or prescription drugs, alcohol addiction, opioid overdose, or mental health problemsTell your healthcare provider if you are:pregnant or planning to become pregnant. Prolonged use of Xtampza ER during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated.breastfeeding. Not recommended during treatment with Xtampza ER. It may harm your baby.living in a household where there are small children or someone who has abused street or prescription drugs.taking prescription or over-the counter medicines, vitamins, or herbal supplements. Taking Xtampza ER with certain other medicines can cause serious side effects that could lead to death.When taking Xtampza ER:Do not change your dose. Take Xtampza ER exactly as prescribed by your healthcare provider. Use the lowest dose possible for the shortest time needed.Take your prescribed dose every 12 hours, at the same time every day. Do not take more than your prescribed dose. If you miss a dose, take your next dose at your usual time.If you cannot swallow Xtampza ER capsules, see the detailed Instructions for Use in the Medication Guide.Always take Xtampza ER capsules with approximately the same amount of food to ensure enough medicine is absorbed.Swallow Xtampza ER whole. Do not snort, or inject Xtampza ER because this may cause you to overdose and die.The contents of the Xtampza ER capsules may be sprinkled on soft food, sprinkled into a cup and then put directly into the mouth, or given through a nasogastric or gastrostomy tube.Call your healthcare provider if the dose you are taking does not control your pain.Do not stop taking Xtampza ER without talking to your healthcare provider.Dispose of expired, unwanted or unused Xtampza ER by promptly flushing down the toilet, if a drug take-back option is not readily available. Visit  www.fda.gov/drugdisposal for additional information on disposal of unused medicines.While taking Xtampza ER, DO NOT:Drive or operate heavy machinery, until you know how Xtampza ER affects you. Xtampza ER can make you sleepy, dizzy, or light-headed.Drink alcohol or use prescription or over-the-counter medicines that contain alcohol. Using products containing alcohol during treatment with Xtampza ER may cause you to overdose and die.The possible side effects of Xtampza ER are:constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, and abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe.Get emergency medical help or call 911 right away if you have:trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion.These are not all the possible side effects of Xtampza ER. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. For more information, go to dailymed.nlm.nih.gov.See full Prescribing Information, including Boxed Warning on Addiction, Abuse and Misuse and other serious risks, and the Medication Guide accompanying this piece or at XtampzaER.com/PI. Speak to your healthcare provider if you have questions about Xtampza ER.APPROVED USEBELBUCA® (buprenorphine buccal film) CIII is:A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain severe enough to require daily, around-the-clock, long-term treatment with an opioid, when other pain treatments such as non-opioid pain medicines or immediate-release opioid medicines do not treat your pain well enough or you cannot tolerate them.A long-acting opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed, you are at risk for opioid addiction, abuse, and misuse that can lead to death.Not for use to treat pain that is not around-the-clock.IMPORTANT SAFETY INFORMATION about BELBUCA®WARNING: ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES AND OTHER CNS DEPRESSANTSAddiction, Abuse, and MisuseBELBUCA exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing BELBUCA, and monitor regularly for these behaviors and conditions.Risk Evaluation and Mitigation Strategy (REMS)To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the FDA has required a REMS for these products. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged tocomplete a REMS-compliant education program,counsel patients and/or their caregivers, with every prescription, on safe use, serious risks, storage, and disposal of these products,emphasize to patients and their caregivers the importance of reading the Medication Guide every time it is provided by their pharmacist, andconsider other tools to improve patient, household, and community safety.Life-Threatening Respiratory DepressionSerious, life-threatening, or fatal respiratory depression may occur with use of BELBUCA. Monitor for respiratory depression, especially during initiation of BELBUCA or following a dose increase. Misuse or abuse of BELBUCA by chewing, swallowing, snorting, or injecting buprenorphine extracted from the buccal film will result in the uncontrolled delivery of buprenorphine and poses a significant risk of overdose and death.Accidental ExposureAccidental exposure to even one dose of BELBUCA, especially in children, can result in a fatal overdose of buprenorphine.Neonatal Opioid Withdrawal SyndromeProlonged use of BELBUCA during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If prolonged opioid use is required in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.Risks from Concomitant Use with Benzodiazepines Or Other CNS DepressantsConcomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation.Important information about BELBUCA:Get emergency help or call 911 right away if you take too much BELBUCA (overdose). When you first start taking BELBUCA, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for the emergency treatment of an opioid overdose.Taking BELBUCA with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.Never give anyone else your BELBUCA. They could die from taking it. Selling or giving away BELBUCA is against the law.Store BELBUCA securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.Do not use BELBUCA if you have:severe asthma, trouble breathing, or other lung problems.a bowel blockage or have narrowing of the stomach or intestines.Before taking BELBUCA, tell your healthcare provider if you have a history of:head injury, seizuresheart rhythm problems (long QT syndrome)liver, kidney, thyroid problemstooth problems, including a history of cavitiespancreas or gallbladder problemsproblems urinatingabuse of street or prescription drugs, alcohol addiction, opioid overdose, or mental health problemsTell your healthcare provider if you are:pregnant or planning to become pregnant. Prolonged use of BELBUCA during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated.breastfeeding. Not recommended during treatment with BELBUCA. It may harm your baby.Living in a household where there are small children or someone who has abused street or prescription drugs.taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking BELBUCA with certain other medicines can cause serious side effects and could lead to death.When taking BELBUCA:Do not change your dose. Apply BELBUCA exactly as prescribed by your healthcare provider. Use the lowest effective dose possible for the shortest time needed.See the detailed Instructions for Use for information about how to apply BELBUCA.Do not apply BELBUCA if the package seal is broken or the film is cut, damaged, or changed in any way.After the film has adhered to your cheek, avoid eating or drinking until the film has completely dissolved, usually within 30 minutes.After BELBUCA is completely dissolved, rinse your mouth with water and swallow. Wait for at least one hour before brushing teeth.Report any problems with your teeth immediately to your healthcare provider and schedule an appointment with a dentist. Tell your dentist that you have started taking BELBUCA.Avoid touching or moving the buccal film with your tongue or fingers.Do not chew, swallow, snort or inject BELBUCA. This will result in uncontrolled delivery of buprenorphine and may cause you to overdose and die.Call your healthcare provider if the dose you are using does not control your pain.Do not stop using BELBUCA without talking to your healthcare provider.Dispose of expired, unwanted, or unused BELBUCA by removing the BELBUCA film from the foil packaging, and promptly flushing down the toilet (if a drug takeback option is not readily available). Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.While using BELBUCA DO NOT:Drive or operate heavy machinery, until you know how BELBUCA affects you. BELBUCA can make you sleepy, dizzy, or lightheaded.Drink alcohol or use prescription or over-the-counter medicines containing alcohol. Using products containing alcohol during treatment with BELBUCA may cause you to overdose and die.The possible side effects of BELBUCA are:nausea, constipation, headache, vomiting, dizziness, and sleepiness. Call your healthcare provider if you have any of these symptoms and they are severe.Get emergency medical help or call 911 right away if you have:trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion.These are not all the possible side effects of BELBUCA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information, go to dailymed.nlm.nih.gov.Please see full Prescribing Information, including Boxed Warning on Addiction, Abuse, and Misuse, and other serious risks, and Medication Guide or speak to your healthcare provider if you have questions about BELBUCA.INDICATIONS AND USAGENUCYNTA® (tapentadol) tablets are:A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage short term (acute) pain in adults and children 6 years of age and older who weigh at least 88 pounds (40 kg), when other pain treatments such as non-opioid pain medicines do not treat your pain well enough or you cannot tolerate them.An opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed, you are at risk for opioid addiction, abuse, and misuse that can lead to death.IMPORTANT SAFETY INFORMATION ABOUT NUCYNTA TABLETSWARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF NUCYNTA TABLETSAddiction, Abuse, and MisuseBecause the use of NUCYNTA tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess regularly for the development of these behaviors and conditions.Life-Threatening Respiratory DepressionSerious, life-threatening, or fatal respiratory depression may occur with use of NUCYNTA tablets, especially during initiation of NUCYNTA tablets or following a dose increase. To reduce the risk of respiratory depression, proper dosing and titration of NUCYNTA tablets are essential.Accidental IngestionAccidental ingestion of even one dose of NUCYNTA tablets, especially by children, can result in a fatal overdose of tapentadol.Risks From Concomitant Use With Benzodiazepines or Other CNS DepressantsConcomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of NUCYNTA tablets and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.Neonatal Opioid Withdrawal SyndromeIf opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of Neonatal Opioid Withdrawal Syndrome which may be life threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery.Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription.Important information about NUCYNTA tablets:Get emergency help or call 911 right away if you take too much NUCYNTA (overdose) tablets. When you first start taking NUCYNTA tablets, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for the emergency treatment of an opioid overdose.Taking NUCYNTA tablets with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.Never give anyone else your NUCYNTA tablets. They could die from taking it. Selling or giving away NUCYNTA tablets is against the law.Store NUCYNTA tablets securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.Do not take NUCYNTA tablets if you have:severe asthma, trouble breathing, or other lung problems.a bowel blockage or have narrowing of the stomach or intestines.Before taking NUCYNTA tablets, tell your healthcare provider if you have a history of:head injury, seizuresproblems urinatingabuse of street or prescription drugs, alcohol addiction, opioid overdose or mental health problemsliver, kidney, thyroid problemspancreas or gallbladder problemsTell your healthcare provider if you:notice your pain getting worse. If your pain gets worse after you take NUCYNTA tablets, do not take more NUCYNTA tablets without first talking to your healthcare provider. Tell your healthcare provider if the pain that you have increases, if you feel more sensitive to pain, or if you have new pain after taking NUCYNTA tablets.are pregnant or planning to become pregnant. Use of NUCYNTA tablets for an extended period of time during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated.are breastfeeding. NUCYNTA tablets pass into breast milk and may harm your baby.are living in a household where there are small children or someone who has abused street or prescription drugs.are taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking NUCYNTA tablets with certain other medicines can cause serious side effects that could lead to death.When taking NUCYNTA tablets:Do not change your dose. Take NUCYNTA tablets exactly as prescribed by your healthcare provider.Use the lowest dose possible for the shortest time needed.For acute (short-term) pain, you may only need to take NUCYNTA tablets for a few days. You may have some NUCYNTA tablets left over that you did not use. See disposal information at the bottom of this section for directions on how to safely throw away (dispose of) your unused NUCYNTA tablets.Take your prescribed dose every 4-6 hours, at the same time every day. Do not take more than your prescribed dose. If you miss a dose, take your next dose at your usual time.Call your healthcare provider if the dose you are taking does not control your pain.If you have been taking NUCYNTA tablets regularly, do not stop taking NUCYNTA tablets without talking to your healthcare provider.Dispose of expired, unwanted, or unused NUCYNTA Tablets by promptly flushing down the toilet, if a drug take-back option is not readily available. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.While taking NUCYNTA tablets, DO NOT:Drive or operate heavy machinery, until you know how NUCYNTA tablets affect you. NUCYNTA tablets can make you sleepy, dizzy, or lightheaded.Drink alcohol or use prescription or over-the-counter medicines that contain alcohol. Using products containing alcohol during treatment with NUCYNTA tablets may cause you to overdose and die.The possible side effects of NUCYNTA tablets:constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe.Get emergency medical help or call 911 right away if you have:trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion.These are not all of the possible side effects of NUCYNTA tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information, go to dailymed.nlm.nih.gov.See full Prescribing Information, including Boxed Warning on Addiction, Abuse and Misuse and other serious risks, and the Medication Guide accompanying this piece or at Nucynta.com/IRpi. Speak to your healthcare provider if you have questions about Nucynta.INDICATIONS AND USAGENUCYNTA® ER (tapentadol) is:A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain severe enough to require daily, around-the-clock, long-term treatment with an opioid when other pain treatments, such as non-opioid pain medicines or immediate-release opioid medicines, do not treat your pain well enough or you cannot tolerate them.Also used to manage pain from damaged nerves (neuropathic pain) that happens with diabetes and is severe enough to require daily, around-the-clock, long-term treatment with an opioid when other pain treatments, such as non-opioid pain medicines, do not treat your pain well enough or you cannot tolerate them.A long-acting (extended-release) opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed, you are at risk for opioid addiction, abuse, and misuse that can lead to death.Not used to treat pain that is not around-the-clock pain.IMPORTANT SAFETY INFORMATION ABOUT NUCYNTA ERWARNING: ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; INTERACTION WITH ALCOHOL and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTSAddiction, Abuse, and MisuseNUCYNTA ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing NUCYNTA ER, and monitor all patients regularly for the development of these behaviors and conditions.Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a REMS for these products. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged tocomplete a REMS-compliant education program,counsel patients and/or their caregivers, with every prescription, on safe use, serious risks, storage, and disposal of these products,emphasize to patients and their caregivers the importance of reading the Medication Guide every time it is provided by their pharmacist, andconsider other tools to improve patient, household, and community safety.Life-Threatening Respiratory DepressionSerious, life-threatening, or fatal respiratory depression may occur with use of NUCYNTA ER. Monitor for respiratory depression, especially during initiation of NUCYNTA ER or following a dose increase. Instruct patients to swallow NUCYNTA ER tablets whole; crushing, chewing, or dissolving NUCYNTA ER tablets can cause rapid release and absorption of a potentially fatal dose of tapentadol.Accidental IngestionAccidental ingestion of even one dose of NUCYNTA ER, especially by children, can result in a fatal overdose of tapentadol.Neonatal Opioid Withdrawal SyndromeProlonged use of NUCYNTA ER during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.Interaction With AlcoholInstruct patients not to consume alcoholic beverages or use prescription or non-prescription products that contain alcohol while taking NUCYNTA ER. The co-ingestion of alcohol with NUCYNTA ER may result in increased plasma tapentadol levels and a potentially fatal overdose of tapentadol.Risks From Concomitant Use With Benzodiazepines or Other CNS DepressantsConcomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.Reserve concomitant prescribing of NUCYNTA ER and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.Limit dosages and durations to the minimum required.Follow patients for signs and symptoms of respiratory depression and sedation.Important information about NUCYNTA ER:Get emergency help or call 911 right away if you take too much NUCYNTA ER (overdose). When you first start taking NUCYNTA ER, when your dose is changed, or if you take too much (overdose), serious or life-threatening breathing problems that can lead to death may occur. Talk to your healthcare provider about naloxone, a medicine for the emergency treatment of an opioid overdose.Taking NUCYNTA ER with other opioid medicines, benzodiazepines, alcohol, or other central nervous system depressants (including street drugs) can cause severe drowsiness, decreased awareness, breathing problems, coma, and death.Never give anyone your NUCYNTA ER. They could die from taking it. Selling or giving away NUCYNTA ER Tablets is against the law.Store NUCYNTA ER Tablets securely, out of sight and reach of children, and in a location not accessible by others, including visitors to the home.Do not take NUCYNTA ER if you have:severe asthma, trouble breathing, or other lung problems.a bowel blockage or have narrowing of the stomach or intestines.Before taking NUCYNTA ER, tell your healthcare provider if you have a history of:head injury, seizuresproblems urinatingabuse of street or prescription drugs, alcohol addiction, opioid overdose or mental health problemsliver, kidney, thyroid problemspancreas or gallbladder problemsTell your healthcare provider if you are:pregnant or planning to become pregnant. Prolonged use of NUCYNTA ER during pregnancy can cause withdrawal symptoms in your newborn baby that could be life-threatening if not recognized and treated.breastfeeding. Not recommended during treatment with NUCYNTA ER. It may harm your baby.living in a household where there are small children or someone who has abused street or prescription drugs.taking prescription or over-the-counter medicines, vitamins, or herbal supplements. Taking NUCYNTA ER with certain other medicines can cause serious side effects.When taking NUCYNTA ER:Do not change your dose. Take NUCYNTA ER exactly as prescribed by your healthcare provider. Use the lowest effective dose for the shortest time needed.Take your prescribed dose every 12 hours, at the same time every day. Do not take more than your prescribed dose in 24 hours. If you miss a dose, take your next dose at your usual timeSwallow NUCYNTA ER whole. Do not cut, break, chew, crush, dissolve, snort, or inject NUCYNTA ER because this may cause you to overdose and die.Call your healthcare provider if the dose you are taking does not control your painDo not stop taking NUCYNTA ER without talking to your healthcare providerDispose of expired, unwanted, or unused NUCYNTA ER Tablets by promptly flushing down the toilet if a drug take-back option is not readily available. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.While taking NUCYNTA ER DO NOT:Drive or operate heavy machinery until you know how NUCYNTA ER affects you. NUCYNTA ER can make you sleepy, dizzy, or lightheaded.Drink alcohol, or use prescription or over-the-counter medicines containing alcohol. Using products containing alcohol during treatment with NUCYNTA ER may cause you to overdose and die.The possible side effects of NUCYNTA ER are:constipation, nausea, sleepiness, vomiting, tiredness, headache, dizziness, abdominal pain. Call your healthcare provider if you have any of these symptoms and they are severe.Get emergency medical help or call 911 right away if you have:trouble breathing, shortness of breath, fast heartbeat, chest pain, swelling of your face, tongue, or throat, extreme drowsiness, light-headedness when changing positions, feeling faint, agitation, high body temperature, trouble walking, stiff muscles, or mental changes such as confusion.agitation, hallucinations, coma, feeling overheated, or heavy sweating.These are not all the possible side effects of NUCYNTA ER. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information, go to dailymed.nlm.nih.gov.See full Prescribing Information, including Boxed Warning on Addiction, Abuse and Misuse and other serious risks, and the Medication Guide accompanying this piece or at Nucynta.com/PI. Speak to your healthcare provider if you have questions about Nucynta ER.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “forecasts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements related to our pursuit of a pediatric extension of exclusivity for the Nucynta franchise. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the company's current expectations, including the risks described under the heading “Risk Factors” in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.Investor Contact:Christopher James, M.D.Vice President, Investor [email protected] Contact:Marissa SamuelsVice President, Corporate Communications [email protected]

GlobeNewswire

Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023

https://finance.yahoo.com/news/collegium-announces-10-poster-presentations-120000163.html

6d0b3cef-cb6f-39f9-98b1-70a0a40af33a

COMM

Key InsightsInstitutions' substantial holdings in CommScope Holding Company implies that they have significant influence over the company's share priceA total of 11 investors have a majority stake in the company with 51% ownership Recent purchases by insiders If you want to know who really controls CommScope Holding Company, Inc. (NASDAQ:COMM), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are institutions with 77% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.Institutional investors would probably welcome last week's 12% increase in share prices after a year of 64% losses as a sign that returns are likely to begin trending higher.Let's delve deeper into each type of owner of CommScope Holding Company, beginning with the chart below. Check out our latest analysis for CommScope Holding Company ownership-breakdownWhat Does The Institutional Ownership Tell Us About CommScope Holding Company?Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.CommScope Holding Company already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see CommScope Holding Company's historic earnings and revenue below, but keep in mind there's always more to the story.earnings-and-revenue-growthInvestors should note that institutions actually own more than half the company, so they can collectively wield significant power. It would appear that 9.8% of CommScope Holding Company shares are controlled by hedge funds. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. The Vanguard Group, Inc. is currently the company's largest shareholder with 14% of shares outstanding. For context, the second largest shareholder holds about 9.8% of the shares outstanding, followed by an ownership of 7.8% by the third-largest shareholder.Story continuesA closer look at our ownership figures suggests that the top 11 shareholders have a combined ownership of 51% implying that no single shareholder has a majority.While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.Insider Ownership Of CommScope Holding CompanyWhile the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.Our most recent data indicates that insiders own some shares in CommScope Holding Company, Inc.. As individuals, the insiders collectively own US$21m worth of the US$824m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling. General Public OwnershipThe general public, who are usually individual investors, hold a 11% stake in CommScope Holding Company. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.Next Steps:I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with CommScope Holding Company (at least 1 which can't be ignored) , and understanding them should be part of your investment process.If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Following a 64% decline over last year, recent gains may please CommScope Holding Company, Inc. (NASDAQ:COMM) institutional owners

https://finance.yahoo.com/news/following-64-decline-over-last-101954294.html

efa3ae86-33b4-31da-bf50-7eb80026b17a

COMM

Whilst it may not be a huge deal, we thought it was good to see that the CommScope Holding Company, Inc. (NASDAQ:COMM) President, Charles Treadway, recently bought US$100k worth of stock, for US$3.65 per share. However, it only increased their shares held by 3.6%, and it wasn't a huge purchase by absolute value, either. See our latest analysis for CommScope Holding Company The Last 12 Months Of Insider Transactions At CommScope Holding CompanyNotably, that recent purchase by President Charles Treadway was not the only time they bought CommScope Holding Company shares this year. Earlier in the year, they paid US$10.41 per share in a US$500k purchase. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$3.73). Their view may have changed since then, but at least it shows they felt optimistic at the time. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.While CommScope Holding Company insiders bought shares during the last year, they didn't sell. They paid about US$6.87 on average. I'd consider this a positive as it suggests insiders see value at around the current price. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!insider-trading-volumeThere are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).Does CommScope Holding Company Boast High Insider Ownership?Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 2.5% of CommScope Holding Company shares, worth about US$20m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.Story continuesSo What Do The CommScope Holding Company Insider Transactions Indicate?The recent insider purchase is heartening. We also take confidence from the longer term picture of insider transactions. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Insiders likely see value in CommScope Holding Company shares, given these transactions (along with notable insider ownership of the company). So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For instance, we've identified 3 warning signs for CommScope Holding Company (1 is concerning) you should be aware of.Of course CommScope Holding Company may not be the best stock to buy. So you may wish to see this free collection of high quality companies.For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Insider Spends US$100k Buying More Shares In CommScope Holding Company

https://finance.yahoo.com/news/insider-spends-us-100k-buying-120325262.html

88cc4807-a96d-3022-ad6b-2407babaa102

CONN

Houston-based retailer Conn’s Inc. (Nasdaq: CONN) reported another quarter of revenue declines and net losses, but the company’s stock rallied in the market after some positive developments in its latest earnings report.Continue reading

American City Business Journals

Conn’s posts revenue decline, net loss again, but stock closes up nearly 19%

https://finance.yahoo.com/m/8a5206b3-2d92-3fef-b022-5eda1504fe4e/conn%E2%80%99s-posts-revenue-decline-.html

8a5206b3-2d92-3fef-b022-5eda1504fe4e

CONN

Conn's, Inc. (NASDAQ:CONN) Q2 2024 Earnings Call Transcript August 30, 2023Conn's, Inc. beats earnings expectations. Reported EPS is $1.39, expectations were $-1.48.Operator: Good morning, and thank you for holding. Welcome to the Conn's, Inc. conference call to discuss earnings for the fiscal quarter ended July 31, 2023. My name is Doug, and I will be your operator today. [Operator Instructions] As a reminder, this conference call is being recorded. The company's earnings release dated August 30, 2023, was distributed before market opened this morning and can be accessed via the company's Investor Relations website at ir.conns.com. During today's call, management will discuss, among other financial performance measures, adjusted retail segment, operating loss and net debt. Please refer to the company's earnings release that was issued today for a reconciliation of these non-GAAP measures to their most comparable GAAP measures.I must remind you that some of the statements made in this call are forward-looking statements within the meaning of the federal securities laws. These forward-looking statements represent the company's present expectations or beliefs concerning future events. The company cautions that such statements are necessarily based on certain assumptions, which are subject to risks and uncertainties, which cause actual results to differ materially from those indicated today. Your speakers today are Norman Miller, the company's Interim CEO; and George Bchara, the company's CFO. I would now like to turn the call over to Mr. Miller. Please go ahead.Norm Miller: Good morning, and welcome to Conn's second quarter fiscal year 2024 earnings conference call. I'll start today's call with an update on our strategic priorities before turning the call over to George, who will review our financial results in more detail. The strategic initiatives we are pursuing to turn around our retail performance and better serve our core credit-constrained customers are taking hold and continue to perform in line with our expectations. For the second quarter, sales financed through our Conn's in-house credit option increased 4.3% year-over-year and sales through our lease-to-own offering increased 2.5%. In addition, we produced record quarterly eCommerce revenue and grew credit applications by over 30%.Story continuesWe also experienced a significant improvement in retail gross margin, which expanded by 230 basis points over the same period a year ago to nearly 37%. This is the highest level in almost two years and reflects the benefits of the pricing and assortment changes we have made since the end of last year. While we expect the economic environment to remain fluid over the near term, we continue to focus on improving profitability, controlling credit risk, and pursuing strategies that leverage our powerful value proposition to serve our customers and drive sales. I am confident in the progress we are making and believe we will emerge from this period as a stronger company that is well positioned to serve the growing needs of our customers. So with this introduction, I want to highlight the strategies we are pursuing, starting with our efforts to better serve our core credit-constrained customers.Since I rejoined the company in October 2022, I have consistently discussed the importance of refocusing our strategy to leverage our unique credit retail business model. I have a strong belief that our business resonates with our core customers who now more than ever need the multiple payment offerings we provide. By combining unmatched payment options across the entire credit spectrum with essential home-based product categories and an elevated shopping experience, we provide a powerful value proposition to our customers. I believe second quarter sales growth within our Conn's in-house and lease-to-own offerings as well as record quarterly eCommerce sales reflect the positive momentum that is underway within our business. This success follows two important initiatives that we have discussed over the past several quarters.First, we adjusted our marketing spend towards channels that are most effective with our credit customer and changed our marketing message to emphasize our credit-oriented value proposition. Second, we completed the launch of our new application process that makes it easier for customers to apply for our payment options with little-to-no impact on their credit score. Following the nearly 10% year-over-year growth in credit applications we experienced in the first quarter, momentum continued in the second quarter as applications increased over 30% to reach the highest level of application growth we have experienced in nine years. Credit applications are a critical leading indicator of sales and our application growth is driving sales within our in-house financing and lease-to-own segments.We have also experienced steady improvements in overall sales trends, which have improved since February as our refocused marketing efforts and strategic priorities take hold, and sales benefit from our new application process and our growing eCommerce business. Same-store sales were down 15.4% for the second quarter, which is the third quarter of sequential improvement and an over 1,000 basis point improvement from last year's third quarter. Top line trends have continued to improve and month-to-date same-store sales in August are down 13% and total sales are down 10.7%. The continual improvements in same-store sales since last year's third quarter have been driven primarily by a significant turnaround in sales financed through our in-house payment offerings as a result of the growth strategies we are pursuing.We have maintained a conservative approach to credit underwriting, which has supported stable performance within our credit segment even as we navigate a more challenging economic environment. In addition, sales within our lease-to-own segment increased during the quarter, reflecting our first positive quarter of lease-to-own sales in 1.5 years. As a result, we believe we are well positioned to achieve positive same-store sales in the coming quarters as our growth strategies continue taking hold and demand for our payment options increases. Softer sales from cash and higher credit quality customers has offset the growth we have experienced in sales through our Conn's in-house and lease-to-own offerings and we expect this trend will continue throughout this fiscal year.We believe sales to cash and higher credit quality customers are being impacted by several factors, including lower discretionary spending for home-related products following an extended period of excess consumer liquidity, pulled forward demand and tighter underwriting in general from prime lenders. Our eCommerce growth is the next strategic priority I'd like to review today. We achieved record quarterly e-commerce sales during the second quarter of $27.2 million, a 41.5% increase over the same quarter last year. In fact, second quarter eCommerce sales are higher than we achieved on an annual basis just three years ago. Year-to-date, eCommerce sales have increased 32.9% to nearly $50 million, and we believe we are well positioned to achieve over $100 million in eCommerce sales this fiscal year compared to $79 million last year.Record quarterly eCommerce sales follows multiple years of investment focused on optimizing our digital strategy and our ability to capitalize on our best-in-class logistics and delivery capabilities. I am encouraged by the continued progress we are making as we capitalize on a tremendous opportunity to scale our online business and drive annual eCommerce sales to over $300 million in the next several years. Looking at our lease-to-own payment solutions in more detail, we continue to focus on optimizing our in-house lease-to-own product known as Improvement Financial, which we believe has the potential to contribute to significant growth in both revenue and earnings in the coming years. Improvement Financial allows us to directly provide another profitable option to target a larger addressable market, including the approximately 670,000 applicants that did not qualify for Conn's in-house financing over the past 12 months.As a reminder, we started to originate our first in-house lease-to-own transactions through Improvement Financial in early 2023, and we have continued to optimize our in-house lease-to-own product. While I continue to believe that our in-house lease-to-own program will be transformative for Conn's, we are taking a more cautious approach to the expansion across our store base to ensure credit performance for this new product remains stable as we navigate an uncertain macroeconomic environment. As a result, we now expect improvement financial will be offered across the majority of our stores and at conns.com next fiscal year. Our overall assumptions remain intact and once improvement financial is mature in the coming years, we continue to believe annual lease-to-own sales can more than double from approximately $81 million last year and grow to over 15% of our retail sales.As you can see, Improvement Financial is a transformative opportunity that we believe will unlock significant value. Looking at our retail footprint in more detail. Year-to-date, we have opened seven new stores and expect to open a total of 10 new stores this fiscal year. As we have previously stated, after these stores open, we intend to pause new store openings over the next couple of years. With major investments across our credit and retail segments behind us, we believe we have a multiyear opportunity to drive retail growth within our existing locations and online without the need to open new stores or distribution centers. We believe this strategy will maximize profitability by increasing revenue per store and leveraging our fixed operating costs.Before I turn the call over to George to share more details on our financials, I want to reiterate my confidence in our business, higher sales to our core credit constrained customers, increased eCommerce sales and the expansion in retail gross margin demonstrate the success our key strategic priorities are having on the business. While we still have work to do, I believe Conn's is headed in the right direction, and I am excited by the opportunities we are pursuing to create long-term value for our customers, our team members and our shareholders. With this overview, I'll turn the call over to George.mattressantonio-caverzan-D1YruV0KUDw-unsplashGeorge Bchara: Thanks, Norm. Our second quarter results demonstrate the success of our efforts to better serve our core credit-constrained customers and turn around our retail performance. I am encouraged by the progress we are making and continue to believe we have an enormous opportunity to profitably grow our business in the future. On a consolidated basis, total revenues were $306.9 million for the second quarter, representing an 11.5% year-over-year decline. For the second quarter, the company reported a GAAP net loss of $1.39 per diluted share compared to net income of $0.09 per diluted share for the same period in fiscal year 2023. As a reminder, reconciliations of GAAP to non-GAAP financial measures are available in our second quarter earnings press release that was issued this morning.Looking at the performance of our retail segment in more detail. Total retail revenues were $246.3 million in the second quarter, representing a 12% year-over-year decline. The decrease in retail revenue was primarily driven by a 15.4% decline in same-store sales and partially offset by new store growth. Same-store sales during the second quarter were impacted by lower discretionary spending for home-related products following an extended period of excess consumer liquidity, which resulted in accelerated sales. Retail gross margin for the second quarter increased 230 basis points to 36.9% compared to 34.6% for the same period in fiscal year 2023, primarily driven by pricing and assortment changes, a more profitable product mix and normalizing freight costs.The increase was partially offset by the deleveraging of fixed distribution costs. SG&A expenses in our retail segment for the second quarter were $101.4 million compared to $98 million for the same period last fiscal year. The increase in SG&A expenses reflect the impact of new stores opened over the past 18 months, which was partially offset by a decline in variable costs and lower labor costs as a result of cost savings initiatives. Due to lower retail sales, SG&A expenses were 41.3% of retail sales for the second quarter compared to 35.1% for the same period in fiscal year 2023. For the second quarter, retail segment operating loss was $10.4 million compared to retail segment operating income of $100,000 for the same period in fiscal year 2023.There were no non-GAAP adjustments to retail segment operating income in the second quarter of fiscal year 2024 compared to an adjusted loss of $1.4 million for the same period in fiscal year 2023. Turning to our second quarter credit segment performance. Finance charges and other revenues declined 5.6% year-over-year to $63.1 million, primarily due to a decline in the average balance of the customer receivable portfolio, partially offset by an increase in insurance commissions and late fees. As a percent of the portfolio, the 60-day delinquency balance was 11.1% at July 31, 2023, compared to 11% at July 31, 2022. In addition, this represents a 50 basis point decline from the first quarter of this year compared to a sequential increase of 70 basis points in the second quarter of last year.The balance of re-aged accounts as a percent of the portfolio was 15.9% compared to 16.1% for the same period in fiscal year 2023. In addition, the carrying value of re-aged accounts continues to improve and remains at one of the lowest levels in almost a decade. For the second quarter of fiscal year 2024, net charge-offs as a percent of the average portfolio balance were 15.8% compared to 13.7% for the same period last fiscal year. During the second quarter, the credit provision for bad debts was $33.2 million compared to $26.8 million for the same period last fiscal year. The $6.4 million year-over-year increase in the credit provision for bad debts was primarily driven by higher year-over-year net charge-offs and a smaller year-over-year reduction in the allowance for bad debts.The company reported credit segment loss before taxes of $4.5 million in the second quarter compared to credit segment income of $7.9 million for the same period last fiscal year. The greater credit segment loss before taxes was primarily due to higher interest expense as well as a reduction in our credit spread, which declined to 7.2% compared to 9.6% in the same period last fiscal year. Turning now to our balance sheet. At July 31, 2023, we had $611.4 million in net debt compared to $531.2 million at July 31, 2022. Net debt as a percent of the ending portfolio balance was approximately 61.9% at the end of the second quarter. To further improve our capital position and access to liquidity, during the second quarter, we entered into a $50 million 3-year delayed draw term loan.As of July 31, 2023, we had $239.7 million of cash plus availability under our revolving credit and delayed draw term loan facilities. In addition, on August 17, we completed a $273.7 million ABS transaction. Our latest ABS transaction was 10x oversubscribed, reflecting the extremely strong demand for our bonds. While the ABS market has improved over the past year, the market remains fluid and recent actions to improve our capital position demonstrate the company's ability to access the capital markets even during volatile market conditions. As a result, we continue to believe our liquidity and access to capital provides us with flexibility to support the current needs of our business while investing in our long-term growth initiatives. As our strategies take hold and continue to perform in line with our expectations, our outlook for fiscal 2024 hasn't changed since our first quarter call.We continue to expect retail gross margins to benefit from lower freight expenses this fiscal year. While we remain focused on managing costs, we continue to expect annual SG&A expenses to increase year-over-year by $15 million to $25 million, primarily due to new stores and investments in our e-commerce growth strategy. We continue to believe our annual interest expense will increase year-over-year by approximately $40 million to $45 million, and we expect our effective tax rate for the remainder of the fiscal year to be impacted by further adjustments to the valuation allowance. From a top line perspective, we expect continued improvements in total retail sales and same-store sales as we benefit from the growth strategies we discussed today.Overall, we believe our second quarter results and expectations for the remainder of the year demonstrate the positive momentum underway across our business and the growing success of our strategic initiatives. Finally, I want to share my thanks to all our team members for their continued hard work, service and dedication. So with this overview, Norm and I are happy to take your questions. Operator, please open the call up to questions.See also 20 Countries where Housing Prices are Declining or Flat and 10 Best Cosmetic Surgery and Aesthetics Stocks to Buy.Q&A SessionOperator: [Operator Instructions] Our first question comes from the line of Brian Nagel with Oppenheimer. Please proceed with your question.Brian Nagel: Hi guys. Good morning.Norm Miller: Good morning, Brian.George Bchara: Good morning.Brian Nagel: Definitely some nice positives here, so congratulations.Norm Miller: Thank you.Brian Nagel: So the first question I have -- I've got a few questions. I'll go through in succession. But the first question, so Norm, you called out the -- your comments, the improving credit application numbers. It sounds like that was accelerated here in the fiscal third quarter. So I guess the question I have there is, as you look at that metric, is it -- the consumers applying for credit or at Conn's accelerated pace? Is it the same consumer? Or are you seeing that mix, so to say, change?Norm Miller: What I would say, Brian, is it's certainly demonstrating demand for loan -- for lending and products. out there and increasing demand in the marketplace. Now part of that is because of our shift in marketing towards that consumer versus a year ago. But even with that shift in marketing emphasis towards the credit consumer. I would say that there's definitely an increasing demand in the marketplace as a result of banks and prime lenders as a general rule tightening which historically, if you look at economic more economic challenge times, it usually benefits our Conn's business and our LTO business. As far as the mix in it, I would say it's kind of -- it's heavily based towards the near prime and the subprime consumer.Brian Nagel: Got it. That's helpful. And then my second question, I guess this will be a bigger picture, but looking at the progression here, you're talking about a lot of the positives here in the second quarter, the initiatives that place Conn's really started to take hold. So as you look at this and you're recognizing your comp store sales while getting better still solidly negative, you're still on a P&L basis, losing money. How do you view the trajectory here? Is it just an ongoing benefit of these initiatives is there some type of unlocks we're going to be hitting here in the forthcoming quarters?Norm Miller: I think it's just steady improvement on it from an ongoing basis now in the third and fourth quarter, especially in the third quarter, we lap some tougher comp numbers. So that's an easier comp numbers. So that will make -- that will be a little bit of a benefit. But unfortunately, it's -- there's not a single silver bullet that's going to unlock and get us ultimately a positive comp. It's -- the -- as you heard, our Conn's financing and our LTO are actually positive comping those segments year-over-year. So part of it is continuing to build on those segments and then mitigating on that cash customer and the high credit quality customer mitigating there and, at the same time, continuing to accelerate that eCommerce business as well, which is, if I would highlight anything, I think, has the potential to be a material unlock to drive incremental sales here over the next 24 months.Brian Nagel: Got it. I appreciate it. Thank you.Norm Miller: Thanks Brian.Operator: Our next question comes from the line of Kyle Joseph with Jefferies. Please proceed with your question.Kyle Joseph: Good morning, guys. Thanks for taking my questions. So the sequential decline in delinquencies normally from a seasonal perspective, we would expect that to increase. So is that a function of underwriting changes, customer mix, a broadly healthier customer? Or what drove that?George Bchara: Yes. And I would expand that, Kyle, to say that even into the third quarter, we've seen delinquencies remained stable, which is down a bit year-over-year. from a trend standpoint. I mean, I think as we've talked about, we've shifted our mix from a performance standpoint so that the bulk of our originations are to that higher credit quality risk Tier A and risk Tier B customer. And we've seen that customer remain more stable here this year from a performance standpoint and are encouraged with what we're seeing there from both an origination standpoint and also from a performance standpoint, even as we're operating in an uncertain and challenged macro environment. The further you go down that credit spectrum, the more stress we see with that consumer.Kyle Joseph: Got it. That makes sense. And then, Norm, I think you alluded to some credit tightening in prime. Obviously, that's going to be a headwind for you guys in the near term on some of those prime sales. But longer term, how does Conn's do when the credit environment is tight? Or for instance, like if we do go into a hard landing, what do you expect -- what are the opportunities there?Norm Miller: Yes. What I would say is it actually -- you're right, if we go into a harder landing and it's more challenging from an economic standpoint, that actually creates more opportunities from us from a sales standpoint. If you go back to 2008, you go back in other economic times, that actually creates sales opportunities for us. The balance we have to have is watching the portfolio because if there's any stress, we feel during that it can be out of the existing portfolio and what happens with that consumer base. But if we're underwriting to George's point, at that higher end of it of those credit quality customers, and we've done that purposefully as we've gone into these uncertain economic times because if it does turn into a more challenging landing, we think the portfolio will weather better, and it will absolutely provide us sales opportunities as folks tighten higher up the credit spectrum.Kyle Joseph: Great. And then one last one for me. Margins really snapped back in the quarter. Any onetime things there? Is this a good kind of run rate? And I know you highlighted that you expect some ongoing improvements there, but just give us a sense for the quick snapback and where you see it heading from here?George Bchara: Yes. No onetime items in the quarter, Kyle. It was really driven by a number of factors that we talked about. First was some pricing and assortment changes that we're starting to see the benefit of here in the third quarter that we would expect to continue, including some pricing changes on ancillary fees that we're seeing the benefit of in the third quarter. And we would -- in the second quarter, we would expect to continue here for the remainder of the year. And then as you look forward, really, we're still seeing the benefit of now lower freight costs, impact margin on the furniture side, and there's some additional upside for the balance of the year there. The other factor, as you look longer term here, we're still dealing with deleveraging on fixed costs on lower sales this quarter.And as sales continue to improve and ultimately turn positive, you'll see another benefit from the leverage of fixed cost on margin. So we're very pleased with where margin is right now and expect levels here to sustain for the remainder of the year.Kyle Joseph: Got it. Thanks for taking my questions.Operator: There are no further questions in the queue. I'd like to hand the call back to management for closing remarks.Norm Miller: Thanks. First, I want to recognize and acknowledge all of our associates for all their hard -- continued hard work and contributions day in and day out. We are who we are because of them. So I appreciate their hard work. And I also appreciate everyone's on the call here, your interest in the company. We look forward to talking to you at the end of the third quarter. Have a good day.Operator: Ladies and gentlemen, this does conclude today's teleconference. Thank you for your participation. You may disconnect your lines at this time, and have a wonderful day.Norm Miller: Thanks, guys.

Insider Monkey

Conn’s, Inc. (NASDAQ:CONN) Q2 2024 Earnings Call Transcript

https://finance.yahoo.com/news/conn-inc-nasdaq-conn-q2-124027352.html

16b0d960-cd63-3452-b928-d82f8ee1de4b

COO

The Cooper Companies Inc (NYSE:COO) has recently been in the spotlight, drawing interest from investors and financial analysts due to its robust financial stance. With shares currently priced at $355.64, The Cooper Companies Inc has witnessed a decline of 2.48% over a period, marked against a three-month change of 0.71%. A thorough analysis, underlined by the GuruFocus Score Rating, suggests that The Cooper Companies Inc is well-positioned for substantial growth in the near future.Warning! GuruFocus has detected 4 Warning Signs with COO. Click here to check it out. COO 30-Year Financial DataThe intrinsic value of COOUnveiling the Investment Potential of The Cooper Companies Inc (COO): A Comprehensive Analysis of Financial Metrics and Competitive StrengthsDecoding the GF ScoreThe GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with a lower GF Score. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.Here is a breakdown of The Cooper Companies Inc's GF Score:1. Financial strength rank: 6/102. Profitability rank: 9/103. Growth rank: 10/104. GF Value rank: 9/105. Momentum rank: 9/10Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. With high ranks in profitability, growth, GF value, and momentum, and a decent rank in financial strength, GuruFocus assigned The Cooper Companies Inc the GF Score of 96 out of 100, which signals the highest outperformance potential.Understanding The Cooper Companies Inc BusinessThe Cooper Companies Inc, with a market cap of $17.61 billion and sales of $3.51 billion, is one of the largest eye care companies in the U.S. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business and is composed of a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and clariti, Cooper controls roughly a quarter of the U.S. contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the U.S., and controls 17% of the U.S. IUD market.Story continuesUnveiling the Investment Potential of The Cooper Companies Inc (COO): A Comprehensive Analysis of Financial Metrics and Competitive StrengthsFinancial Strength BreakdownAccording to the Financial Strength rating, The Cooper Companies Inc's robust balance sheet exhibits resilience against financial volatility, reflecting prudent management of capital structure. With a favorable Debt-to-Revenue ratio of 0.74, The Cooper Companies Inc's strategic handling of debt solidifies its financial health.Profitability Rank BreakdownThe Profitability Rank shows The Cooper Companies Inc's impressive standing among its peers in generating profit. The Cooper Companies Inc's strong Predictability Rank of 5.0 stars out of five underscores its consistent operational performance, providing investors with increased confidence.Growth Rank BreakdownRanked highly in Growth, The Cooper Companies Inc demonstrates a strong commitment to expanding its business. The company's 3-Year Revenue Growth Rate is 7.8%, which outperforms better than 51.1% of 724 companies in the Medical Devices & Instruments industry. Moreover, The Cooper Companies Inc has seen a robust increase in its earnings before interest, taxes, depreciation, and amortization (EBITDA) over the past few years. Specifically, the three-year growth rate stands at 2.3, and the rate over the past five years is 5.8. This trend accentuates the company's continued capability to drive growth.Unveiling the Investment Potential of The Cooper Companies Inc (COO): A Comprehensive Analysis of Financial Metrics and Competitive StrengthsConclusionGiven The Cooper Companies Inc's financial strength, profitability, and growth metrics, the GuruFocus Score Rating highlights the firm's unparalleled position for potential outperformance. This analysis underscores the company's robust financial health, consistent profitability, and impressive growth trajectory, making it a compelling investment opportunity. GuruFocus Premium members can find more companies with strong GF Scores using the following screener link: GF Score ScreenThis article first appeared on GuruFocus.

GuruFocus.com

Unveiling the Investment Potential of The Cooper Companies Inc (COO): A Comprehensive Analysis ...

https://finance.yahoo.com/news/unveiling-investment-potential-cooper-companies-160327518.html

657ef199-6d90-3638-9cf5-56ff5ea548a0

COO

Marquee industry conference will showcase data from CBR's Newborn Possibilities Program® TRUMBULL, Conn., Sept. 8, 2023 /PRNewswire/ -- CooperSurgical, a global leader in fertility and women's health, announced that Cord Blood Registry® (CBR®) will have a key role in the upcoming Cord Blood Connect meeting from September 8th – 11th, which is the annual meeting of the Cord Blood Association. The Cord Blood Association is an international nonprofit organization that promotes both public and family newborn stem cell preservation and accelerates the use of cord blood and birthing tissues to benefit patients and advance medicine.CBR Logo (PRNewsfoto/CooperSurgical®)"Cord Blood Connect is a critical meeting for public and family cord blood banks, allowing them a forum to discuss industry innovations, patient needs, and evolving industry standards," stated Holly Sheffield, President, CooperSurgical. "We are proud to be the Platinum Sponsor of this event, and to be presenting new scientific data, as well as moderating a forum with key industry voices to discuss the future of cord blood banking. Our presence and participation is one example of CooperSurgical's commitment to elevating this industry."CBR's abstract titled "Experience with enrollments and releases within a medical needs program at a large U.S. private cord blood bank" was accepted as a poster presentation at Cord Blood Connect. The objective of the study was to examine indications for enrollments and unit releases in CBR's Newborn Possibilities Program. Through this program, CBR offers free cord blood and tissue processing and five years of storage for families with a qualifying medical need. The results of the study suggested the structure of the Newborn Possibilities Program is effective in identifying families who have a higher likelihood of utilizing their cord blood unit for a transplant or experimental infusion. The investigators also noted that cord blood banks should continue to re-evaluate the eligibility criteria for their medical needs program in light of relevant updates in the potential utility of newborn stem cells including changes in transplant medicine indications and treatment procedures, as well as clinical trials and experimental protocols using related cord blood units. Future research related to pathways of referral to medical needs programs may inform education gaps among women's health providers.Story continues"We're delighted to see our Newborn Possibilities Program being highlighted as a poster presentation at Cord Blood Connect," commented Peter Bawin, Global Vice President, Commercial Life Sciences, CooperSurgical. "This program was designed with families in mind, especially if a specific health history indicated a medical need that may potentially be treated using newborn stem cells. As the largest private newborn stem cell company in the world, we are happy to take the lead in finding ways to expand access to more families, especially as the science continues to evolve around this area of medicine."Mr. Bawin will be moderating a panel titled "Future of Cord Blood Banking" on Saturday, September 9th featuring global leaders from the major family and public cord blood banks. The panel will discuss challenges facing the industry, along with the opportunities that exist given the changing landscape in hematopoietic transplant and the growing field of cell therapies. It also plans to explore how cord blood banks can be proactive in shaping the future of the industry.For more information about Cord Blood Connect and CBR's participation, please visit https://www.cb-association.org/cord-blood-connect.About CBR by CooperSurgicalCord Blood Registry® (CBR®) is the largest private newborn stem cell company in the world, helping parents store stem cells from cord blood and cord tissue for their children. Founded in 1994, CBR is the #1 choice for parents1 and most recommended by OB/GYNs for newborn stem cell preservation.2 The company has released over 700 samples intended for use in transplant medicine and regulated investigational regenerative medicine applications. CBR is here to help expand the possibilities of what newborn stem cell therapies can do for families and give parents the confidence to Bank on CBR™. More information can be found at www.cordblood.com.About CooperSurgicalCooperSurgical® is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most in life. CooperSurgical is at the forefront of delivering innovative assisted reproductive technology and genomic solutions that enhance the work of ART professionals to the benefit of families. We currently offer over 600 clinically relevant medical devices to women's healthcare providers, including testing and treatment options.CooperSurgical is a wholly-owned subsidiary of CooperCompanies (NYSE: COO). CooperSurgical, headquartered in Trumbull, CT, produces and markets a wide array of products and services for use by women's health care clinicians. More information can be found at www.coopersurgical.com.About CooperCompaniesCooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.Disclaimer:The use of cord blood is determined by the treating physician and is influenced by many factors, including the patient's medical condition, the characteristics of the sample, and whether the cord blood should come from the patient or an appropriately matched donor. Cord blood has established uses in transplant medicine; however, its use in regenerative medicine is still being researched. There is no guarantee that potential medical applications being studied in the laboratory or clinical trials will become available.Cord tissue use is still in early research stages, and there is no guarantee that treatments using cord tissue will be available in the future. Cord tissue is stored whole. Additional processing prior to use will be required to extract and prepare any of the multiple cell types from cryopreserved cord tissue. Cbr Systems, Inc.'s activities for New York State residents are limited to collection of umbilical cord tissue and long-term storage of umbilical cord–derived stem cells. Cbr Systems, Inc.'s possession of a New York State license for such collection and long-term storage does not indicate approval or endorsement of possible future uses or future suitability of these cells.References:Internal source. Data on file.Blind survey, Egg Strategy, 10/19, funded by CBR.Contact:[email protected] original content to download multimedia:https://www.prnewswire.com/news-releases/cord-blood-registry-announces-thought-leadership-role-at-cord-blood-connect-301922405.htmlSOURCE CooperSurgical®

PR Newswire

Cord Blood Registry® Announces Thought Leadership Role at Cord Blood Connect

https://finance.yahoo.com/news/cord-blood-registry-announces-thought-194400424.html

bed0ce63-e183-33e8-bb28-8653b3107aa2

COP

ConocoPhillips (COP) closed at $122.72 in the latest trading session, marking a +0.83% move from the prior day. This change outpaced the S&P 500's 0.14% gain on the day. At the same time, the Dow added 0.22%, and the tech-heavy Nasdaq gained 0.09%.Coming into today, shares of the energy company had gained 5.08% in the past month. In that same time, the Oils-Energy sector gained 3.78%, while the S&P 500 lost 1.27%.Investors will be hoping for strength from ConocoPhillips as it approaches its next earnings release. The company is expected to report EPS of $2.24, down 37.78% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $15.47 billion, down 28.41% from the year-ago period.COP's full-year Zacks Consensus Estimates are calling for earnings of $8.87 per share and revenue of $60.36 billion. These results would represent year-over-year changes of -34.39% and -26.53%, respectively.It is also important to note the recent changes to analyst estimates for ConocoPhillips. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 1.72% higher within the past month. ConocoPhillips is holding a Zacks Rank of #3 (Hold) right now.Valuation is also important, so investors should note that ConocoPhillips has a Forward P/E ratio of 13.72 right now. This valuation marks a discount compared to its industry's average Forward P/E of 15.74.Story continuesInvestors should also note that COP has a PEG ratio of 0.75 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. COP's industry had an average PEG ratio of 0.77 as of yesterday's close.The Oil and Gas - Integrated - United States industry is part of the Oils-Energy sector. This group has a Zacks Industry Rank of 152, putting it in the bottom 40% of all 250+ industries.The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportConocoPhillips (COP) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

ConocoPhillips (COP) Outpaces Stock Market Gains: What You Should Know

https://finance.yahoo.com/news/conocophillips-cop-outpaces-stock-market-215019104.html

baa7d68e-4b6e-3fad-9d60-4a2a862dc975

COP

Oil prices had been stuck in a rut over the past year, bouncing between $65 and $80 a barrel. Higher oil prices would be a boon for all oil stocks. Pioneer Natural Resources (NYSE: PXD), ConocoPhillips (NYSE: COP), and Devon Energy (NYSE: DVN) stand out to a few Fool.com contributors for their oil-fueled dividends.Continue reading

Motley Fool

Oil Prices Are on the Rise: 3 Dividend Stocks to Play the Energy Rally

https://finance.yahoo.com/m/b5cf922a-a0cb-3b93-a44f-996320f10433/oil-prices-are-on-the-rise-3.html

b5cf922a-a0cb-3b93-a44f-996320f10433

COR

Investors in Cencora, Inc. COR need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 17, 2023 $120.00 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.What do the Analysts Think?Clearly, options traders are pricing in a big move for Cencora shares, but what is the fundamental picture for the company? Currently, Cencora is a Zacks Rank #3 (Hold) in the Medical Services industry that ranks in the Bottom 27% of our Zacks Industry Rank. Over the last 60 days, one analyst has increased the earnings estimate for the current quarter, while four have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from $2.82 per share to $2.79 in that period.Given the way analysts feel about Cencora right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.Looking to Trade Options?Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk.Click to see the trades now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportStory continuesCencora, Inc. (COR) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Implied Volatility Surging for Cencora (COR) Stock Options

https://finance.yahoo.com/news/implied-volatility-surging-cencora-cor-141500476.html

6ac43418-338b-3653-b35d-6538f672924e

COR

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.Why This 1 Growth Stock Should Be On Your WatchlistFor growth investors, a company's financial strength, overall health, and future outlook take precedence, so they'll want to zero in on the Growth Style Score. This Score examines things like projected and historical earnings, sales, and cash flow to find stocks that will generate sustainable growth over time.AmerisourceBergen (COR)Chesterbrook, PA-based Cencora is one of the world’s largest pharmaceutical services companies, which focuses on providing drug distribution and related services to reduce health care costs and improve patient outcomes.COR boasts a Growth Style Score of B and VGM Score of A, and holds a Zacks Rank #3 (Hold) rating. Its bottom-line is projected to rise 8.1% year-over-year for 2023, while Wall Street anticipates its top line to improve by 8.8%.Six analysts revised their earnings estimate higher in the last 60 days for fiscal 2023, while the Zacks Consensus Estimate has increased $0.10 to $11.92 per share. COR also boasts an average earnings surprise of 3.5%.On a historic basis, AmerisourceBergen has generated cash flow growth of 12.4%, and is expected to report cash flow expansion of 26% this year.COR should be on investors' short lists because of its impressive growth fundamentals, a good Zacks Rank, and strong Growth and VGM Style Scores.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportStory continuesCencora, Inc. (COR) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Why AmerisourceBergen (COR) is a Top Growth Stock for the Long-Term

https://finance.yahoo.com/news/why-amerisourcebergen-cor-top-growth-134506650.html

2b01d62f-3d65-3904-b1e8-f5678f928fcc

COST

slobo / Getty ImagesCostco is your No. 1 stop when it comes to buying in bulk and getting a great price on your total bill. Whether you are doing your weekly grocery shopping for the home, stocking up for a party or just wanting to make sure the pantry is full, Costco has you covered.I Flip Thrift Store Finds: Here Are the 14 Things I Always Make a Profit OnDiscover: How To Get Cash Back on Your Everyday PurchasesBut did you know that Costco also has luxury goods as well? You might be surprised at the selection offered and the luxury goods you can pick up for a great price without sacrificing any value in the process. It might seem a bit odd at first to shop for watches, necklaces, earrings and jewelry at Costco. However, upon a second look, you’ll see that the price difference is shockingly lower at Costco without giving up any of the luxurious qualities in the process.Here are seven luxury goods that are cheaper at Costco.Color Diamond 14kt White Gold Stud EarringsPrice: $349.99Putting jewels in your ears never goes out of style, but paying too much for earrings is never in fashion. Luckily, Costco has a pair of Round Brilliant 0.25 ctw VS2 Clarity, I Color Diamond 14kt White Gold Screwback Stud Earrings for less than $400.Color Diamond 14kt Gold & Titanium Flexible Cuff BraceletPrice: $699.99The saying goes that diamonds are “a girl’s best friend” but when it comes to shopping for diamonds, Costco is your best friend. The Round Brilliant 0.36 ctw VS2 Clarity, I Color Diamond 14kt Gold & Titanium Flexible Cuff Bracelet is offered for just under $700 at Costco. That’s five diamonds in all, offered “natural and untreated” by Costco.Find Out: Are These 8 Costco Items With Cult Followings Worth the Hype (and Money)?14kt Yellow Gold Rope ChainPrice: $699.99You will be seeing nothing but green in your pocket when you purchase your yellow gold rope chain necklace at Costco. Made in Italy, this elegant rope chain is built from 14kt yellow gold and diamond cut, providing an 18-inch chain length that fastens securely with the lobster-style necklace clasp. Never worry about it falling off your neck or paying too much when you buy this piece at Costco.Story continuesAkoya Cultured Pearl StrandPrice: $1,999.99You don’t have to dive to the bottom of the sea or to the bottom of your bank account to purchase a beautiful pearl necklace. All you have to do is shop at Costco, where an Akoya Cultured 8.5-9mm Pearl Strand with 14kt White Gold Clasp comes in at just about $2,000. Plus, if you purchase online and spend $1,000 on qualifying Jewelry items — which this fits the bill for Costco’s qualifications — you will receive $150 off in the cart on your order until May 8.18kt Yellow Gold Woven BraceletPrice: $1,699.99If you have a watch on one wrist, make sure the other is covered with an 18kt Yellow Gold woven bracelet, available at Costco for a great price. With a high polish finish and custom design right from Italy, you’ll feel like a royal genius, knowing that you didn’t spend all your money to look like a king or queen.Diamond Platinum Eternity BandPrice: $5,799.99The Emerald Cut & Round Brilliant VS2 Clarity, G Color Diamond Platinum Eternity Band at Costco is stunning — not just from the look, but also the amount you’ll pay for full carat weight for sizes 5 through 8. The metal is 950 Platinum, rounded out with near-colorless diamonds. Buying this ring at Costco ensures that the shine from the rock on your finger to the amount of money you saved lasts for a long time to come.Timex Model 23 Blush Dial Rose Gold-Tone Case Ladies Quartz WatchPrice: $94.97With a rose gold-tone case and bracelet, Timex has created a classy watch that won’t cost you an arm or a leg when you buy it for under $100 at Costco. The blush textured Guilloché Dial and Seconds Sub-Dial make it the perfect blend of classy and utilitarian.More From GOBankingRates8 Essentials You'll Be Shocked You Can Buy at Dollar TreeDriver's License Scam Could Cost You Thousands: 13 Ways To Protect Yourself3 Ways to Recession Proof Your Retirement5 Best Ways To Stay Safer From Identity Theft When You're OnlineThis article originally appeared on GOBankingRates.com: 7 Luxury Items That Are Cheaper at Costco

GOBankingRates

7 Luxury Items That Are Cheaper at Costco

https://finance.yahoo.com/news/7-luxury-goods-cheaper-costco-190012691.html

9d135b52-db3f-3939-aa90-20ff26be5807

COST

The warehouse club made it very clear that it might not have cool tech, but it has something its rivals can't match.Continue reading

TheStreet.com

Why Costco is a better deal than Kroger, Target, and Walmart

https://finance.yahoo.com/m/bb1924e4-4772-3466-a3c4-8b927c4d656e/why-costco-is-a-better-deal.html

bb1924e4-4772-3466-a3c4-8b927c4d656e

COTY

Several companies in the Zacks Cosmetics industry are battling inflationary pressures and supply-chain bottlenecks. Reduced discretionary spending due to an overall inflationary landscape affects demand for several companies’ products.Nevertheless, efforts to boost digital operations and innovations have worked for companies like Coty Inc. COTY, e.l.f. Beauty, Inc. ELF, Inter Parfums, Inc. IPAR and Helen of Troy Limited HELE.About the IndustryThe Zacks Cosmetics industry includes companies providing beauty and personal care products. Players in the industry manufacture, distribute, sell and market skincare, fragrance, makeup and hair care products. Many firms in the space market via sales representatives, whereas some sell products through retailers, independent and chain drug stores and pharmacies, upscale perfumeries, department stores and beauty salons. The companies also operate through retailer websites, third-party distributors and in-flight and duty-free shops. Some of the products offered by the industry participants include moisturizers, serums, toners and cleansers under skincare; perfume sprays, candles and soaps under fragrance; lipsticks, mascaras, powders, eye shadows, foundation and nail polishes under makeup; and shampoos, conditioner and hair color products under hair care.Trends Shaping the Future of the Cosmetics IndustryInflationary Headwinds: Companies in the cosmetics space are encountering inflationary pressure on operating costs, including labor, supplies and travel, among others. Several players continue to battle supply-chain disruptions stemming from port congestions, increasing freight prices and wide-scale shortages of materials. Rising costs, higher interest rates and increasing household debt are compelling consumers to cut down on discretionary purchases, thus impacting demand for the players.Volatile Currency Movements: Several industry players remain vulnerable to unfavorable currency movements due to their exposure to international markets. This is because a strengthening U.S. dollar may require a company to either raise prices or contract profit margins in locations outside the United States. Some industry players expect adverse currency fluctuations to affect their performances in 2023.Story continuesInnovation & Digitization – Major Drivers: Consumers keep looking for unique product offerings incorporating the latest technologies and expert scientific formulations in the beauty and skincare space. Focus on resonating with consumers’ ever-changing preferences has kept cosmetic players occupied in terms of innovation and product launches. Increased consumer awareness has also stimulated demand for organic skincare and “clean beauty” products. Further, Cosmetic players’ foremost priority has been to broaden their market reach by boosting e-commerce capabilities. Companies in the space have made significant progress, evident from tools like virtual try, new digital payment solutions and digital marketing efforts. Players have also been fueling brand portfolios through prudent buyouts and strategic alliances. Such upsides are likely to continue supporting the top-line performance of cosmetics companies.Zacks Industry Rank Indicates Dull ProspectsThe Zacks Cosmetics industry is housed within the broader Zacks Consumer Staples sector. The industry currently carries a Zacks Industry Rank #189, which places it in the bottom 24% of more than 250 Zacks industries.The group’s Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates solid near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.The industry’s position in the bottom 50% of the Zacks-ranked industries results in a positive aggregate earnings outlook for the constituent companies. Looking at the aggregate earnings estimate revisions, it appears that analysts are gradually gaining confidence in this group’s earnings growth potential. Since the beginning of May 2023, the industry’s consensus earnings estimate for the current financial year has fallen 16.1%.Before we present a few stocks that you may want to consider for your portfolio, let’s look at the industry’s recent stock-market performance and valuation picture.Industry Vs. Broader MarketThe Zacks Cosmetics industry has underperformed the Zacks S&P 500 composite and the broader Zacks Consumer Staples sector over the past year.The industry has declined 25.9% over this period compared with the S&P 500’s growth of 12.4%. The broader sector has moved down 3.2% in the said time frame.One-Year Price PerformanceIndustry's Current ValuationOn the basis of forward 12-month Price-to-earnings (P/E), which is commonly used for valuing consumer staples stocks, the industry is currently trading at 29.18X compared with the S&P 500’s 19.36X and the sector’s 17.33X.In the past five years, the industry has traded as high as 45.92X, as low as 19.64X, and at the median of 30.55X, as the chart below shows.Price-to-Earnings Ratio (Past 5 Years)4 Cosmetic Stocks Worth WatchingInter Parfums: The Zacks Rank #1 (Strong Buy) company manufactures, distributes and markets a wide range of fragrances and related products. Inter Parfums is benefiting from solid growth across European and U.S. operations, courtesy of the impressive performance of its brands. IPAR is reaping benefits from the booming fragrance market globally. The company is expanding its business through new licenses or acquisitions. Management’s focus on innovation and product launches is a key driver. You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for IPAR’s current fiscal year earnings per share (EPS) has moved up 4.1% to $4.55 in the past 30 days. Shares of Inter Parfums have dropped 0.3% in the past three months.Price and Consensus: IPAR Helen of Troy: The provider of consumer products across Beauty, Housewares and Health & Home segments, currently carries a Zacks Rank #2 (Buy). HELE is making significant investments in critical areas to continue driving growth. To this end, it invests in consumer-centric innovation, digital marketing and media, and enhanced production and distribution capacity, among others.Helen of Troy is progressing well with Project Pegasus, which aims to expand operating margins via improved efficiency and lower costs. The company’s solid investments in its Leadership Brands, which is a portfolio of market-leading brands, are yielding.The Zacks Consensus Estimate for Helen of Troy’s current fiscal year EPS has remained unchanged in the past 30 days at $8.86. The company’s stock has increased 15.6% in the past three months. HELE has an expected EPS growth rate of 8% for three-five years.Price and Consensus: HELE e.l.f. Beauty: The provider of cosmetic and skincare products carries a Zacks Rank #2. e.l.f. Beauty appears well-placed to benefit from its commitment to solidifying its brand portfolio through innovation. Focus on effective marketing strategies helps the company reach new audiences and penetrate new platforms. e.l.f. Beauty is undertaking significant investments in its digital business, which is yielding.The Zacks Consensus Estimate for ELF’s current fiscal year EPS has increased by a penny in the past 30 days to $2.37. The company’s stock has gained 26% in the past three months. ELF has an expected EPS growth rate of 21.7% for three-five years.Price and Consensus: ELF Coty: The manufacturer, marketer and distributor of beauty products presently carries a Zacks Rank #3. Coty is benefiting from its focus on six strategic pillars aimed at sustainable growth, including expanding makeup brands and mass fragrances and establishing a strong skincare portfolio. The company is strengthening its e-commerce and direct-to-consumer capabilities. COTY is committed to optimizing the overall cost structure.The Zacks Consensus Estimate for Coty’s current fiscal year EPS has moved down 6.3% in the past 30 days to 45 cents. COTY’s stock has declined 5.4% in the past three months. COTY has an expected EPS growth rate of 2.8% for three-five years.Price and Consensus: COTYWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportCoty (COTY) : Free Stock Analysis ReportHelen of Troy Limited (HELE) : Free Stock Analysis ReportInter Parfums, Inc. (IPAR) : Free Stock Analysis Reporte.l.f. Beauty (ELF) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

4 Cosmetics Stocks Worth Watching Amid Industry Headwinds

https://finance.yahoo.com/news/4-cosmetics-stocks-worth-watching-120500438.html

1e2d8ef9-183a-39b2-9521-21e7b2dfbf65

COTY

For Immediate ReleaseChicago, IL – September 8, 2023 – Today, Zacks Equity Research discusses Coty Inc. COTY, e.l.f. Beauty, Inc. ELF, Inter Parfums, Inc. IPAR and Helen of Troy Ltd. HELE.Industry: CosmeticsLink: https://www.zacks.com/commentary/2145847/4-cosmetics-stocks-worth-watching-amid-industry-headwindsSeveral companies in the Zacks Cosmetics industry are battling inflationary pressures and supply-chain bottlenecks. Reduced discretionary spending due to an overall inflationary landscape affects demand for several companies' products.Nevertheless, efforts to boost digital operations and innovations have worked for companies like Coty Inc., e.l.f. Beauty, Inc., Inter Parfums, Inc. and Helen of Troy Ltd..About the IndustryThe Zacks Cosmetics industry includes companies providing beauty and personal care products. Players in the industry manufacture, distribute, sell and market skincare, fragrance, makeup and hair care products. Many firms in the space market via sales representatives, whereas some sell products through retailers, independent and chain drug stores and pharmacies, upscale perfumeries, department stores and beauty salons.The companies also operate through retailer websites, third-party distributors and in-flight and duty-free shops. Some of the products offered by the industry participants include moisturizers, serums, toners and cleansers under skincare; perfume sprays, candles and soaps under fragrance; lipsticks, mascaras, powders, eye shadows, foundation and nail polishes under makeup; and shampoos, conditioner and hair color products under hair care.Trends Shaping the Future of the Cosmetics IndustryInflationary Headwinds: Companies in the cosmetics space are encountering inflationary pressure on operating costs, including labor, supplies and travel, among others. Several players continue to battle supply-chain disruptions stemming from port congestion, increasing freight prices and wide-scale shortages of materials. Rising costs, higher interest rates and increasing household debt are compelling consumers to cut down on discretionary purchases, thus impacting demand for the players.Story continuesVolatile Currency Movements: Several industry players remain vulnerable to unfavorable currency movements due to their exposure to international markets. This is because a strengthening U.S. dollar may require a company to either raise prices or contract profit margins in locations outside the United States. Some industry players expect adverse currency fluctuations to affect their performances in 2023.Innovation & Digitization – Major Drivers: Consumers keep looking for unique product offerings incorporating the latest technologies and expert scientific formulations in the beauty and skincare space. Focus on resonating with consumers' ever-changing preferences has kept cosmetic players occupied in terms of innovation and product launches. Increased consumer awareness has also stimulated demand for organic skincare and "clean beauty" products.Further, Cosmetic players' foremost priority has been to broaden their market reach by boosting e-commerce capabilities. Companies in the space have made significant progress, evident from tools like virtual try, new digital payment solutions and digital marketing efforts. Players have also been fueling brand portfolios through prudent buyouts and strategic alliances. Such upsides are likely to continue supporting the top-line performance of cosmetics companies.Zacks Industry Rank Indicates Dull ProspectsThe Zacks Cosmetics industry is housed within the broader Zacks Consumer Staples sector. The industry currently carries a Zacks Industry Rank #189, which places it in the bottom 24% of more than 250 Zacks industries.The group's Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates solid near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.The industry's position in the bottom 50% of the Zacks-ranked industries results in a positive aggregate earnings outlook for the constituent companies. Looking at the aggregate earnings estimate revisions, it appears that analysts are gradually gaining confidence in this group's earnings growth potential. Since the beginning of May 2023, the industry's consensus earnings estimate for the current financial year has fallen 16.1%.Before we present a few stocks that you may want to consider for your portfolio, let's look at the industry's recent stock-market performance and valuation picture.Industry Vs. Broader MarketThe Zacks Cosmetics industry has underperformed the Zacks S&P 500 composite and the broader Zacks Consumer Staples sector over the past year.The industry has declined 25.9% over this period compared with the S&P 500's growth of 12.4%. The broader sector has moved down 3.2% in the said time frame.Industry's Current ValuationOn the basis of forward 12-month Price-to-earnings (P/E), which is commonly used for valuing consumer staples stocks, the industry is currently trading at 29.18X compared with the S&P 500's 19.36X and the sector's 17.33X.In the past five years, the industry has traded as high as 45.92X, as low as 19.64X, and at the median of 30.55X.4 Cosmetic Stocks Worth WatchingInter Parfums: The Zacks Rank #1 (Strong Buy) company manufactures, distributes and markets a wide range of fragrances and related products. Inter Parfums is benefiting from solid growth across European and U.S. operations, courtesy of the impressive performance of its brands. IPAR is reaping benefits from the booming fragrance market globally.The company is expanding its business through new licenses or acquisitions. Management's focus on innovation and product launches is a key driver. You can see the complete list of today's Zacks #1 Rank stocks here.The Zacks Consensus Estimate for IPAR's current fiscal year earnings per share (EPS) has moved up 4.1% to $4.55 in the past 30 days. Shares of Inter Parfums have dropped 0.3% in the past three months.Helen of Troy: The provider of consumer products across Beauty, Housewares and Health & Home segments, currently carries a Zacks Rank #2 (Buy). HELE is making significant investments in critical areas to continue driving growth. To this end, it invests in consumer-centric innovation, digital marketing and media, and enhanced production and distribution capacity, among others.Helen of Troy is progressing well with Project Pegasus, which aims to expand operating margins via improved efficiency and lower costs. The company's solid investments in its Leadership Brands, which is a portfolio of market-leading brands, are yielding.The Zacks Consensus Estimate for Helen of Troy's current fiscal year EPS has remained unchanged in the past 30 days at $8.86. The company's stock has increased 15.6% in the past three months. HELE has an expected EPS growth rate of 8% for three-five years.e.l.f. Beauty: The provider of cosmetic and skincare products carries a Zacks Rank #2. e.l.f. Beauty appears well-placed to benefit from its commitment to solidifying its brand portfolio through innovation. Focus on effective marketing strategies helps the company reach new audiences and penetrate new platforms. e.l.f. Beauty is undertaking significant investments in its digital business, which is yielding.The Zacks Consensus Estimate for ELF's current fiscal year EPS has increased by a penny in the past 30 days to $2.37. The company's stock has gained 26% in the past three months. ELF has an expected EPS growth rate of 21.7% for three-five years.Coty: The manufacturer, marketer and distributor of beauty products presently carries a Zacks Rank #3. Coty is benefiting from its focus on six strategic pillars aimed at sustainable growth, including expanding makeup brands and mass fragrances and establishing a strong skincare portfolio. The company is strengthening its e-commerce and direct-to-consumer capabilities. COTY is committed to optimizing the overall cost structure.The Zacks Consensus Estimate for Coty's current fiscal year EPS has moved down 6.3% in the past 30 days to 45 cents. COTY's stock has declined 5.4% in the past three months. COTY has an expected EPS growth rate of 2.8% for three-five years.Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.See Stocks Free >>Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch/Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.Media ContactZacks Investment Research800-767-3771 ext. [email protected]://www.zacks.comPast performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance  for information about the performance numbers displayed in this press release.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportHelen of Troy Limited (HELE) : Free Stock Analysis ReportInter Parfums, Inc. (IPAR) : Free Stock Analysis ReportCoty (COTY) : Free Stock Analysis Reporte.l.f. Beauty (ELF) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Zacks Industry Outlook Highlights Coty, e.l.f. Beauty, Inter Parfums and Helen of Troy

https://finance.yahoo.com/news/zacks-industry-outlook-highlights-coty-125300571.html

4ec0508c-0eac-3b82-8c28-cf21ae882394

CPB

Investors in Campbell Soup Company CPB need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 19, 2024 $20 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.What do the Analysts Think?Clearly, options traders are pricing in a big move for Campbell Soup shares, but what is the fundamental picture for the company? Currently, Campbell Soup is a Zacks Rank #3 (Hold) in the Food - Miscellaneous industry that ranks in the Bottom 40% of our Zacks Industry Rank. Over the last 30 days, two analysts have increased their earnings estimates for the current quarter, while three analysts have revised their estimates downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from $1 per share to 92 cents in that period.Given the way analysts feel about Campbell Soup right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.Looking to Trade Options?Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk.Click to see the trades now >>Story continuesWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportCampbell Soup Company (CPB) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Is the Options Market Predicting a Spike in Campbell Soup (CPB) Stock?

https://finance.yahoo.com/news/options-market-predicting-spike-campbell-123000068.html

76faf0eb-419b-39d6-aaf0-11aeb47e2b98

CPB

Kraft Heinz, Kellogg, General Mills, and other leading snack makers could serve up gains of 20% or more. Their healthy dividends are a plus.Continue reading

Barrons.com

These 6 Food Stocks Have Gotten Hit Hard. It’s Time to Chow Down.

https://finance.yahoo.com/m/cc1cdf93-0d3c-3b43-ae17-6fdbeb696dd8/these-6-food-stocks-have.html

cc1cdf93-0d3c-3b43-ae17-6fdbeb696dd8

CPRT

Investors should be girding themselves for next Thursday's results for the August-ended quarter after the close.Continue reading

Investor's Business Daily

Adobe Stock, Already At Year's Highs, Faces Earnings Test; Oracle, Lennar Also On Earnings Calendar

https://finance.yahoo.com/m/e5e7f1de-f9d4-3b4f-82a9-8e5982686886/adobe-stock-already-at.html

e5e7f1de-f9d4-3b4f-82a9-8e5982686886

CPRT

Copart, Inc. (CPRT) closed at $44.60 in the latest trading session, marking a -1.91% move from the prior day. This move lagged the S&P 500's daily loss of 0.32%. At the same time, the Dow added 0.17%, and the tech-heavy Nasdaq lost 0.89%.Prior to today's trading, shares of the company had gained 4.09% over the past month. This has outpaced the Business Services sector's loss of 0.45% and the S&P 500's loss of 0.12% in that time.Copart, Inc. will be looking to display strength as it nears its next earnings release, which is expected to be September 14, 2023. On that day, Copart, Inc. is projected to report earnings of $0.31 per share, which would represent year-over-year growth of 10.71%. Our most recent consensus estimate is calling for quarterly revenue of $950.04 million, up 7.55% from the year-ago period.It is also important to note the recent changes to analyst estimates for Copart, Inc.Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Copart, Inc. is holding a Zacks Rank of #2 (Buy) right now.Investors should also note Copart, Inc.'s current valuation metrics, including its Forward P/E ratio of 33.73. For comparison, its industry has an average Forward P/E of 33.73, which means Copart, Inc. is trading at a no noticeable deviation to the group.Story continuesThe Auction and Valuation Services industry is part of the Business Services sector. This group has a Zacks Industry Rank of 6, putting it in the top 3% of all 250+ industries.The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.You can find more information on all of these metrics, and much more, on Zacks.com.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportCopart, Inc. (CPRT) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Copart, Inc. (CPRT) Dips More Than Broader Markets: What You Should Know

https://finance.yahoo.com/news/copart-inc-cprt-dips-more-220020876.html

458708c0-7196-3a07-a840-a0095c1ef8ba

CPT

During the COVID crisis, America saw an exodus from its major population centers in the Northeast and West to the South and the Sun Belt.Cities like Miami, Tampa, Dallas and Austin all offered lower costs of living while still having many of the cultural attractions as other big cities. As a result, their real estate markets exploded. The obvious play for real estate investors might be apartment REITs with assets concentrated in the Sun Belt.Mid-America Apartment Communities Inc. (NYSE:MAA) is an S&P 500 company with a heavy concentration in the Sun Belt. Over 55% of its portfolio is in Texas, Florida and Georgia.Camden Property Trust (NYSE:CPT) is another S&P 500 REIT that has invested heavily in the Sun Belt. More than half of the company's net operating income (NOI) is derived from major markets in Florida, Georgia and Texas.But there is another investment opportunity that is gaining popularity, especially as the stock market has become increasingly volatile. Private market real estate funds and fractional investing allow retail investors to be more selective in the specific markets and properties they invest in.One investment platform even allows individuals to invest in the growth of specific cities. While the median sale price of homes across the U.S. is up only 1.8% year-over-year, according to data from Redfin, prices in markets like Dallas and Miami are up 5.2% and 10.4%, respectively.Trending: Elon Musk has reportedly bought 6,000 acres of land just outside of Austin. Here’s how to invest in the city’s growth before he floods it with new tech workers.Retail investors can also choose to buy shares of specific long-term and short-term rental properties in several markets across the U.S. In fact, Jeff Bezos made an early investment in a company that offers shares of rental properties with a minimum investment of only $100.The benefit to these types of investments is that their performance isn't tied to the stock market. Share prices of private funds and fractional investments is directly related to the value of the assets and the income they continue to generate.Story continuesThe downside, however, to some investors is the available liquidity. Redemption options are often limited within the target investment term. While this helps protect the long-term value of the investment, it's important that investors only contribute capital that they're comfortable leaving tied up for five years or more.Read next:Investing in real estate just got a whole lot simpler. With as little as $100, average investors are becoming landlords thanks to this Jeff Bezos-backed startup.Blackstone made a $13 billion bet on the growth in student housing. Here's how you can carve out your own piece of the student housing market with just $500.Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.This article America Is A Nation On The Move. Here's How Investors Can Profit From It originally appeared on Benzinga.com.© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Benzinga

America Is A Nation On The Move. Here's How Investors Can Profit From It

https://finance.yahoo.com/news/america-nation-move-heres-investors-183639749.html

6969e17e-8ef4-3d00-b7ae-ab1372372704

CPT

HOUSTON, September 07, 2023--(BUSINESS WIRE)--Camden Property Trust (NYSE:CPT) (the "Company") announced today that the Company will participate in the BofA Securities 2023 Global Real Estate Conference to be held September 12 – 13, 2023. Camden’s presentation has been scheduled for Tuesday, September 12, 2023, at 3:40 PM Eastern Time. The event will be webcast live in a listen-only mode at camdenliving.com in the Investors section, and an audio archive will be available on the Company’s website shortly after the event concludes. A copy of Camden’s most recent investor presentation will also be available in the Investors section of the Company’s website.The Company also provided operating statistics for third quarter 2023 as detailed below.Same Property Occupancy2Q23Jul 2023Aug 2023Occupancy95.4%95.6%95.8%Same Property New Lease and Renewal Data – Date Signed(1)2Q23Jul 2023Aug 2023New Lease Rates2.2%1.4%0.0%Renewal Rates5.9%5.2%4.9%Blended Rates4.1%3.3%2.3%Same Property New Lease and Renewal Date – Date Effective(2)2Q23July 2023Aug 2023New Lease Rates2.2%2.0%1.0%Renewal Rates6.3%6.3%6.0%Blended Rates4.0%4.1%3.6%(1) Average change in same property new lease and renewal rates vs. expiring lease rates when signed.(2) Average change in same property new lease and renewal rates vs. expiring lease rates when effective.Camden Property Trust, an S&P 500 Company, is a real estate company primarily engaged in the ownership, management, development, redevelopment, acquisition, and construction of multifamily apartment communities. Camden owns interests in and operates 172 properties containing 58,961 apartment homes across the United States. Upon completion of 5 properties currently under development, the Company’s portfolio will increase to 60,514 apartment homes in 177 properties. Camden has been recognized as one of the 100 Best Companies to Work For® by FORTUNE magazine for 16 consecutive years, most recently ranking #33.Story continuesFor additional information, please contact Camden’s Investor Relations Department at (713) 354-2787 or access our website at camdenliving.com.View source version on businesswire.com: https://www.businesswire.com/news/home/20230907025843/en/ContactsKim Callahan, 713-354-2549

Business Wire

Camden Property Trust Announces Participation in BofA Securities 2023 Global Real Estate Conference and Provides Third Quarter 2023 Operating Update

https://finance.yahoo.com/news/camden-property-trust-announces-participation-210000914.html

976e7bb6-1f8d-371c-bcaa-08301769b079

CPTN

SAN JOSE, Calif., August 31, 2023--(BUSINESS WIRE)--Cepton, Inc. ("Cepton") (Nasdaq: CPTN), a Silicon Valley innovator and leader in high performance lidar solutions, announced today its participation in the following investor conferences in September 2023:RBC Global Industrials ConferenceDate: Tuesday – Wednesday, September 12 – 13, 2023Location: Las Vegas, NVParticipants: Hull Xu, Chief Financial Officer, and Mitch Hourtienne, Senior VP of Business DevelopmentPresentation: Cepton is scheduled to present at 8:35 – 9:05 a.m. PDT on September 13.Northland Capital Markets Institutional Investor ConferenceDate: Tuesday, September 19, 2023Location: virtualParticipants: Dr. Jun Pei, Chief Executive Officer, and Hull Xu, Chief Financial OfficerCepton management will be available for one-on-one or group investor meetings at the above-mentioned investor conferences. Please contact your RBC or Northland Capital representatives or email [email protected] for additional information.About CeptonCepton is a Silicon Valley innovator of lidar-based solutions for automotive (ADAS/AV), smart cities, smart spaces, and smart industrial applications. With its patented lidar technology, Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D perception solutions across industries.Cepton has been awarded a significant ADAS lidar series production award with Koito on the General Motors business. Cepton is also engaged with all Top 10 global OEMs.Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, CA and has a center of excellence facility in Troy, MI to provide local support to automotive customers in the Metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow Cepton on Twitter and LinkedIn.Story continuesView source version on businesswire.com: https://www.businesswire.com/news/home/20230831755158/en/ContactsCepton, Inc. Contacts Investors: [email protected] Media: Faithy Li, [email protected]

Business Wire

Cepton, Inc. Announces Participation in September 2023 Investor Conferences

https://finance.yahoo.com/news/cepton-inc-announces-participation-september-130000530.html

b0f0de11-07ef-38a6-9790-ddcb96491eec

CPTN

Vancouver --News Direct-- Cepton IncThis content is not available due to your privacy preferences.Update your settings here to see it.Cepton, Inc co-founder and CEO Dr Jun Pei joined Steve Darling from Proactive to delve into the convergence of lidar technology and eye safety.Addressing concerns about lidar impact on human eyes and its role in eye safety, Dr Pei outlined the company's approach to ensuring safety standards are met. He emphasized that all devices placed on vehicles must adhere to regulatory eye safety standards. He also clarified misconceptions about the impact of different wavelengths on safety, highlighting that safety involves a combination of factors including power, pulse rate, and exposure time, in addition to wavelengths.Dr Pei pointed out that Cepton choice of 905nm wavelengths for its lidar technology is not only for safety but also due to other advantages, such as lower power consumption and reduced heat generation, which align with AI safety thresholds. When communicating with customers, he underscored the significance of third-party certification and data-driven evidence as assurances of safety. This approach aligns with Cepton commitment to providing reliable and safe products.Discussing lidar's performance in various weather conditions, he explained that the technology operates in the near-infrared range, which extends visibility slightly beyond that of cameras. While lidar can penetrate rain and fog to some extent, he cautioned against relying solely on automation, particularly in extreme weather conditions.Dr Pei shared insights into Cepton design choices, specifically the use of 905nm lasers. He mentioned the maturity and safety of this choice and discussed how Cepton regulates emitted light and adjusts receiver lens size based on external light conditions, enhancing the overall functionality and safety of its lidar technology.Contact DetailsProactive Investors+1 [email protected] source version on newsdirect.com: https://newsdirect.com/news/lidar-and-eye-safety-explained-by-cepton-ceo-dr-jun-pei-905314063

News Direct

Lidar and eye safety explained by Cepton CEO Dr Jun Pei

https://finance.yahoo.com/news/lidar-eye-safety-explained-cepton-170513573.html

d397957f-cf1d-3837-a832-26e36b81fd02

CRAI

BOSTON, September 05, 2023--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that the Company will participate in the 16th Annual Barrington Research Virtual Fall Investment Conference on Thursday, September 14, 2023. CRA Chairman and Chief Executive Officer Paul Maleh, Chief Financial Officer Daniel Mahoney, and Chief Corporate Development Officer Chad Holmes will be available for virtual one-on-one investor meetings.About Charles River Associates (CRA)Charles River Associates® is a leading global consulting firm specializing in economic, financial, and management consulting services. CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides corporations through critical business strategy and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. Headquartered in Boston, CRA has offices throughout the world. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at www.crai.com. Follow us on LinkedIn, Twitter, and Facebook.View source version on businesswire.com: https://www.businesswire.com/news/home/20230901748383/en/ContactsDaniel MahoneyChief Financial OfficerCharles River Associates617-425-3505Nicholas ManganaroSharon Merrill Associates, [email protected] 617-542-5300

Business Wire

Charles River Associates (CRA) to Participate in Barrington Research Virtual Fall Investment Conference

https://finance.yahoo.com/news/charles-river-associates-cra-participate-123000064.html

6a56c6b9-9444-3183-a120-cd13236738d2

CRAI

Consulting services is one of the industries least affected by the pandemic. This is because even in a volatile situation, organizations require extensive advice on how to protect their employees, and stay closer to consumers and shareholders. The multi-billion-dollar industry has witnessed exponential growth since the 2008 financial crisis, enjoying a steady rate of revenues, profits, and cash-flow growth.The Zacks-defined consulting services industry is currently in the top 36% of the Zacks Industry Rank. Year to date, the industry has provided 22.7% returns, well above the 17.2% return provided by the market’s benchmark — the S&P 500 Index. Since it is ranked in the top half of Zacks Ranked Industries, we expect the consulting services industry to outperform the market over the next 3 to 6 months.The industry is in good shape, driven by a healthy demand environment for services. The U.S. economy remains solid despite the continuous hiking of interest rate in the last one and a half years by the Fed. This industry is one of the pioneers of remote working, which has become part of the new normal. The nature of work enables industry players to function efficiently through the increased use of technology.With the end of the pandemic, the focus of the industry is currently on channeling money and efforts to more effective operational components, such as high-end technology, digital transformation, and data-driven decision-making.Services are becoming more customer-centric through higher speed, incremental deliverables, and cloud technology. So, the consulting services industry is likely to witness healthy growth on internationalization and expansion of newer verticals, such as design thinking, digital and cybersecurity.According to NMS Consulting, the market size of the management consulting industry is estimated to reach $330 billion globally in 2023. In the United States the industry has reached $65 billion with a growth rate of 7.7% per annum.Story continuesStocks in FocusAt this stage, several stocks look attractive for future growth. However, a three-pronged picking method will make the task easy. First, select stocks with strong revenue and earnings potential for the rest of 2023. Second, these stocks have seen positive earnings revisions in the last 60 days. Third, each of our picks carries either a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here.The chart below shows the price performance of five stock mentioned below in the past three months.Zacks Investment ResearchImage Source: Zacks Investment ResearchHuron Consulting Group Inc. HURN is the parent company of Huron Consulting Services LLC, an independent provider of financial and operational consulting services. HURN’s experienced and credentialed professionals use their expertise in accounting, finance, economics, and operations to serve a wide variety of both financially sound and distressed organizations. HURN operates through three segments: Healthcare, Education, and Commercial.Zacks Rank #1 Huron Consulting Group has an expected revenue and earnings growth rate of 17% and 31.8%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 9.4% over the last 60 days.Accenture plc ACN has been steadily gaining traction in its outsourcing and consulting businesses backed by high demand for services that can improve operating efficiencies and save costs. ACN has been strategically enhancing its cloud and digital marketing suite through buyouts and partnerships. ACN’s strong operating cash flow has helped it reward shareholders in the form of dividend payments and share repurchases, and pursue opportunities in areas that show true potential.Zacks Rank #2 Accenture has an expected revenue and earnings growth rate of 4.5% and 6.7%, respectively, for the current year (ending August 2024). The Zacks Consensus Estimate for current-year earnings has improved 0.1% over the last 60 days.Franklin Covey Co. FC provides training and consulting services in the areas of execution, sales performance, productivity, customer loyalty, and educational improvement for organizations and individuals worldwide. FC operates through three segments: Direct Offices, International Licensees, and Education Practice. FC also provides a suite of individual-effectiveness and leadership-development training and products.Zacks Rank #3 Franklin Covey has an expected revenue and earnings growth rate of 10.5% and 32.1%, respectively, for the current year (ending August 2024). The Zacks Consensus Estimate for current-year earnings has improved 11.6% over the last 60 days..Stantec Inc STN provides professional consulting services in the areas of infrastructure and facilities to the public and private sectors clients in Canada, the United States, and internationally. STN provides consulting services in engineering, architecture, interior design, landscape architecture, surveying, environmental sciences, project management, and project economics.STN also offers planning and design consulting services to clients in residential, logistics, retail, infrastructure, energy, higher education, and urban regeneration sectors; architectural and interior design, and planning services in the science and technology, commercial workplace, higher education, residential, and hospitality markets.Zacks Rank #3 Stantec has an expected revenue and earnings growth rate of 7.5% and 13.4%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.8% over the last 60 days.Charles River Associates (CRAI) has a widely-diversified business with service offerings across areas of functional expertise, client base and geographical regions. Solid international network provides CRAI the opportunity to work with the world's leading professionals on multiple issues. CRAI’s professional team has helped it maintain solid reputation of premium consulting services.Zacks Rank #2 Charles River Associates has an expected revenue and earnings growth rate of 5.3% and 12.8%, respectively, for the next year. The Zacks Consensus Estimate for current-year earnings has improved 1.1% over the last 30 days.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportAccenture PLC (ACN) : Free Stock Analysis ReportCharles River Associates (CRAI) : Free Stock Analysis ReportHuron Consulting Group Inc. (HURN) : Free Stock Analysis ReportStantec Inc. (STN) : Free Stock Analysis ReportFranklin Covey Company (FC) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

5 Stocks to Gain From a Thriving Consulting Services Industry

https://finance.yahoo.com/news/5-stocks-gain-thriving-consulting-115600460.html

46c3c68f-330f-3395-8abc-899f972520bd

CRDF

- New lead program in first-line RAS-mutated metastatic colorectal cancer (mCRC) and expanded Pfizer relationship; interim topline data expected in mid-2024 -- Advance to first-line mCRC follows strong signal from new clinical and preclinical findings and guidance from FDA, and represents an increased market opportunity -- Cash, cash equivalents, and short-term investments of approximately $89.4 million as of June 30, 2023, projected runway into 2025 -SAN DIEGO, Aug. 9, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the second quarter ended June 30, 2023, and provided a business update.Cardiff Oncology, Inc. (PRNewsfoto/Cardiff Oncology, Inc.)"2023 has been transformative for Cardiff Oncology, highlighted by the advancement of our lead program to the first-line mCRC setting and an expansion of our relationship with Pfizer," said Mark Erlander, Ph.D., Chief Executive Officer of Cardiff Oncology. "The shifting of our clinical development program to the first-line was a data-driven decision based on a strong signal from new clinical and preclinical findings, with agreement from the FDA. There are 48,000 new patients in the U.S. annually in the first-line RAS-mutated mCRC setting, with no ongoing clinical trials or new treatments approved in the past 20 years. We believe that there is a tremendous opportunity for onvansertib to provide a meaningful benefit to a substantial number of patients who are fighting cancer in challenging indications. Looking ahead, we anticipate commencing enrollment in our first-line trial this fall with interim topline data expected in mid-2024."Upcoming expected milestonesmPDAC data readout from Phase 2 trial expected in Q3 '23SCLC data readout from Phase 2 trial expected in Q3 '23 (investigator-initiated trial with UPMC)First patient dosed in first-line mCRC trial expected fall '23TNBC data readout from Phase 1b/2 trial expected Q4 '23/Q1 '24 (investigator-initiated trial with Dana-Farber Cancer Institute)First-line mCRC randomized data readout expected in mid-2024Story continuesCompany highlights for the quarter ended June 30, 2023 and resent announcements Announced new lead program in mCRC and expanded Pfizer relationship.Cardiff Oncology will initiate a first-line trial, CRDF-004, a Phase 2 randomized trial generating preliminary safety and efficacy data and evaluating two different doses of onvansertib to confirm an optimal dose. Onvansertib will be added to standard-of-care consisting of FOLFIRI plus bevacizumab, or FOLFOX plus bevacizumab.Contingent upon the results of CRDF-004, Cardiff Oncology will initiate CRDF-005, a Phase 3, randomized trial with registrational intent. The FDA has agreed that a seamless trial with objective response rate at an interim point is an acceptable endpoint to pursue accelerated approval, with progression-free survival and trend in overall survival being the endpoints for full approval.Pfizer Ignite will be responsible for the clinical execution of the CRDF-004 trail, leveraging Pfizer's significant R&D capabilities, scale and expertise.Our new partnership with Pfizer Ignite expands the relationship established in November 2021 when Pfizer made an equity investment in Cardiff Oncology and nominated Adam Schayowitz, Ph.D., Vice President & Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and Melanoma, Pfizer Global Product Development as a Scientific Advisory Board member.Second Quarter 2023 Financial Results Liquidity, cash burn, and cash runwayAs of June 30, 2023, Cardiff Oncology had approximately $89.4 million in cash, cash equivalents, and short-term investments.Net cash used in operating activities for the second quarter of 2023 was approximately $7.1 million, an increase of approximately $0.4 million from $6.7 million for the same period in 2022.Based on its current expectations and projections, the Company believes its current cash resources are sufficient to fund its operations into 2025.Operating resultsTotal operating expenses were approximately $12.3 million for the three months ended June 30, 2023, an increase of $1.8 million from $10.5 million for the same period in 2022. The increase in operating expenses was primarily due to higher salaries and staff costs primarily due to increased headcount and stock-based compensation for additional grants to employees.About Cardiff Oncology, Inc.Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.Forward-Looking StatementsCertain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended December 31, 2022, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.Cardiff Oncology Contact:James Levine Chief Financial Officer 858-952-7670 [email protected] Contact:  Kiki Patel, PharmD  Gilmartin Group  [email protected] Contact:  Richa Kumari Taft Communications  551 344-5592   [email protected] Oncology, Inc.Condensed Statements of Operations(in thousands, except for per share amounts)(unaudited)Three Months Ended June 30,Six Months Ended June 30,2023202220232022Royalty revenues$                108$                   91$                 191$                 165Costs and expenses:Research and development8,0207,44817,07214,656Selling, general and administrative4,2963,0867,3797,026Total operating expenses12,31610,53424,45121,682Loss from operations(12,208)(10,443)(24,260)(21,517)Interest income, net1,0532531,993383Other income (expense), net5(253)(106)(302)Net loss (11,150)(10,443)(22,373)(21,436)Preferred stock dividend(6)(6)(12)(12)Net loss attributable to common stockholders$         (11,156)$          (10,449)$          (22,385)$          (21,448)Net loss per common share — basic and diluted$              (0.25)$              (0.24)$              (0.50)$              (0.50)Weighted-average shares outstanding — basic and diluted44,67743,30644,67743,269 Cardiff Oncology, Inc.Condensed Balance Sheets(in thousands)(unaudited)June 30, 2023December 31, 2022AssetsCurrent assets:Cash and cash equivalents$                  19,369$                  16,347Short-term investments70,05988,920Accounts receivable and unbilled receivable161771Prepaid expenses and other current assets3,1425,246Total current assets92,731111,284Property and equipment, net1,3561,269Operating lease right-of-use assets1,9782,251Other assets1,3901,387Total Assets$                  97,455$                116,191Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable$                     2,939$                     1,956Accrued liabilities5,5015,177Operating lease liabilities683675Total current liabilities9,1237,808Operating lease liabilities, net of current portion1,7532,040Total Liabilities10,8769,848Stockholders' equity86,579106,343Total liabilities and stockholders' equity$                  97,455$                116,191 Cardiff Oncology, Inc.Condensed Statements of Cash Flows(in thousands)(unaudited)Six Months Ended June 30,20232022Operating activitiesNet loss$          (22,373)$          (21,436)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation18869Stock-based compensation expense2,6452,207Amortization of premiums on short-term investments(405)557Release of clinical trial funding commitment—139Changes in operating assets and liabilities4,1541,520Net cash used in operating activities(15,791)(16,944)Investing activities:Capital expenditures(259)(412)Net purchases, maturities and sales of short-term investments19,07226,378Net cash provided by investing activities18,81325,966Financing activities:Net cash provided by financing activities——Net change in cash and cash equivalents3,0229,022Cash and cash equivalents—Beginning of period16,34711,943Cash and cash equivalents—End of period$           19,369$           20,965 CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-reports-second-quarter-2023-results-and-provides-business-update-301897225.htmlSOURCE Cardiff Oncology, Inc.

PR Newswire

Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update

https://finance.yahoo.com/news/cardiff-oncology-reports-second-quarter-200500268.html

c69043ef-ee04-37ea-bec6-153911372f6c

CRDF

SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that company management will present at the Baird Global Healthcare Conference on September 12, 2023 and the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023.Cardiff Oncology, Inc. (PRNewsfoto/Cardiff Oncology, Inc.)Details of the presentations can be found below.Baird Global Healthcare Conference [only available to live participants]Location: InterContinental New York BarclayPresenter: Mark Erlander, CEOFormat: Fireside ChatDate: 09/12/2023Time: 9:05 AM ETH.C. Wainwright 25th Annual Global Investment ConferenceLocation: Lotte New York Palace HotelPresenter: Mark Erlander, CEOFormat: Company PresentationDate: 09/13/2023Time: 11:30 AM ETInterested parties can register for and access the live webcast for H.C. Wainwright by visiting the "Events" section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.About Cardiff Oncology, Inc.Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.Story continuesCardiff Oncology Contact:James LevineChief Financial [email protected] Contact:Kiki Patel, PharmD Gilmartin [email protected] Contact:Richa KumariTaft Communications551 344-5592 [email protected] CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september-301916201.htmlSOURCE Cardiff Oncology, Inc.

PR Newswire

Cardiff Oncology to Present at Upcoming Investor Conferences in September

https://finance.yahoo.com/news/cardiff-oncology-present-upcoming-investor-120000370.html

ff5a2f6c-7a20-3817-b244-a88fb2f97f4a

CREG

SMART POWERR CORP.XI’AN, China, May 26, 2023 (GLOBE NEWSWIRE) -- Smart Powerr Corp. (NASDAQ: CREG) (“CREG” or the “Company”), an industrial waste-to-energy solution provider in China, announced today that it received written notification from Listing Qualifications Department of The Nasdaq Stock Market LLC (the “Nasdaq”) that, as a result of not having timely filed its quarterly report on Form 10-Q for the year ended March 31, 2023 (the “Form 10-Q”), the Company does not comply with the Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the U.S. Securities and Exchange Commission (the “SEC”).Under the Nasdaq Listing Rule 5810(c)(2)(F)(i), the Company is required to submit its plan to regain compliance (the “Compliance Plan”) no later than July 24, 2023. If the plan is accepted by Nasdaq, CREG can be granted up to 180 calendar days from the Initial Delinquency Filing’s due date or until November 20, 2023, to regain compliance.The Company was unable to file its Form 10-Q by its original deadline without unreasonable effort or expense, and the Nasdaq notification has no immediate impact on the listing of the Company’s shares of common stock on the Nasdaq Capital Market.This announcement is made in compliance with the Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a notification of deficiency.About Smart Powerr Corp.Smart Powerr Corp. (Nasdaq: CREG) (“CREG” or “the Company”) is based in Xi’an, China and provides environmentally friendly waste-to-energy technologies to recycle industrial byproducts for steel mills, cement factories and coke plants in China. The byproducts include heat, steam, pressure, and exhaust, which we use to generate large amounts of lower-cost electricity and reduce the need for outside electrical sources. The Chinese government has adopted policies to encourage the use of recycling technologies to optimize resource allocation and reduce pollution. Currently, recycled energy represents only an estimated 1% of total energy consumption. The recycled energy resource market is viewed as a fast-growing market due to intensified environmental concerns and rising energy costs as Chinese economy continues to expand. The Company’s management and engineering teams have over 20 years of experience in industrial energy recovery in China. For more information about CREG, please visit http://smartpowerr.com.Story continuesSafe Harbor StatementThis press release may contain certain “forward-looking statements” relating to the business of CREG and its subsidiary companies. All statements, other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including, but not limited to, the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions relating to the registered direct offering and those discussed in the Company’s annual and periodic reports that are filed with the Securities and Exchange Commission and available on its website at http://www.sec.gov. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.For more information, please contact:Mr. Jackie Shi,VP & Chief Financial OfficerSmart Powerr Corp.Tel: +86- 139 9287 0723Email: [email protected] / [email protected]

GlobeNewswire

Smart Powerr Corp. Receives Notice of Filing Delinquency From Nasdaq

https://finance.yahoo.com/news/smart-powerr-corp-receives-notice-203000109.html

fe5e18a7-50a7-3c9b-93e7-1486cd97cb86

CREG

SMART POWERR CORP.XI'AN, China, June 26, 2023 (GLOBE NEWSWIRE) --  Smart Powerr Corp. (NASDAQ: CREG) ("CREG" or the “Company"), an industrial waste-to-energy solution provider in China, today announced that it received a notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (the “Nasdaq”) that, based on the Company’s filings of Form 10-Q for the period ended March 31, 2023 on June 21, 2023, Nasdaq has determined that the Company complies with its Listing Rule 5250(c)(1) (the “Listing Rule”).On June 21, 2023, the Company filed its quarterly reports on Form 10-Q for the periods ended March 31, 2023. Accordingly, Nasdaq has determined that the Company complies with the Listing Rule and closed the matter.About Smart Powerr Corp.Smart Powerr Corp. (Nasdaq: CREG) ("CREG" or "the Company") is based in Xi'an, China and provides environmentally friendly waste-to-energy technologies to recycle industrial byproducts for steel mills, cement factories and coke plants in China. The byproducts include heat, steam, pressure, and exhaust, which we use to generate large amounts of lower-cost electricity and reduce the need for outside electrical sources. The Chinese government has adopted policies to encourage the use of recycling technologies to optimize resource allocation and reduce pollution. Currently, recycled energy represents only an estimated 1% of total energy consumption. The recycled energy resource market is viewed as a fast-growing market due to intensified environmental concerns and rising energy costs as Chinese economy continues to expand. The Company’s management and engineering teams have over 20 years of experience in industrial energy recovery in China. For more information about CREG, please visit http://creg-cn.comSafe Harbor StatementThis press release may contain certain "forward-looking statements" relating to the business of CREG and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including, but not limited to, the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions relating to the registered direct offering and those discussed in the Company's annual and periodic reports that are filed with the Securities and Exchange Commission and available on its website at http://www.sec.gov. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.Story continuesFor more information, please contact:Mr. Jackie Shi,VP & Chief Financial OfficerSmart Powerr Corp.Tel: +86- 139 9287 0723 Email: [email protected] / [email protected]

GlobeNewswire

Smart Powerr Corp. Regains Compliance with NASDAQ

https://finance.yahoo.com/news/smart-powerr-corp-regains-compliance-203000095.html

57ca98ca-eb35-3bb8-8790-dc0718cd80e0

CRIS

Curis, Inc. (NASDAQ:CRIS) Q2 2023 Earnings Call Transcript August 3, 2023Curis, Inc. misses on earnings expectations. Reported EPS is $-0.12 EPS, expectations were $0.12.Operator: Good afternoon and welcome to the Curis’ Second Quarter 2023 Business Update Call. All participants will be in a listen-only mode. [Operator Instructions] After the company's prepared remarks, call participants will have the opportunity to ask a question. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Diantha Duvall, Curis’ Chief Financial Officer. Ms. Diantha, please go ahead.Diantha Duvall: Thank you, and welcome to Curis’ second quarter 2023 business update call. Before we begin, I would like to encourage everyone to go to the Investors section of our website at www.curis.com to find our second quarter 2023 business update release and related financial tables. I would also like to remind everyone that during the call, we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and actual results may differ materially. For additional details, please see our SEC filings. Joining me on today's call are Jim Dentzer, President and Chief Executive Officer; and Jonathan Zung, Chief Development Officer. We will also be available for a question-and-answer period at the end of our call. I'd now like to turn the call over to Jim.Jim Dentzer: Thank you, Diantha. Good afternoon everyone, and welcome to Curis’ second quarter business update call. Big news this quarter is of course the removal of the partial clinical hold on our TakeAim Leukemia study and getting that done a full quarter faster than we expected. It's a testament to the hard work of our team at Curis and the strong support of our clinical investigators. I'd like to take this moment to express my gratitude and appreciation to everyone involved. In our discussions with FDA, we were also able to confirm that 300 milligrams BID is the recommended Phase 2 dose for monotherapy in leukemia. With that confirmation, we're excited to announce that we are expanding monotherapy enrollment in the TakeAim Leukemia study at 300 milligrams BID for relapsed/refractory patients with spliceosome or FLT3 mutation.Story continuesIn addition, we're working with our clinical investigators on a frontline study combining emavusertib with azacitidine and venetoclax to treat all patients with AML regardless of their mutation status. We expect to have data from both the monotherapy and combination studies in 2024. Now let's transition to our TakeAim Lymphoma study where we're focusing on patients with primary CNS lymphoma. There's a high unmet need in this patient population and we believe combining emavusertib with ibrutinib could potentially address the problem of ibrutinib resistance and provide a meaningful new therapeutic option for these patients. We're currently enrolling patients and expect to have data in 2024. On the financial front, we were able to further strengthen our balance sheet with a $15 million equity financing achieved with no discount and no warrant coverage.I'm sure everyone on this call knows how rare this is in the current market. All-in-all, it was a terrific quarter for Curis and we're excited to be back in the clinic at the recommended Phase 2 dose of 300 milligrams and closely collaborating with our clinical investigators to develop a novel therapeutic with the potential to be a cornerstone therapy in heme malignancies. With that, I'll turn the call back over to Diantha to review our financial results for the quarter. Diantha?Health, Medicine, LifePhoto by national cancer institute on UnsplashDiantha Duvall: Thank you, Jim. Curis reported a net loss of $12 million or $0.12 per share as compared to a net loss of $15.9 million or $0.17 per share for the same period in 2022. Curis reported a net loss of $23.5 million or $0.24 per share for the six months ended June 30, 2023, as compared to a net loss of $32 million or $0.35 per share for the same period of 2022. Revenues for the second quarter of 2023 were $2.2 million as compared to $2.4 million for the same period in 2022. Revenues for the six months ended June 30, 2023 and 2022 were both $4.5 million. Research and development expenses were $10 million for the second quarter of 2023 as compared to $12.3 million for the same period in 2022. The decrease in research and development expenses for the quarter is primarily attributable to a decrease in personnel costs.Research and development expenses were $19.2 million for the six months ended June 30, 2023 as compared to $23.8 million for the same period in 2022. General and administrative expenses were $4.2 million for the second quarter of 2023 as compared to $5.1 million – excuse me, as compared to $5.1 million for the same period in 2022. The decrease in general and administrative expenses was driven primarily by a decrease in personnel costs. General and administrative expenses were $9 million for the six months ended June 30, 2023 as compared to $10.8 million for the same period in 2022. For the second quarter of 2023 other income net was $0.2 million as compared to other expense net of $0.9 million for the same period in 2022. The other income net was $0.2 million for the six month end of June 30, 2023 as compared to other expense net of $1.9 million for the same period in 2022.Other income and expense net primarily consists of interest income partially offset by expense related to future royalty payments. Including the proceeds from the July financing, Curis’ cash, cash equivalents and investments totaled $77.4 million and there were approximately 117.7 million shares of common stock outstanding. We continue to be in a strong cash position and expect that our existing cash, cash equivalents and investments should enable us to maintain our planned operations into 2025. With that, I’d like to turn the call over for questions. Operator?See also 25 Best Vacations for Single Guys to Get Laid and 50 Perfume Award Winners In The Last 10 Years.To continue reading the Q&A session, please click here.

Insider Monkey

Curis, Inc. (NASDAQ:CRIS) Q2 2023 Earnings Call Transcript

https://finance.yahoo.com/news/curis-inc-nasdaq-cris-q2-095744137.html

7bdc9182-ad18-349e-be95-3d169b6878f0

CRIS

LEXINGTON, Mass., Sept. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences:(PRNewsfoto/Curis, Inc.)The H.C. Wainwright 25th Annual Global Investment Conference being held September 11 – 13, 2023. Presentation details are as follows:Format: Company PresentationDate: Tuesday, September 12, 2023Time: 8:30am ETThe 2023 Cantor Global Healthcare Conference being held September 26 – 28, 2023. Presentation details are as follows:Format: Panel PresentationDate: Wednesday, September 27, 2023Time: 9:10am ETWebcasts will be available on the Curis website at www.curis.com in the 'Investors' section.About Curis, Inc.Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, emavusertib (CA-4948). Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with hematologic malignancies, such as non-Hodgkin's lymphoma and other B cell malignancies, both as a monotherapy and in combination with BTK inhibitor ibrutinib, and the Phase 1/2 TakeAim Leukemia study in patients with acute myeloid leukemia and myelodysplastic syndrome, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.Story continuesCisionView original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-healthcare-conferences-in-september-301919160.htmlSOURCE Curis, Inc.

PR Newswire

Curis to Present at Upcoming Healthcare Conferences in September

https://finance.yahoo.com/news/curis-present-upcoming-healthcare-conferences-121300151.html

3c6e6af7-e24b-31db-a680-6b57370d81cd

CRL

Charles River Laboratories International, Inc. CRL is well-poised for growth in the coming quarters, backed by RMS segment continued growth benefitted from broad-based growth in all geographic regions for small research models. Further, the CRADL initiative is contributing to the growth rate. However, stiff competition and foreign exchange headwinds do not bode well for Charles River.In the past year, this Zacks Rank #3 (Hold) stock has lost 2% compared with a 14.1% decline of the industry. However, the S&P 500 composite registered a 13.1% rise in the same time frame.Operating as a full-service, early-stage contract research organization, Charles River has a market capitalization of $10.47 billion. The company has a long-term growth rate of 10.6% compared with the industry’s 13.5%.Let’s delve deeper.Growth CatalystRMS Business Rebounds: The RMS segment continues to benefit from broad-based growth in all geographic regions for small research models. Further, the company is showing strong growth within the end sourcing solutions business led by the CRADL operations or Charles River Accelerator and Development Labs initiative. Global biopharmaceutical companies, small and midsized biotechs and academic and government accounts significantly contributed to the growth rate. At the beginning of 2023, the company was facing a dull performance in China.DSA Arm Continues to Thrive: Charles River is currently the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide. The company is gaining from its extensive expertise in discovering preclinical candidates and in the design, execution and reporting of safety assessment studies for numerous compounds, including cell and gene therapies and small and large-molecule pharmaceuticals.Upbeat Guidance: For 2023, CRL’s revenue growth is now expected in the band of 2.5-4.5% (from the earlier band of 2-4.5%) on a reported basis. Organic revenue growth is expected to be 5.5-7.5% (5-7.5%). The Zacks Consensus Estimate for total revenues is pegged at $4.11 billion, indicating a 3.4% rise from 2022.Story continuesZacks Investment ResearchImage Source: Zacks Investment ResearchAdjusted earnings per share for 2023 are now expected in the range of $10.30-$10.90 ($9.90-$10.90). The current Zacks Consensus Estimate is pegged at $10.33DownsidesForeign Exchange Translation Impacts Sales: Foreign exchange is a significant headwind for Charles River due to a considerable percentage of its revenues coming from outside the United States. The strengthening of the Euro and some other developed market currencies has constantly hampered the company’s performance in the international markets.Competitive Landscape: Charles River competes in the marketplace based on its therapeutic and scientific expertise in early-stage drug research, quality, reputation, flexibility, responsiveness, pricing, innovation and global capabilities. The company primarily faces a broad range of competitors of different sizes and capabilities in its three business segments. For RMS, it has five main competitors: one is a government-funded, not-for-profit entity, one is privately held in Europe and three are privately held in the United States.Estimate TrendCharles River has been witnessing a positive estimate revision trend for 2023. The Zacks Consensus Estimate for its earnings has moved 1.6% north to $10.48 per share in the past 90 days.The Zacks Consensus Estimate for CRL’s 2023 revenues is pegged at $4.12 billion, suggesting a 3.6% rise from the year-ago reported number.Key PicksSome better-ranked stocks in the broader medical space are Haemonetics HAE, Quanterix QTRX and SiBone SIBN. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Haemonetics’ stock has risen 19.9% in the past year. Earnings estimates for Haemonetics have increased from $3.56 to $3.74 in 2023 and $3.96 to $4.07 in 2024 in the past 30 days. It currently sports a Zacks Rank #1.HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it posted an earnings surprise of 38.16%.Estimates for Quanterix’s 2023 loss per share have narrowed from $1.19 to 97 cents in the past 30 days. Shares of the company have increased 167.5% in the past year against the industry’s decline of 1.7%. It currently carries a Zacks Rank #2 (Buy).QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.Estimates for SiBone’s2023 loss have narrowed from $1.42 to $1.27 per share in the past 30 days. Shares of the company have increased 31% in the past year compared with the industry’s rise of 1.9%. It currently carries a Zacks Rank #2.SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 20.37%. In the last reported quarter, SiBone delivered an earnings surprise of 26.83%.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportHaemonetics Corporation (HAE) : Free Stock Analysis ReportCharles River Laboratories International, Inc. (CRL) : Free Stock Analysis ReportQuanterix Corporation (QTRX) : Free Stock Analysis ReportSiBone (SIBN) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Here's Why You Should Retain Charles River (CRL) Stock Now

https://finance.yahoo.com/news/heres-why-retain-charles-river-143500348.html

98c7cd39-ba67-3453-8048-ff8df8d569ba

CRL

It has been about a month since the last earnings report for Charles River Laboratories (CRL). Shares have lost about 6.1% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Charles River due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.Charles River Q2 Earnings Beat, Guidance NarrowedCharles Riverreported adjusted earnings per share of $2.69 for second-quarter 2023, reflecting a 2.9% decline from the year-ago earnings. The metric however surpassed the Zacks Consensus Estimate by 2.3%.On a GAAP basis, earnings declined 11.3% year over year to $1.89 per share.The year-over-year decline was primarily due to non-operating items, including increased interest expense and a higher tax rate as well as the impact of the Avian Vaccine divestiture.RevenuesRevenues in the second quarter totaled $1.06 billion, beating the Zacks Consensus Estimate by 1%. The top line improved 8.9% from the year-ago number (up 11.2% organically, excluding the impact of acquisition, divestiture and foreign currency translation).Segment in DetailCharles River’s second-quarter total Research Models and Services (RMS) revenues of $209.9 million were up 12.6% year over year (up 13.9% organically). Organic revenue growth was driven by broad-based growth of research models in all geographies, particularly in China, as well as research model services, primarily the Insourcing Solutions business. Our model estimated the RMS business to grow 9.2% on a reported basis (10% growth organically) in the second quarter.Discovery and Safety Assessment (DSA) revenues of $663.5 million rose 12.1% (up 11.7% organically). Organic revenue growth was mainly driven by growth in the Safety Assessment business on meaningful price increases and higher study volume. Going by our model, the DSA business was expected to register 6.3% growth in the second quarter (10% growth organically).Story continuesManufacturing Solutions revenues totaled $186.5 million, down 4.2% year over year (up 6.6% organically). The organic revenue growth was primarily driven by the contract development and manufacturing organization and Microbial Solutions businesses.MarginsThe gross profit in the reported quarter was $398.9 million, up 11.8% from the prior-year quarter. Gross margin of 37.6% expanded 98 basis points (bps) year over year despite a 7.2% rise in the total costs of the company.Selling, general & administrative expenses soared 51.7% to $199.8 million.Adjusted operating income totaled $199.2 million, reflecting an 11.5% decline from the prior-year quarter. The adjusted operating margin in the second quarter contracted 433 bps to 18.8%.Liquidity and Cash PositionCharles River exited the second quarter with cash and cash equivalents of $200.4 million compared with $201.6 million at the end of the first quarter.Cumulative net cash provided by operating activities at the end of the second quarter was $257.5 million compared with the prior-year period’s $252.1 million.2023 GuidanceThe company has narrowed its 2023 guidance.For 2023, revenue growth is now expected in the band of 2.5-4.5% (from the earlier band of 2-4.5%) on a reported basis. Organic revenue growth is expected in the range of 5.5-7.5% (5-7.5%). The Zacks Consensus Estimate for total revenues is pegged at $4.11 billion, indicating a 3.4% rise from 2022.Adjusted earnings per share for 2023 is now expected in the range of $10.30-$10.90 ($9.90-$10.90). The current Zacks Consensus Estimate is pegged at $10.33How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates review.VGM ScoresAt this time, Charles River has an average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of B on the value side, putting it in the second quintile for this investment strategy.Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Charles River has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.Performance of an Industry PlayerCharles River is part of the Zacks Medical Services industry. Over the past month, Avantor, Inc. (AVTR), a stock from the same industry, has gained 0.7%. The company reported its results for the quarter ended June 2023 more than a month ago.Avantor, Inc. reported revenues of $1.74 billion in the last reported quarter, representing a year-over-year change of -8.7%. EPS of $0.28 for the same period compares with $0.37 a year ago.For the current quarter, Avantor, Inc. is expected to post earnings of $0.25 per share, indicating a change of -26.5% from the year-ago quarter. The Zacks Consensus Estimate has changed -3.5% over the last 30 days.Avantor, Inc. has a Zacks Rank #4 (Sell) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportCharles River Laboratories International, Inc. (CRL) : Free Stock Analysis ReportAvantor, Inc. (AVTR) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Charles River (CRL) Down 6.1% Since Last Earnings Report: Can It Rebound?

https://finance.yahoo.com/news/charles-river-crl-down-6-153027433.html

c5379b0e-7899-34bf-b540-28df70173387

CRM

Many Salesforce, Inc. (NYSE:CRM) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various explanations. However, when multiple insiders sell stock over a specific duration, shareholders should take notice as that could possibly be a red flag.While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing. Check out our latest analysis for Salesforce The Last 12 Months Of Insider Transactions At SalesforceIn the last twelve months, the biggest single sale by an insider was when the Co-Founder, Marc Benioff, sold US$105m worth of shares at a price of US$211 per share. That means that an insider was selling shares at slightly below the current price (US$225). As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. However, while insider selling is sometimes discouraging, it's only a weak signal. We note that the biggest single sale was only 1.8% of Marc Benioff's holding.In the last year Salesforce insiders didn't buy any company stock. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!insider-trading-volumeIf you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).Insiders At Salesforce Have Sold Stock RecentlyThe last quarter saw substantial insider selling of Salesforce shares. Specifically, Co-Founder Marc Benioff ditched US$105m worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain.Story continuesDoes Salesforce Boast High Insider Ownership?I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Salesforce insiders own about US$6.6b worth of shares (which is 3.0% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.So What Do The Salesforce Insider Transactions Indicate?An insider sold Salesforce shares recently, but they didn't buy any. And even if we look at the last year, we didn't see any purchases. But it is good to see that Salesforce is growing earnings. It is good to see high insider ownership, but the insider selling leaves us cautious. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. For example - Salesforce has 2 warning signs we think you should be aware of.If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Salesforce Insiders Sell US$106m Of Stock, Possibly Signalling Caution

https://finance.yahoo.com/news/salesforce-insiders-sell-us-106m-110013839.html

973b9219-2d3c-3605-a0bf-299f678259f1

CRM

Cathie Wood's Ark Invest is quite bullish on artificial intelligence (AI), especially where software is concerned because it promises a large increase in labor productivity. Ark analysts believe automation could more than double the output of the average knowledge worker, and for that reason, they expect AI software revenue to increase by 42% annually to reach $14 trillion by 2030. Many companies will benefit as that tailwind takes shape, but Salesforce (NYSE: CRM) and The Trade Desk (NASDAQ: TTD) look attractive at their current valuations.Continue reading

Motley Fool

Cathie Wood Says Artificial Intelligence (AI) Software May Be a $14 Trillion Market: 2 Superb Growth Stocks to Buy Now and Hold Through the Boom

https://finance.yahoo.com/m/f4aa662d-53af-3758-80d9-19335c21303b/cathie-wood-says-artificial.html

f4aa662d-53af-3758-80d9-19335c21303b

CRMT

America's Car-Mart, Inc. (NASDAQ:CRMT) Q1 2024 Earnings Call Transcript September 5, 2023America's Car-Mart, Inc. misses on earnings expectations. Reported EPS is $0.63 EPS, expectations were $0.98.Operator: Good morning, everyone. Thank you for holding, and welcome to America's Car-Mart's First Quarter Fiscal 2024 Conference Call. Before we begin today's call is being recorded and will be available for replay for the next 12 months. During today's call, management may make certain statements that are considered forward-looking, which inherently involve risks and uncertainties that could cause actual results to differ materially from management's present view. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The company cannot guarantee the accuracy of any forecast or estimate nor does it undertake any obligation to update such forward-looking statements.Race, Need for Speed, Car, CarsPhoto by Jan Kopřiva on UnsplashFor more information regarding forward-looking information, please see Part 1 of the company's annual report on Form 10-K for the fiscal year ended April 30, 2023, and its current and currently -- quarterly reports furnished to or filed with the Securities and Exchange Commission on Forms 8-K and 10-Q. Please see the company's website for the earnings release for the first quarter of fiscal 2024, along with the second news release about a leadership transition. Participating on the call this morning are Jeff Williams, CEO; Doug Campbell, President; and Vickie Judy, CFO. I will now turn the call over to Jeff Williams, CEO. You may begin.Jeff Williams: Okay. Well, thank you for joining us on the call this morning, and thank you for your interest in America's Car-Mart. I'm pleased to report that we delivered strong revenue growth for the quarter. We had solid improvements in many areas of our business. Near-term credit results are a challenge, and we'll discuss that in more detail in just a few minutes. Before we get into the details, I'm excited to cover our other news today that President, Doug Campbell, will succeed me as CEO effective October 1. Over the last year in his role as President, Doug has more than demonstrated his readiness for the new role. In my role as CEO and a board member, there are many responsibilities, but succession planning has been at the very top of the list for me, identifying a candidate with a strong cultural fit, the skill set to capitalize on opportunities and navigate the challenges ahead is why we first engaged with Doug almost two years ago now.Story continuesDoug's appreciation of the company's culture, strong industry knowledge and being a change agent is why he's the perfect fit to lead us to the next level. Our transition plan will allow for a smooth handoff and I'll be here to fully support Doug as we move forward. So congratulations, and thank you, Doug. I'll now turn it over to Vickie and Doug to review the quarter results, update you on the status of initiatives and provide an outlook on our business. Doug?Doug Campbell: Thanks, Jeff. I want to thank Jeff for all that he's done for the company over his 18 years of service and in particular, the last 6 years as CEO. We have continued to source inventory and grow our business despite the industry being very constrained and volatile over the last couple of years. While competitors are exiting the business unable to manage capital constraints, we have been investing in our business. It's in stark contrast with how others are managing through the environment and a testament to Jeff's both leadership and vision for the company in what has been one of the most challenging environments in the history of our industry. I owe Jeff a debt of gratitude for the time he has spent with me over the last year, and during that time, we've cultivated a fantastic working relationship that will serve us in facilitating the transition ahead.I'm equally appreciative to our Chair and our Board members who have been investing in my development and their feedback and guidance has been valuable. On a personal note, I'm deeply humbled and thankful for the opportunity. As I look forward, I'm more enthusiastic about our future here at America's Car-Mart than it was a year ago. We're focused on the long-term health and success of our business and are demonstrating our ability to operate in any environment. Before we transition over to the quarterly results, I'd like to thank our associates who worked tirelessly to deliver improvements in sales volume, gross margin, procurement efforts, wholesale performance and reductions in repair spend. Their relentless pursuit to both put and keep our customers on the road continues to be a winning combination.Let's start with sales performance. Our sales performance was strong, generating 15,912 units sold, which was up 2.4% over the prior year's quarter. Same-store sales base is up 8.2%. That had a nice impact on inventory turns as those moved up from 5.9 to 7.2 turns. Growth in online credit applications was up 19% for the quarter, which was mentioned in the press release. That accounts for about 70% of all of our applications. Overall, application volume was up 8.1% when including the contract that we see in our dealerships. This is especially impressive when you consider that we've now begun to augment our advertising spend because of the power of LOS and its ability to drive online traffic. The LOS continues to be the primary driver for our sales growth despite what is a down cycle for many with the remainder of the industry down in sales year-over-year during the same period.Credit availability continues to be an issue for the industry and is tighter than previous year when looking at COX Automotive dealer track credit availability index. It has shown some mild improvement in the last month or two, but it's still worse when comparing it to pre-pandemic periods. This is a benefit for us as consumers now look to us for access to credit. When I think about average selling prices during the quarter, they were up by 4.1% year-over-year. About half of that was related to the price of the vehicle. The other half was related to the ancillary products that we sell. On the last call, I discussed that the cars we were purchasing during the spring market were up about 3%, so there should be no surprise here. However, we also mentioned that the cars that we are buying are newer and have lower mileage.This ultimately makes it eligible for longer warranties, which generates more revenue in the selling prices. As a reminder, this is now even more pronounced when you consider the price increase that we made to our service contracts in December of last year. The industry saw wholesale pricing decline sharply in May and June, while prices in July decreased at a more normalized rate. During the first quarter, our procurement teams lowered purchase prices sequentially throughout the quarter, contributing to a 3% reduction in prices from where we started. August wholesale pricing is showing price increases, which is at normal this time of year. It could be related to the sales strength we're seeing in the overall marketplace in August or low inventory days supply on the ground.And I think some speculation of what will happen between negotiations with the UA team and the Big 3 in Detroit. We're keeping a close eye on that and what's transpiring and working to mitigate any effects and some of its effects there. Gross margin came in at 34.6%, which was up 20 basis points compared to last year and up 120 basis points when I look at it sequentially versus the fourth quarter. We went into a fair bit of detail in the press release regarding gross margin and articulated what our plan was on the last call. So I don't want to be too redundant. But to put it simply, we're executing at an elevated level on the plan that we had laid out. We are now -- we are buying newer and lower mileage assets and those are trickling through our ecosystem.We're improving the performance of our operations teams as it relates to vehicle repairs and we continue to scale our reconditioning initiative, which has a target savings of $300 to $500 per unit. We're seeing progress in all three areas, which isn't surprising, but I guess I'm really encouraged at the rate at which we're seeing in some of this benefit. We had estimated that we could recover 260 basis points of gross margin to achieve a 36% target that we alluded to on the last call. However, there are other opportunities that we're now exploring. I'll give you an example. Transportation would be one of these. Last year, we changed the technology stack that we use to move vehicles throughout our ecosystem by optimizing loads and routes. We began to roll this out in the fourth quarter, but Q1 is the first full quarter we're seeing the benefit.It represented an improvement of 20 basis points in gross margin when compared to the first quarter of last year. And ultimately, we're now saving about 15% on the way we move our vehicles. There are other opportunities with ancillary products, wholesale and repairs that we're looking at to drive even further improvements beyond what was initially indicated. Some of these opportunities can be realized during this fiscal year. Others will be more long term in nature. I'll now turn it over to Vickie, who will cover our financial results.Vickie Judy: Good morning, and thank you, Doug. For the current quarter, our net charge-offs as a percentage of average finance receivables were 5.8%. That's compared to 5.1% for the first quarter of '23 and 6.3% sequentially. It is above our five-year average of 5% and our 10-year average of 5.6% for first quarters. Both of these include the low credit loss pandemic period. For some comparisons to pandemic, our first quarter losses for fiscal year '18 and '19 were 6.1%. A little over half of the increase in losses contributed compared to the first quarter of fiscal '23 was due to the higher severity of losses and the remainder being an increased frequency in the losses. Our recovery values were down from historically high levels in the prior year quarter of 32% and held flat sequentially at approximately 27%.As of July 31, the allowance for loan losses was 23.91% of finance receivables, net of deferred revenue. And as discussed in the press release, our provision exceeded actual charge-offs by $14.8 million. We have over $125 million of deferred revenue on the balance sheet. And in addition, we also collected an additional $12 million in interest income, an increase of 27.3% when compared to Q1 of fiscal '23. We also mentioned in the press release the benefit of the LOS and attracting additional customers. It's also going to be instrumental in helping us improve deal structures and ultimately, the success rate of our customers once it is fully implemented across all lots. Our customer scores during the quarter remained consistent with the prior year.On the delinquency side, our accounts plus past due was at 4.4% compared to 3.6% in the prior year quarter. The month ending on a Monday versus a Sunday in the prior year contributed to part of this as well as the continuing negative impact of the inflationary environment on our customers. Total collections were up 12% to $166 million and total collections per active customer per month were $535 compared to $516 in the prior year quarter. We continue to work with our customers on payment options and modifications in an effort to keep them in the vehicle and successful on their contract. The average originating contract term for the quarter was 44.7 months compared to 42.8 for the prior year quarter and up slightly from 43.5 months sequentially.We added 1.9 months to the originating contract term compared to the prior year first quarter to assist our customers with an affordable payment. Our weighted average contract term for the entire portfolio, including modifications, was 46.9 months compared to 44 for the prior year quarter. The weighted average age of the portfolio increased to approximately 10.4 months. The percentage of the portfolio held by the highest credit quality customers continues to improve compared to the prior year. On the SG&A side, we've been focused on identifying efficiencies in the business across the board. And as mentioned in the release, we had a savings with our SG&A spend of over $600,000 from the fourth quarter, excluding the stock-based compensation. A large percentage of the savings was in advertising.We continue to shift more of our advertising dollars to digital spend, which is more efficient and also help supplement our LOS efforts. Our customer count increased by 8.1% over the prior year to almost 105,000 customers. Our SG&A spend per average customer improved over the prior year first quarter and over the sequential quarter. Our investments are being made to better serve this growing base while improving the efficiencies as we move forward. And although we continually evaluate our return on investment and allocation of capital, it becomes even more important in this environment of increasing funding costs. With that in mind, we did close two underperformed dealerships during the quarter to better allocate our available capital. We'll continue to review and monitor capital invested in each dealership and other investments to maximize returns.At quarter end, we had $6.3 million in unrestricted cash and approximately $159 million in additional availability under our revolving credit facilities based on our current borrowing base of receivables and inventory. Our total securitized non-recourse notes payable was $711.8 million, with $86 million in restricted cash related to those notes. We closed on our third securitization in early July with net proceeds of $356 million and a coupon of 8.8%. And this paid off our revolving line of credit. Our total debt, net of cash to finance receivables ratio is at 42.9% and up from 41.5% at April 30. Interest expense increased $6.9 million with approximately 60% of that related to the increased rates over the prior year and the remainder a result of the increased borrowings.I'll now let Jeff to close this out.Jeff Williams: Okay. Well, thank you, Vickie. The demand for our offering will continue to increase. Our model is the very best way to serve our high-touch customer base and the unique challenges that require a balance between face-to-face decentralized decisioning and leveraging scale where it makes sense. We're striking just the right balance, and that's more apparent as we continue to pick up market share. Current demand exceeds what we can supply. We believe that affordability will improve over time as basic transportation must be available for average consumers. Currently, many customers are sitting out and will flow back into the market over time. In many respects, our customers are always in recession, which makes the current environment ideal as we focus on affordability and delivering outstanding service to keep our customers on the road.Foundational investments are nearing completion and will be leveraged, allowing us to become a more efficient data-driven company. We've not yet seen the benefit that will come. We're on track to sell between 40 and 50 retail units per dealership per month in the next few years and eventually serve 1,000 customers per dealership. We believe credit results will improve, especially as we look at the opportunities with the LOS, increasing car quality and execution levels. We believe gross profit percentages will improve and will leverage SG&A as we move forward. And as discussed in the press release, we're in a unique period in the industry, and we have significant opportunities in the acquisitions areas. And we're talking to several strong operators with highly accretive opportunities, very excited about that.We have great days ahead and Doug is ready to lead our team forward. Thank you to all of our passionate associates who have signed on to our vision to be the best and dreams big about what we could be while taking care of our customers one at a time. Thank you, and we'll now open it up for questions. Operator?See also Wall Street Analysts See Upside Potential for 10 Stocks with Rising Price Targets and 10 Countries That Produce the Best Quality Leather in the World.Q&A SessionOperator: Thank you. [Operator Instructions] And our first question comes from John Murphy from Bank of America. Your line is now open.John Murphy : Good morning, everybody. Congrats to Jeff and Doug on the next legs of your careers here. I guess just a first question. When you think about the extension in contract terms to help with the monthly affordability equation, I'm just curious if you think that ever reverses? Or is this something that is now structurally in place and that we'll continue to see lengthening? Or has there been a period of time Car-Mart's history or over time where contract terms have actually shortened once they've been entered over time?Jeff Williams : Yeah. We do see an opportunity in the future to reel back in and decrease terms as we go forward. Our customers' wages continue to go up. And I think the last few months, few quarters, we've seen real wage increases for our consumers. So we do feel like eventually, we can move that term in the other direction. But that's going to be based to a large extent on what happens with car prices and wages as we go forward and other inflationary pressures. But we would certainly like to really in term, and we do think there's a very realistic and real possibility of us moving that direction, especially as we look at the LOS and all the different features and functions and benefits we're going to get when that tool gets fully rolled in.John Murphy : That's helpful. And then just a follow-up on some of the comments that were made in the press release about the changes in purchase and disposition of vehicles. And I'm just wondering if you could sort of expand on what changes have actually occurred? And is it something where we're just looking at slightly newer vehicles that are being put into inventory that have lower recon costs, and that's the efficiencies that are gained and just what's actually changing there that's making that more efficient over time? Because I thought you've been pretty good at that historically, but it sounds like you see room for improvement.Doug Campbell : Yeah. Thanks for the question. I would say historically, we have been very good at that. It was, I think, my very first call on -- that I spoke about how we had used that as a lever to mitigate some of the costs. And we went to a little bit older car with a little bit higher mileage. And while it had its benefits upfront, there's a repair cost associated with that downstream, which has been somewhat problematic. And so what we're trying to do is get back to our historical norms. But beyond that, we've seen efficiency gains what I would call that are more closer to pre-pandemic levels. And so the car we used to sell might have been nine or 10 years old, we're able to shave a year off that and improve the overall mileage by 10,000 to 12,000 miles, what I would call versus pre-pandemic.So the car inherently is a lower mileage car, which should generate less in repairs and ultimately, I think it gives us a second chance at retailing the unit, should we have to go down the repossession route. It creates a second chance to -- for the inventory to have another purpose in our business.Jeff Williams : John, I would add in the last two or three years with the pandemic and the chip shortage and the used car issues and all the supply chain issues we had that there was some real disruption in our historical performance on product and procurement and is kind of working itself out at the same time that we're making some good improvements internally.John Murphy : All right. Thank you very much, guys. I'll get back in the queue. That's very interesting. Thank you.Jeff Williams: Thank you.Operator: Thank you. [Operator Instructions] And our next question comes from Kyle Joseph from Jefferies. Your line is now open.Kyle Joseph : Hey, good morning, guys. Congrats Jeff. Let me know if you or everyone go play golf. Anyway, so kind of piggybacking on that last question in terms of gross profit margin. Obviously, used car prices have been elevated. It seemed like they may be coming back to earth for a while. But longer term, do you think the gross profit margin has changed systemically? Or do you think gradually over time and get back to where it was?Doug Campbell : Yeah. Thanks, Kyle, for the question. I think there's an opportunity to sort of have a middle ground there. But as we sort of called out earlier, maybe we set our expectations a little too low on that 36%, and we're realizing in real time. There's benefits beyond what we initially anticipated, especially when you consider items like transportation that maybe wasn't sort of initially on the table, but we're looking at any and all things in the business to sort of drive improvements there. One thing that I didn't mention in the last answer was what we own those cars relative to the book value. And if I just go back, if I used, I call it, this time last year to the current time. So over the last 12 or 13 months, how we own those cars relative to the book has improved 8% or 9%.So it's a combination of an improvement of how these cars are starting life in our portfolio. There's the improvement in a younger car with lower miles which all should have benefits downstream in terms of credit loss and fair market value retention, right? It sort of takes some of that risk and exposure off the table.Kyle Joseph : Got it. Very helpful. And then, yeah, my follow-up would be the health of the underlying consumer. I know you mentioned the quarter ended on a different day and -- but at the end of the day, the low-end consumer still employed inflation pressures are easing a bit? How would you gauge the health of your underlying consumer?Vickie Judy : Yeah. I don't think we're seeing any large changes yet. Again, to your point, unemployment still very low. They're working, wages are still good, hours worked are still good. But there are still a lot of inflationary pressures and just the adjustment to those inflationary pressures and the lack of stimulus that was there for a point in time. So credit, the use of credit has gone back up for our consumers. We're seeing that kind of across the board. But again, our consumers are almost typically always in a recession, living paycheck to paycheck. So it's really just an adjustment and getting them back used to the higher car payments and keeping them in their car.Jeff Williams : But overall, the health of our consumer is increasing quarter-over-quarter. As we move forward, we believe that's going to be a better situation for us as we go forward and as Vickie mentioned, unemployment rates are historically low and real wages are gaining some steam in the areas we serve and the customers we serve.Vickie Judy : And I think a piece of that is, as Doug mentioned, the tightening in the lending environment, we are seeing a different cohort of consumers come down into our market. We continue to see that.Kyle Joseph : Got it. Thanks Vickie, thanks, Doug, thanks Jeff.Jeff Williams : Thanks, Kyle.Operator: And thank you. [Operator Instructions]And our next question comes from John Rowan from Janney Montgomery Scott. Your line is now open.John Rowan : Good morning. Congrats Jeff and Doug. I guess some other larger lenders have postulated that with the potential for our strike, and you guys mentioned this in your prepared remarks a little bit, that there would be an increase in dealer inventory, guys would take up floor plan loans. Obviously, fiscal 2023 midyear, you were very heavy in inventory. Are you planning on raising inventory levels at all if this strike looks like it's going in one direction? And I'm not sure really -- obviously, everything flows downstream. I don't necessarily think there's necessarily an immediate shortage in used cars, but just curious if you think there'll be a ripple effect that could cause you to raise inventory levels?Doug Campbell : I don't -- so I think about it differently. It's a great question and certainly been on our minds. I don't know sort of which way it's going, but we're sort of trying to prepare ourselves for any variation of an outcome. I think ultimately, if you go back to the last strike on record, I think it was the GM strike, and you go track overall used car prices, which you saw was upward pressure, especially on those brands. I think it was a General Motor strike. If you go back and look at those brands, you saw a nice increase in pop and pricing is days supply diminished on the ground. It almost happened in real time because there's a lot of speculation in and around that. And so when you have three automakers, right, potentially going on strike and the deadline is looming here, you have to sort of be ready for that, and it's going to be more than just the overall impact on those three automakers.It will just be a shortage of supply on the ground. If you looked at absolute supply in our industry, it's still really at sort of all-time lows. And so the instance of something like this happening could drive values up. And so for us, that is some headwind on the buying side. We can combat that with being more selective on the cars we buy. But to your point, I think what you're alluding to is, do we stock up for an event like that? I don't think that is necessarily a lever we would pull. However, I do think if there was some appreciation in value, it becomes a tailwind on the fair market values that we have for the cars that were taken back the repo vehicles. So there's good and bad to us being having the lending side to this, and -- we're just trying to make sure we're ready.We don't know sort of which way it's going to go, but our job is to be ready for that, and we're looking at those options available to us now.Jeff Williams : You mentioned on the last call, too, that a lot of competition that we have is struggling with capital. We had a couple of sizable competitors go out of business in the last six months or so, too. So there's some positive on the supply side in addition to some potential negatives too. So that all balances out. And we're pretty nimble on our procurement. So we'll be able to address and adjust any situation we see.John Rowan : Great. Thank you.Jeff Williams : Thanks, John.Operator: And thank you. [Operator Instructions] And our next question comes from Vincent Caintic from Stephens. Your line is now open.Vincent Caintic : Hey, good morning. Thanks for taking my questions. Doug, congratulations and look forward to working with you and Jeff, it's been a pleasure working with you for the past several years, and we'll miss you. So first one to zoom out just kind of a broad question about the CEO transition. And if you could walk us through that. It sounds like this process has been going on for the past few years. So I just wanted to kind of get a sense for why now is a good time for the transition and then Doug, anything in particular you'd like to focus on as we start your tenure?Jeff Williams : Well, yes, as to the timing, this is just a good time in our history. We've -- we've been through some pretty difficult times. Things are still tough, but getting a little bit better in some of these long-term, highly complex, labor-intensive investments and initiatives we've had in place. Doug has been able to participate in those for the last year. And those are all coming into play and with Doug and his experience and his talent level. It's just -- it's a perfect time for us as a company, especially with the transition being extended. There will be plenty of support, plenty of time to transition appropriately as we go forward. So this is just a good time for me, for Doug and for our company and our associates and shareholders. It's a good time in history to be making this change, especially with the transition plan we have in place.Doug Campbell : My first, obviously, opportunity to be a CEO of the company. And again, I'm humbled, but at the end of the day, there are a lot of associates who are relying on smooth transition -- shareholders relying on a smooth transition. And the more we thought about it, the longer Jeff stayed on to help assist with the transition for the things we know and especially on the credit side of the business of Vincent that it sort of made more sense to accelerate making the announcement and then having Jeff stand up for a longer period of time as opposed to postponing it and doing the transition to a shorter period of time. And I think leading to your question, I'll probably spend more time on the credit side of the business, the underwriting side of the business and see what improvements that we have there, especially given credit loss.And when I think about some of the improvements we made in other areas of the business, I'm excited to sort of roll up my sleeves and see what other opportunities are there as well.Vincent Caintic : Okay. Great. That's super helpful. My next question, I wanted to touch on the shelf filing that was filed a couple of weeks ago and in some of the comments that were made in the shelf filing, particularly the kind of the unprecedented opportunities you might be seeing, if you could talk about that in more detail what you're seeing and sort of what you're looking for that makes you excited about those opportunities?Jeff Williams : Yeah. The industry, obviously, has been in turmoil. We've had major competitors going out of business. There's a lot of folks that have been in the business for decades that don't have an exit strategy, don't have a succession plan, the cost of being in the business continues to go up. So there's a lot of very good, very strong operators out there of size that are looking for a succession plan or how to get out of the business. And so what we do and what we've offered on the acquisition side is appealing to more and more good operators, and we've got some good discussions going on. Very optimistic about being able to continue to pick up productivity and profits from our existing store base and then add this acquisition's effort on separate and apart from all the other good stuff going on.And it could be really a good point, a great point in history for us to be going out and getting more aggressive with acquisitions and we're setting ourselves up to do just that. And the shelf registration was just another aspect to that opportunity and giving us more options on the financing side, if and when needed, to support some acquisitions.Vincent Caintic : Okay. Great. Thank you. And if I could maybe sneak one more in for Vickie. Just on the credit side, the credit reserves have been increasing and understandably about the mix and the term and so forth. Just as the way things stand right now, do you foresee that the credit reserves where we're at, is that sort of the right level? Or should we be anticipating just help term and mix things continue to change? Thank you.Vickie Judy : Sure. Well, we continue to look at that quarterly based on historical numbers and what's happening in the current market as well as some forecasting for some economic events. So we did increase it slightly in the fourth quarter. We were able to keep it level this quarter. So it's hard to say quarter-over-quarter, but we're working on a lot of things. As we mentioned in the press release and in a few of my comments in bringing down term, working on down payments hopefully reducing some selling price finance as we move forward. So those will all be things that we're working on to hopefully offset the impact of any allowance increases. But that's certainly a possibility as we move forward here and depending on what happens over the next few quarters.Vincent Caintic : Okay, that's super helpful. Thanks, again, everyone.Vickie Judy : Thank you.Jeff Williams : Thank you, Vincent.Operator: And, thank you. And I am showing no further questions. I would now like to turn the call back over to Jeff Williams for closing remarks.Jeff Williams : Okay. Well, once again, thank you for listening to our call, and thank you for your interest in America's Car-Mart. Doug, congratulations again on your promotion to CEO. We'll have a smooth transition and we appreciate and respect all of our associates out there that have passion for what we do and support each other and support our customers at a very high level. So thank you, and have a great day.Operator: This concludes today's conference call. Thank you for participating. You may now disconnect.

Insider Monkey

America’s Car-Mart, Inc. (NASDAQ:CRMT) Q1 2024 Earnings Call Transcript

https://finance.yahoo.com/news/america-car-mart-inc-nasdaq-121846530.html

d8b6094b-1aca-3aa4-8bbe-1d83811623ab

CRMT

Week to date, shares of America's Car-Mart (NASDAQ: CRMT) were down 17% at 2:34 p.m. ET on Thursday, according to data provided by S&P Global Market Intelligence. The used car store chain reported strong sales results for the fiscal first quarter ending July 31. As a result, Car-Mart reported just $0.63 in earnings per share, down from $2.07 in the year-ago quarter.Continue reading

Motley Fool

Why America's Car-Mart Stock Was Down This Week

https://finance.yahoo.com/m/5edb4e73-4063-3a24-a03e-d43c950c4291/why-america-s-car-mart-stock.html

5edb4e73-4063-3a24-a03e-d43c950c4291

CRNC

Cerence Operating CompanyBURLINGTON, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, will be presenting at the Goldman Sachs Communacopia & Technology Conference in San Francisco, CA on September 6, 2023.The conference includes a fireside chat featuring Stefan Ortmanns, Cerence’s CEO. The webcast will be accessible from the “Events” section of the company’s website (https://www.cerence.com/investors/events-and-resources).To learn more about Cerence, visit www.cerence.com, and follow the company on LinkedIn and Twitter.About Cerence Inc.Cerence (NASDAQ: CRNC) is the global industry leader in creating unique, moving experiences for the mobility world. As an innovation partner to the world’s leading automakers and mobility OEMs, it is helping advance the future of connected mobility through intuitive, AI-powered interaction between humans and their vehicles, connecting consumers’ digital lives to their daily journeys no matter where they are. Cerence’s track record is built on more than 20 years of knowledge and 475 million cars shipped with Cerence technology. Whether it’s connected cars, autonomous driving, e-vehicles, or two-wheelers, Cerence is mapping the road ahead. For more information, visit www.cerence.com.Investor Contact Information:Rich YerganianSenior Vice President of Investor RelationsCerence Inc.Tel: 617-987-4799Email: [email protected]

GlobeNewswire

Cerence to Present at the Goldman Sachs Communacopia & Technology Investor Conference

https://finance.yahoo.com/news/cerence-present-goldman-sachs-communacopia-120000712.html

802a432a-abf4-35b5-836e-9c242a791a89

CRNC

Cerence Operating CompanyMentz joins Cerence from Amazon and will lead Cerence’s global sales and marketing organization, working with customers worldwide to transform the in-car experienceCerence Names Accomplished Automotive Technology Executive Christian Mentz as Chief Revenue OfficerCerence Inc. today announced it has named Christian Mentz, a highly regarded business leader in automotive technology, as the company’s Chief Revenue Officer. In this role, Mr. Mentz will lead Cerence’s global sales and business development, sales engineering, and marketing organizations, driving the company’s go-to-market strategy, accelerating growth, and expanding the company’s relationships with its automaker and mobility customers worldwide.BURLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, today announced it has named Christian Mentz, a highly regarded business leader in automotive technology, as the company’s Chief Revenue Officer. In this role, Mr. Mentz will lead Cerence’s global sales and business development, sales engineering, and marketing organizations, driving the company’s go-to-market strategy, accelerating growth, and expanding the company’s relationships with its automaker and mobility customers worldwide.Mr. Mentz joins Cerence after more than four years in progressing roles at Amazon. In his most recent role at Amazon Smart Vehicles, Christian successfully led the global Business and Marketing organization, driving commercial operations and go-to-market strategies across a wide range of automotive digital cabin products and services. Prior to joining Amazon, Mr. Mentz held several automotive sales and leadership roles during a more than ten-year tenure at Nuance Communications, including Vice President - Automotive Sales & Sales Engineering. Mr. Mentz has continuously demonstrated passion for innovation and advancing technologies throughout his career, having held several consulting and advisory roles for technology companies, including as an advisor to AI and machine learning firm Dessa.“Christian is a tenured and accomplished executive who brings transformational leadership and a proven ability to build deep customer relationships,” said Stefan Ortmanns, CEO, Cerence. “Christian’s long and successful career and progressive leadership give him unique, direct experience in automotive AI and voice technology that will be critical as Cerence accelerates toward the next generation of AI-powered, immersive customer experiences.”Story continues“Having spent a substantial part of my career working on the intersection of AI and automotive to drive advancements and collaboration in infotainment and the digital cabin, I am honored and excited to join Cerence as its Chief Revenue Officer,” said Christian Mentz. “As our industry continues to undergo significant transformation, I look forward to working with the entire Cerence team to leverage our deep expertise as a pioneer in automotive and generative AI to propel innovation in partnership with our customers worldwide.”Mr. Mentz holds a Master’s Degree in Communications from The Philipp University of Marburg, Germany, and continued his education in Change and Innovation Management at the University of St. Gallen, Switzerland.To learn more about Cerence, visit www.cerence.com, and follow the company on LinkedIn and Twitter.About Cerence Inc.Cerence (NASDAQ: CRNC) is the global industry leader in creating unique, moving experiences for the mobility world. As an innovation partner to the world’s leading automakers and mobility OEMs, it is helping advance the future of connected mobility through intuitive, AI-powered interaction between humans and their vehicles, connecting consumers’ digital lives to their daily journeys no matter where they are. Cerence’s track record is built on more than 20 years of knowledge and 475 million cars shipped with Cerence technology. Whether it’s connected cars, autonomous driving, e-vehicles, or two-wheelers, Cerence is mapping the road ahead. For more information, visit www.cerence.com.Contact InformationKate Hickman | Tel: 339-215-4583 | Email: [email protected] photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ee36fe30-9e57-4d87-a2e9-a134a9e68f81

GlobeNewswire

Cerence Names Accomplished Automotive Technology Executive Christian Mentz as Chief Revenue Officer

https://finance.yahoo.com/news/cerence-names-accomplished-automotive-technology-120000197.html

d916f9cd-b50a-3813-aab2-ec38586f684e

CRNX

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.So should Crinetics Pharmaceuticals (NASDAQ:CRNX) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn. Check out our latest analysis for Crinetics Pharmaceuticals Does Crinetics Pharmaceuticals Have A Long Cash Runway?You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. When Crinetics Pharmaceuticals last reported its balance sheet in June 2023, it had zero debt and cash worth US$265m. Importantly, its cash burn was US$161m over the trailing twelve months. So it had a cash runway of approximately 20 months from June 2023. Notably, analysts forecast that Crinetics Pharmaceuticals will break even (at a free cash flow level) in about 4 years. Essentially, that means the company will either reduce its cash burn, or else require more cash. You can see how its cash balance has changed over time in the image below.debt-equity-history-analysisHow Well Is Crinetics Pharmaceuticals Growing?Crinetics Pharmaceuticals actually ramped up its cash burn by a whopping 77% in the last year, which shows it is boosting investment in the business. That does give us pause, and we can't take much solace in the operating revenue growth of 4.0% in the same time frame. Taken together, we think these growth metrics are a little worrying. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.Story continuesCan Crinetics Pharmaceuticals Raise More Cash Easily?Even though it seems like Crinetics Pharmaceuticals is developing its business nicely, we still like to consider how easily it could raise more money to accelerate growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).Since it has a market capitalisation of US$903m, Crinetics Pharmaceuticals' US$161m in cash burn equates to about 18% of its market value. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution.Is Crinetics Pharmaceuticals' Cash Burn A Worry?On this analysis of Crinetics Pharmaceuticals' cash burn, we think its cash runway was reassuring, while its increasing cash burn has us a bit worried. One real positive is that analysts are forecasting that the company will reach breakeven. Even though we don't think it has a problem with its cash burn, the analysis we've done in this article does suggest that shareholders should give some careful thought to the potential cost of raising more money in the future. Readers need to have a sound understanding of business risks before investing in a stock, and we've spotted 3 warning signs for Crinetics Pharmaceuticals that potential shareholders should take into account before putting money into a stock.Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts)Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Will Crinetics Pharmaceuticals (NASDAQ:CRNX) Spend Its Cash Wisely?

https://finance.yahoo.com/news/crinetics-pharmaceuticals-nasdaq-crnx-spend-130251581.html

15382036-a50d-323a-96f5-139a43c1fe64

CRNX

After a shaky August for the markets, we have now entered the year’s final third and the bad news is that, going by the history books, September represents the market’s worst month of the year.The good news, however, is that according to Oppenheimer’s head of technical analysis, Ari Wald, any anticipated lull will be short-lived.“The key takeaway in our work is that, whether or not the advance is resuming imminently, it should only be a matter of time,” Wald recently said. “The Russell 2000’s ability to uphold its 200-day average, combined with risk-on leadership and bullish inter-market checks, reinforces our view that a seasonal correction should prove temporary and an opportunity to buy into a middle-innings bull cycle.”So, what should investors be buying ahead of the bull market’s eventual resumption? At Oppenheimer, the stock analysts have some answers to that question, and they have tapped two equities with the potential to double in value over the next 12 months.Are other Street analysts just as confident? It looks like it. According to the TipRanks database, both stocks are rated as Strong Buys by the analyst consensus, who also see triple-digit gains on the horizon. So, let’s see why the financial prognosticators except these shares to jump big time.Zura Bio (ZURA)First up is Zura Bio, a clinical-stage biopharmaceutical firm researching and developing new drugs with a focus on immunology. More specifically, the company has a line-up of new drug candidates, each at or entering Phase 2 clinical trials, targeting a variety of autoimmune disorders. The drug candidates are each designed to follow a different path toward combatting auto-immune disease, providing relief for patients with these difficult conditions.In June of this year, Zura made two announcements which should interest investors. The first, from June 6, concerns ZB-106 (tibulizumab), a drug candidate licensed from Eli Lilly earlier this year with potential as a first-in-class medication with dual action as an anti-il-17 and anta-BAFF antagonist. The company reported completion of an $80 million private placement financing round, that guaranteed the drug would advance to Phase 2 in the clinic. The drug candidate is scheduled to enter Phase 2 testing against systemic sclerosis and hidradenitis suppurativa during the second half of next year; it has already passed tolerability testing in healthy volunteers.Story continuesAlso of interest, on June 23, Zura joined both the Russell 3000 and Russell 2000 stock indexes. These indexes aim to capture a broader, more accurate, view of the US stock markets, by including more of the small- and mid-sized public firms and reducing the dependence on the market’s mega-cap stocks as a gauge of performance.Directing our attention back to Zura’s clinical pipeline, ZB-880, or torudokimab, emerges as a promising Phase 2 candidate for asthma treatment. The drug candidate is a high affinity monoclonal antibody that targets IL33 for neutralization; it has already shown an acceptable tolerability profile in earlier stage clinical trials. Per the 2Q23 update, the company is preparing to initiate the Phase 2 clinical trial next year.Also in the clinic is ZB-168, a fully human, anti-IL7Rα monoclonal antibody under study as a treatment for several conditions including ulcerative colitis and atopic dermatitis. The drug is active against the IL7 and TSLP immune pathways. Zura plans to initiate Phase 2 trials of this drug next year. The company holds an exclusive, worldwide, license for the development, and the eventual commercialization, of ZB-168 in all indications.The ZB-106 track, particularly, caught the attention of Oppenheimer’s Justin Kim. The 5-star analyst writes of this candidate and the stock, “With a focus on Phase 2-ready asset ZB-106, aka tibulizumab (an anti-BAFF/IL-17 dual-antagonist), we are intrigued by this asset’s potential to uniquely address HS, where the market opportunity for next generation IL-17 therapies is continuing to be better appreciated by the Street, and systemic sclerosis, where the anti-BAFF activity of the drug could provide clinical benefit where significant unmet need exists. We note the story for Zura and ZB-106 is at an early stage, but believe the upside could well match the long-term risk-reward. We are bullish.”Kim goes on to rate ZURA shares as Outperform (i.e. Buy), and he sets a 12-month price target of $17, indicating his confidence in a robust 147% upside potential. (To watch Kim’s track record, click here)Kim is hardly the only bullish analyst on Zura – the stock has a unanimous Strong Buy consensus rating based on 4 recent positive analyst reviews. The shares are trading for $6.87, and their $18.25 average price target implies a one-year potential gain of ~166%. (See ZURA stock forecast)Crinetics Pharmaceuticals (CRNX)The endocrine system is one of our most important bodily systems, comprising glands and hormones that regulate the body’s growth and functions. Endocrine diseases can be some of the most dangerous, and some of the most difficult to treat. Crinetics Pharmaceuticals, the second stock we’ll look at here, focuses on these diseases, particularly the more rare endocrine diseases. The company is working on therapies to provide patients with effective disease control.Pursuing this end, Crinetics has developed a varied pipeline, featuring both clinical-stage drug candidates and pre-clinical research programs. The endocrine conditions targeted are equally varied, and include well-known names such as diabetes and thyroid eye disease, as well as lesser-known conditions such as acromegaly and carcinoid syndrome. The latter two are the subjects of Crinetics’ most advanced clinical trial studies.These clinical trials focus on the drug candidate paltusotine (CRN00808). The company currently has three trials of paltusotine ongoing, including the Phase 3 PATHFNDR-1 and -2 trials of the drug in the treatment of acromegaly and a Phase 2 trial in the treatment of carcinoid syndrome. Paltusotine belongs to a new class of orally-dosed, selective, non-peptide somatostatin receptor type 2 (SST2) agonists and shows high promise in the treatment of acromegaly.On the acromegaly track, Crinetics is expected to release topline data from the Phase 3 PATHFNDR-1 study this month. The study is a placebo-controlled trial of orally dosed paltusotine in patients switching from standard-of-care peptide depots.During Q2 of this year, Crinetics completed enrollment in the PATHFNDR-2 trial, another placebo-controlled Phase 3 study of oral paltusotine. Topline data from this study is anticipated for 1Q24.Following up on these studies, Crinetics plans to submit its new drug application (NDA) to the FDA regulatory agency next year. The company is seeking regulatory approval of the drug for both treatment and maintenance of treatment in acromegaly.The acromegaly track, and the high potential of paltusotine for success, attracted Oppenheimer’s Leland Gershell to this stock. The analyst writes in a recent note, “We anticipate positive upcoming news flow around lead candidate paltusotine’s opportunity to treat acromegaly, which we see as the main value driver for the stock in the near term. We believe paltusotine is likely to succeed in both of its Phase 3 trials in this indication, with the first to report in September and the second in 1Q24, which together should pave the way to US and EU approvals and launches by CRNX in 2025 and 2026, respectively. We expect its distinct advantages over the standard of care to enable paltusotine to take substantial market share and project peak revenue of $250M.”Quantifying his position on Crinetics, Gershell gives the stock an Outperform (i.e. Buy) rating with a $40 price target pointing toward a strong 138% upside on the one-year horizon. (To watch Gershell’s track record, click here)Once again, we’re looking at a stock with a Strong Buy consensus rating, and once again where the bullish take is unanimous – Crinetics has 7 recent positive analyst reviews on file. The stock’s trading price of $16.78 and average price target of $45.14 combine to suggest an upside of 169% for the year ahead. (See CRNX stock forecast)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

TipRanks

Oppenheimer Says These 2 Stocks Could Double Your Money — Here’s Why They Could Jump

https://finance.yahoo.com/news/oppenheimer-says-2-stocks-could-005531827.html

dfcfef79-d450-325d-bfc2-3301a5a844ea

CROX

Investing.com -- U.S. stocks were mixed on Thursday as investors continued to worry about the possibility of interest rates remaining higher for longer.Here are some of the biggest U.S. stock movers today:Apple (NASDAQ:AAPL) stock fell 3.3% after a WSJ report that said China is expanding its ban on iPhones to state-owned firms and government agencies, potentially hitting future demand in this important market.GameStop (NYSE:GME) stock fell 0.6% after the troubled video games retailer exceeded estimates for quarterly revenue and posted a smaller-than-expected loss.ChargePoint (NYSE:CHPT) stock slumped over 13% after the owner of EV charging stations missed revenue expectations in its quarterly earnings report.C3.ai (NYSE:AI) stock fell 11% after the artificial intelligence start-up said its path to profitability will be delayed, fueling concern over its ability to take advantage of a surge in excitement over AI.McDonald’s (NYSE:MCD) stock rose 0.9% after Wells Fargo upgraded the fast food giant to ‘overweight’ from ‘equal weight’, saying the company is “firing on all cylinders.”Dell Technologies (NYSE:DELL) stock fell 2% after Barclays downgraded the tech company to 'underweight’ from ‘equal weight’, saying its AI presence will not be enough to ward off the macro troubles. Crocs (NASDAQ:CROX) stock fell 0.8% after B. Riley downgraded the iconic shoe retailer to ‘neutral’ from ‘buy’, citing concerns about excess footwear inventory in stores.Related ArticlesMidday movers: Apple, Chargepoint, C3ai and moreExclusive-ChatGPT traffic slips again for third month in a rowHow the Saudis became a top shareholder in Telefonica, Spain's telecoms giant

Investing.com

Midday movers: Apple, Chargepoint, C3ai and more

https://finance.yahoo.com/news/apple-chargepoint-dell-fall-premarket-074352902.html

25c183aa-d1cf-3b53-97b3-73c0c7134e8f

CROX

It hasn't been a smooth ride for Crocs (NASDAQ: CROX) in recent years. Continue reading to understand why Crocs is a top beaten-down growth stock to buy right now. Consumer products companies can build a competitive advantage with powerful brand recognition.Continue reading

Motley Fool

1 Growth Stock Down 46% to Buy Right Now

https://finance.yahoo.com/m/933be1c8-3ca4-3615-8dca-19c2186abcf4/1-growth-stock-down-46-to.html

933be1c8-3ca4-3615-8dca-19c2186abcf4

CRVO

By David Bautz, PhDNASDAQ:CRVOREAD THE FULL CRVO RESEARCH REPORTInitiating CoverageWe are initiating coverage of CervoMed Inc. (NASDAQ:CRVO) with a valuation of $17.00. CervoMed is a biopharmaceutical company that is developing central nervous system (CNS) treatments for acute and chronic neurodegenerative diseases. The company’s lead development compound is neflamapimod, which is being developed as a therapy for dementia with Lewy bodies (DLB). The compound targets and inhibits p38 mitogen-activated protein kinase (MAPK) alpha (“p38⍺”). Chronic activation of p38⍺ is thought to impair how neurons in the brain communicate through synapses, which ultimately leads to synaptic dysfunction. Inhibition of p38⍺ in the brain may improve neuroinflammation and improve cognitive and motor function that is seen in early-stage neurodegenerative diseases. Neflamapimod was previously tested in a Phase 2a clinical trial in DLB, with results showing a statistically significant improvement compared to placebo on measures of dementia severity and functional mobility.Extensive Clinical Experience with NeflamapimodNeflamapimod was in-licensed from Vertex Pharmaceuticals in 2014. It was discovered using Vertex’s proprietary structure-based drug discovery program. The compound had completed both single- and multiple-dose Phase 1 trials in healthy volunteers as well as a Phase 2a clinical trial in rheumatoid arthritis. Post-licensing and prior to the Phase 2a clinical trial in DLB, neflamapimod was tested in two Phase 2a trials and one Phase 2b trial in Alzheimer’s disease. Results from those trials showed that the drug was well tolerated, crosses the blood-brain barrier, and is pharmacologically active in the brain, with the demonstration of significant reduction, relative to placebo, of spinal fluid levels of markers of synaptic dysfunction and neurodegeneration.Phase 2b Clinical Trial Fully Funded by NIH/NIAIn January 2023, CervoMed was awarded a $21.0 million grant from the National Institute of Aging (NIA), which is estimated to fully fund the Phase 2b trial of neflamapimod in DLB. An initial disbursement of $6.9 million was made in February 2023, with an anticipated $8.1 million disbursement to be made in February 2024 and the remainder of the grant to be disbursed in February 2025.Story continuesMultiple Catalysts by the End of 2024We anticipate a number of catalysts over the next 12-18 months, including the publication of additional Phase 2a data from the DLB study in the second half of 2023, completion of enrollment in the Phase 2b DLB trial in the first half of 2024, and topline data from the placebo controlled portion of the Phase 2b DLB trial in the second half of 2024.Large Commercial Opportunity in DLBDLB is the second most common neurodegenerative disorder after Alzheimer’s disease and is more common than Parkinson’s disease. There are an estimated 700,000 patients each in the U.S. and E.U. The only currently approved therapy is cholinesterase inhibition, which is only moderately effective. As screening techniques that distinguish DLB from other neurodegenerative disease become more sophisticated, the rate of diagnosis will likely increase which could lead to an expanded market opportunity.ValuationWe value CervoMed using a probability-adjusted discounted cash flow model that takes into account potential future revenues of neflamapimod for the treatment of DLB in the U.S. and the E.U. The company has indicated that it may pursue additional indications for neflamapimod in the future, but for now we only consider DLB for modeling purposes. Additional indications for neflamapimod represents potential upside to our valuation. We model for CervoMed to enter into commercialization partnerships and to receive 15% royalties on net sales of neflamapimod for the treatment of DLB in both the U.S. and E.U.The following assumptions were made for generating our model: 1) A Phase 3 trial will initiate in 2025 followed by an NDA filing in 2027 and approval in the U.S. in 2028; 2) An MAA filing in the E.U. will occur in 2028 and approval in the E.U. will occur in 2029; 3) the list price for neflamapimod will be $30,000 in the U.S. and $15,000 in the E.U. upon launch, with a 3% yearly increase in price; 4) peak sales in the U.S. of approximately $2.4 billion and in the E.U. of approximately $1.2 billion seven and six years after launch in each jurisdiction, respectively; 5) a 15% gross-to-net adjustment; 6) patent exclusivity loss in 2035 with a subsequent 50% drop in revenues the following year.Using a 15% discount rate and a 33% probability of approval leads to a net present value for neflamapimod in DLB of $134.5 million. We combine this with the company’s estimated cash balance following the merger ($13 million) to derive a net present value for CervoMed of $147.5 million. Dividing by the current share count (5.7 million) plus an estimated 3.0 million shares for future dilution leads to a valuation of $17 per share.SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.

Zacks Small Cap Research

CRVO: Initiating Coverage of CervoMed, Inc.; Phase 2b Trial in Dementia with Lewy Bodies Underway…

https://finance.yahoo.com/news/crvo-initiating-coverage-cervomed-inc-121600153.html

533919dc-a0bb-356b-861b-d752e1eee61f

CRVO

BOSTON, Sept. 5, 2023 /PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced that the Company's senior management team will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11 at 9:00 a.m. ET. The company will also be holding 1x1 meetings at the conference.CervoMedA live webcast of the presentation, along with accompanying slides, will be accessible here, and will be available for replay for 90 days following the event.About CervoMedCervoMed Inc. is a clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The Company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha (p38a). Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in dementia with Lewy bodies (DLB) and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB. CervoMed was formed in August 2023 with completion of the merger of EIP Pharma Inc. with Diffusion Pharmaceuticals.For more information, please visit www.cervomed.com or engage with us on Twitter and LinkedIn.Forward-Looking StatementsThis press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of CervoMed Inc. (the "Company"), including, but not limited to, the therapeutic potential of neflamapimod; anticipated milestones related to the development of the Company's clinical programs, including timelines for trial enrollment and reporting of data; and the potential commercial opportunity of neflamapimod, if approved. Terms such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately," or other words that convey uncertainty of future events or outcomes may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company's control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company's available cash resources and the availability of additional funds on acceptable terms; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the U.S. Food and Drug Administration; the Company's ability to maintain its listing on the Nasdaq Capital Market, as well as comply with applicable Nasdaq rules and regulations; the market price of the Company's securities, which may be volatile due to a variety of factors, including changes in the competitive and highly regulated industry in which the Company operates; variations in operating performance across competitors; changes in laws and regulations affecting the Company's business; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K, in the proxy statement/prospectus/information statement that is included in the Company's registration statement on Form S-4 (File No. 333-271823) that was filed with the SEC, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified).  New factors emerge from time to time, and it is not possible for the Company to predict all such factors, nor can we assess the impact of each such factor on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this presentation, except to the extent required by law.Story continuesCisionView original content to download multimedia:https://www.prnewswire.com/news-releases/cervomed-to-present-at-hc-wainwright-25th-annual-global-investment-conference-301916119.htmlSOURCE CervoMed Inc.

PR Newswire

CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

https://finance.yahoo.com/news/cervomed-present-h-c-wainwright-110000280.html

7ae85aab-cd46-3b9a-af90-ed6036e1f2e7

CRVS

The oldest advice in the financial markets is to buy low and sell high. The trick to winning, however, is to find the right stocks to buy, and to remember that ‘buy low’ doesn’t always mean these stocks can’t go lower.Sometimes the best bargains really do come in at the lowest prices. There are plenty of stocks under $10 that won’t break your bank and still offer substantial upside potential. How substantial? Well, the analysts at investment banking giant Oppenheimer have pinpointed two winners among these low-cost stocks, and they see the upside beginning at 200% or better.What’s more, after using TipRanks’ database, we found out that both have scored enough positive reviews from the broader analyst community to earn a ‘Strong Buy’ consensus rating. Let’s see why these stocks are drawing plaudits across the board.Corvus Pharmaceuticals (CRVS)The first Oppenheimer pick we’re looking at is Corvus, a clinical-stage biopharmaceutical company focused on cancer treatment. The company’s approach is based on ITK inhibition, and its lead product candidate, CPI-818, also known as soquelitinib, acts as a selective ITK inhibitor with potential for treating both cancers and autoimmune/inflammatory diseases. The drug is an investigational, orally-administered small-molecule compound currently under clinical study for treating patients with T cell lymphoma.Corvus has an active research pipeline featuring soquelitinib in three additional pre-clinical tracks. This drug candidate is wholly owned by Corvus and researched in-house. The firm also has two additional clinical-stage research tracks: ciforadenant and mupadolimab. These are under development in partnership agreements – ciforadenant with the KCRC and mupadolimab with Angel Pharmaceuticals, a Chinese partner.In clinical updates, Corvus recently reported ongoing patient enrollment in the Phase 1/1b clinical trial of soquelitinib for relapsed TCL. Data released earlier this summer showed three complete responses and three partial responses out of 30 patients enrolled at the optimum dose of 200mg twice daily. The company believes that the current Phase 1/1b trial will provide the safety and efficacy data needed to inform the design of a potential Phase 3 registrational trial. The company plans to meet with the FDA within the next several weeks to discuss next steps.Story continuesOn the partner-led clinical trials, the KCRC is enrolling patients in the Phase 2 portion of a Phase 1b/2 trial of ciforadenant. Up to 60 patients are expected to be enrolled, and initial data is expected to be available before year-end. The company’s Chinese partner, Angel, is enrolling patients in a Phase 1/1b trial of mupadolimab for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell cancers. This trial will test mupadolimab both as a monotherapy and as a combination therapy with pembrolizumab.The clinical programs here are the key to Corvus, according to Oppenheimer analyst Jeff Jones. Jones says of the stock, “We view CRVS’s three clinical-stage programs as highly promising… Recent clinical updates for soquelitinib continue to support single agent activity in a biomarker defined subset of patients with r/r PTCL, with near-term (3Q23) FDA feedback anticipated to illuminate the path to a pivotal Phase 3 trial. Soquelitinib has the potential to be used in oncology and inflammatory/autoimmune diseases, with both soquelitinib and ciforadenant having the potential for activity in a broad range of tumor types, including the potential to enhance the activity of immune checkpoint inhibitors (ICIs).”Based on the potential of Corvus’s clinical programs, and its $2.06 share price, Jones thinks that now is the time to get in on the action. The analyst rates CRVS an Outperform (i.e. Buy), while his $7 price target implies a substantial 240% upside for the year ahead. (To watch Jones’ track record, click here)Looking at the consensus breakdown, most other analysts are on the same page. With 3 Buys and 1 Hold, the word on the Street is that CRVS is a Strong Buy. The $6.63 average price target puts the upside potential at ~222%. (See CRVS stock forecast)Astria Therapeutics (ATXS)The second Oppenheimer choice is Astria Therapeutics, a clinical-stage biopharma working on treatments for HAE (Hereditary Angioedema). This is a serious condition characterized by episodes of extreme swelling, usually in the face and limbs. The disease can also attack the abdomen or airway, is painful, can be disabling, and in severe cases, can even be life-threatening.The company’s chief product is STAR-0215, potentially a best-in-class monoclonal antibody inhibitor of plasma kallikrein. The drug candidate is designed for long-term dosing every 3 to 6 months and acts as a prophylactic treatment, effectively preventing HAE attacks.STAR-0215 has been successful in its clinical studies and shows high potential for further clinical trial successes. Astria last year released positive preliminary results from the Phase 1a trial in healthy subjects. Early this year, the company initiated its ALPHA-STAR proof-of-concept trial in patients with HAE. Initial results from this proof-of-concept study, including both single and multiple dose cohorts, are expected for release in the middle of next year.Before that, the company expects to release final results from three single-dose, healthy subject cohorts during the fourth quarter of 2023. At the same time, the company will initiate a long-term open-label trial, ALPHA-SOLAR, to test STAR-0215’s long-term safety, tolerability, and efficacy in the treatment of HAE. All of these trials are supported by the FDA’s grant of Fast Track status to the drug candidate.For Oppenheimer analyst Hartaj Singh, the active clinical program, with plenty of catalysts down the road, is the main feature for investors to consider.“Given encouraging initial clinical results from a differentiated profile, we think that STAR-0215 could have promising PoC updates with a reliable MoA in 2024… By YE23, data on 6-month dosing cohorts should be available, per management. If the data is acceptable, we believe that significant upside exists for the share price… With cash of $203M at end of 2Q, we see a cash runway for ATXS to fund itself into 1H25. The potential best-in-class benefit/risk profile leads us to being long-term buyers,” Singh opined.Quantifying his stance, Singh rates ATXS an Outperform (i.e. Buy) and gives the stock a $30 price target to suggest a robust 242% upside on the one-year horizon. (To watch Singh’s track record, click here)Taking a macro view of Astria, we find that the stock has a Strong Buy consensus rating based on 5 unanimously positive analyst reviews. The average price target here is $26.20, representing ~200% upside potential from the current share price of $8.75. (See ATXS stock forecast)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

TipRanks

2 ‘Strong Buy’ Stocks Under $10 That Oppenheimer Sees Surging Over 200% — Here’s Why They Could Jump

https://finance.yahoo.com/news/2-strong-buy-stocks-under-140134800.html

a17fd859-c75a-3ede-8f49-15a11e6d3590

CRVS

Corvus Pharmaceuticals, Inc.Plans to initiate soquelitinib potentially registrational Phase 3 clinical trial in Q1 2024Company to host conference call and webcast tomorrow at 8:30 a.m. ET / 5:30 a.m. PTBURLINGAME, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, confirmed today that it completed an End-of-Phase/Pre-Phase 3 meeting with FDA on its plans to initiate a Phase 3 registrational clinical trial of soquelitinib (formerly CPI-818), the Company's ITK inhibitor product candidate, in relapsed peripheral T cell lymphoma (PTCL).“We are pleased with the outcome of our End-of-Phase/Pre-Phase 3 meeting with FDA, allowing us to advance ITK inhibition with soquelitinib into a potentially registrational clinical trial for patients with relapsed peripheral T cell lymphoma,” said Richard A. Miller, co-founder, president and chief executive officer of Corvus. “We appreciate the FDA’s input and their confirmation on the key aspects of the trial design, including sample size, dosing, eligibility, comparator arm and endpoints. We are now focused on finalizing the study protocol, qualifying trial sites and completing other standard steps required to initiate the trial. Based on current timelines, we anticipate that we can initiate the trial in the first quarter of 2024.”The soquelitinib Phase 3 potentially registrational clinical trial is designed to enroll a total of 150 patients with relapsed PTCL that have received three or fewer prior therapies. Patients will be randomized 1:1 to soquelitinib 200 mg two-times a day or standard of care chemotherapy. The primary endpoint will be progression-free survival. Secondary endpoints will include objective response rate and overall survival. The Company is recruiting U.S. and international investigators and anticipates that leading academic and private medical centers with significant experience in lymphoma research will participate in the trial, including a principal investigator who has conducted other Phase 3 clinical trials in T cell lymphoma and authored many peer-reviewed articles on lymphomas.Story continuesDr. Miller added, “Soquelitinib’s proposed mechanism of action, based on selective ITK inhibition, represents a platform opportunity with the potential to address a wide range of indications beyond hematologic cancers, including solid tumors and autoimmune/allergic diseases.”Data highlighting the potential of selective inhibition of ITK to potentially enhance anti-tumor immune response to hematologic and solid tumors and provide a novel potential approach to cancer immunotherapy were recently published online as a preprint at bioRxiv.org. In addition, data demonstrating soquelitinib’s anti-tumor activity in patients with T cell lymphoma (TCL) and its therapeutic potential in Th2 and Th17-mediated autoimmune and allergic diseases was presented in a poster at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, which took place in December 2022. The preprint and ASH poster presentation are available on the Publications and Presentations page of the Corvus website.Conference Call DetailsCorvus will host a conference call and webcast tomorrow, Thursday, September 7, 2023, at 8:30 a.m. ET (5:30 a.m. PT), to discuss the soquelitinib Phase 3 clinical trial plan and other business updates. The conference call can be accessed by dialing 1-877-407-0784 (toll-free domestic) or 1-201-689-8560 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days.About Corvus PharmaceuticalsCorvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK and is planned to enter a Phase 3 potentially registrational clinical trial for patients with relapsed peripheral T cell lymphoma. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.About SoquelitinibSoquelitinib (CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function. The immunologic effects of soquelitinib lead to what is known as Th1 skewing and is made possible by the high selectivity of soquelitinib for ITK. Research on soquelitinib’s mechanism of action suggests that it has the potential to control differentiation of normal T helper cells and enhance immune responses to tumors by augmenting the generation of cytotoxic killer T cells and the production of cytokines that inhibit cancer cell survival. Soquelitinib has been shown to prevent T cell exhaustion, a major limitation of current immunotherapy and CAR-T therapies. Optimal doses of soquelitinib have been shown to affect T cell differentiation and induce the generation of Th1 helper cells while blocking the development of both Th2 and Th17 cells and production of their secreted cytokines. Th1 T cells are required for immunity to tumors, viral infections and other infectious diseases. Th2 and Th17 helper T cells are involved in the pathogenesis of many autoimmune and allergic diseases. The Company believes the inhibition of specific molecular targets in T cells may be of therapeutic benefit for patients with cancers, including solid tumors, and in patients with autoimmune and allergic diseases. Based on interim results from a Phase 1/1b clinical trial in patients with refractory T cell lymphomas, which demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies, the Company plans to initiate a potentially registrational Phase 3 clinical trial of soquelitinib in patients with relapsed peripheral T cell lymphoma (PTCL).About Peripheral T Cell LymphomaPeripheral T cell lymphoma (PTCL) is a heterogeneous group of malignancies accounting for about 10% of non-Hodgkin’s lymphomas (NHL) in Western populations, reaching 20% to 25% of NHL in some parts of Asia and South America. The most common subtypes are PTCL-not otherwise specified (PTCL-NOS) and T follicular helper cell lymphoma. Initial therapy for these diseases is typically combination chemotherapy, however, approximately 75% of patients either do not respond or relapse within the first two years. Patients in relapse are treated with various chemotherapy agents but have poor overall outcomes with median progression-free survival in the 3 to 4 month range and overall median survival of 6 to 12 months. There are no approved drugs in relapsed PTCL based on randomized trials.PTCL is a disease of mature helper T cells that express ITK, often containing numerous genetic mutations and frequently associated with viral infection. Most often the malignant cells of PTCL express a Th2 phenotype.Forward-Looking StatementsThis press release contains forward-looking statements, including statements related to the potential safety and efficacy of the Company’s product candidates including soquelitinib and ciforadenant; the potential use of soquelitinib to treat a variety of solid tumors and hematological cancers as well as autoimmune/allergic diseases; the Company’s ability and its partners’ ability, as well as the timing thereof, to develop and advance product candidates through and successfully complete preclinical studies and clinical trials, including the Company’s Phase 1/1b clinical trial of soquelitinib and its potentially registrational Phase 3 clinical trial for soquelitinib; the timing and its ability to launch clinical trials including the potentially registrational Phase 3 clinical trial for soquelitinib; and clinical trial designs and plans. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Quarterly Report on Form 10-Q for the three months ended June 30, 2023, filed with the Securities and Exchange Commission on August 8, 2023, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of soquelitinib and its other product candidates; the accuracy of the Company’s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the Company’s ability to enroll sufficient numbers of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States, and other foreign countries; the costs of clinical trials may exceed expectations; and the Company’s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.INVESTOR CONTACT:Leiv LeaChief Financial OfficerCorvus Pharmaceuticals, [email protected] CONTACT:Sheryl SeapyReal [email protected]

GlobeNewswire

Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA

https://finance.yahoo.com/news/corvus-pharmaceuticals-confirms-planned-initiation-200500185.html

63b54e6c-89bf-37a9-8929-5884a81058ef

CSBR

HACKENSACK, NJ / ACCESSWIRE / August 1, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions, today announced an agreement to adopt BioVolume's leading 3D imaging and thermal technology as their primary means of capturing efficacy results. Through this multi-year agreement Champions Oncology will incorporate BioVolume's cutting-edge thermal and 3D imaging platform into its broad portfolio of in vivo preclinical offerings. In alignment with Champions consistent focus on delivering the highest quality data and scientific excellence, the adoption of BioVolume technology will enable achievement of greater accuracy, reduced variability, and the generation of reliable insights to advance oncology drug development programs across different therapeutic modalities.BioVolume is advancing global preclinical oncology by providing greater study accuracy and helping strengthen drug filings for clinical trials with a digital record of preclinical efficacy. Specifically, BioVolume detects, segments, and measures subcutaneous tumor growth in rodents. By providing traceable imaging for each volume measurement alongside the additional capture of tumor height, it ensures greater reproducibility of study data and offers a statistically significant reduction in variability compared to calipers which rely on manual measurement. In silico modelling of BioVolume data demonstrates that reducing variability can decrease the chance of missing a therapeutic effect by a factor of seven in comparison to existing caliper-based processes.Maria Mancini, Chief Operating Officer at Champions Oncology said, "We are excited to announce our partnership with BioVolume. Adopting innovative technologies to digitize preclinical lab processes is critical to generating new breakthroughs in cancer research. The partnership will enable us to provide full transparency in study data collection and analysis, more accurate and consistent data, and greater scientific confidence to the pharma and biotech research community.""Champions Oncology and BioVolume are both forward-looking companies committed to advancing science, and we look forward to working together to enable faster, smarter and more confident decisions to be made in the identification and development of new cancer therapeutics," said Karl Turley, BioVolume Chief Operating Officer. "Cancer research is affected by a reproducibility crisis, and we believe our unique imaging platform will help tackle this challenge by transforming reproducibility in preclinical efficacy assessments."About Champions OncologyChampions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.Media Contact:Rachel Bunting, MS, MBAVP, Global [email protected]: www.championsoncology.comFacebook: https://www.facebook.com/championsoncology/LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/Twitter: https://twitter.com/ChampionsOncol1Instagram: https://www.instagram.com/championsoncology/About BioVolumeBioVolume is the world's first 3D imaging solution that has been developed in partnership with a leading pharmaceutical company and wider industry for visualizing and measuring subcutaneous tumor growth in preclinical oncology research. It was conceived to enable faster, smarter and more confident decisions to be made in the identification and development of new cancer therapeutics. To learn more about BioVolume, please visit www.biovolume.comMedia Contact:Karl TurleyChief Operating [email protected]: Champions Oncology, Inc.View source version on accesswire.com: https://www.accesswire.com/771263/Champions-Oncology-Announces-a-Multi-Year-Agreement-and-Strategic-Collaboration-with-BioVolume-to-Transform-Reproducibility-in-Preclinical-Oncology-Efficacy-Studies

ACCESSWIRE

Champions Oncology Announces a Multi-Year Agreement and Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies

https://finance.yahoo.com/news/champions-oncology-announces-multi-agreement-124500515.html

5fb89d0f-fbd2-3a03-9132-e8940112bd7a

CSBR

HACKENSACK, NJ / ACCESSWIRE / August 22, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, kicks-off its annual series of events by hosting a scientific symposium at the Museum of Science, in Boston, Massachusetts on September 26th.This year's event, titled "Uncovering Integrative Approaches for Oncology Drug Development" will focus on how the integrated use of clinically relevant patient-derived models, multi-omics analytics, and high complexity phenotypical assays are impacting the entire drug development continuum across multiple therapeutic modalities.With a remarkable lineup of nine speakers representing biopharma companies including AstraZeneca, Codagenix, Blueprint Medicines, Bicycle Therapeutics, C4 Therapeutics, and Corellia AI, talks will provide the latest insights about exciting preclinical and clinical programs and discuss the use of innovative integrated approaches to accelerate their oncology programs. The event will be opened by a distinguished keynote speaker, Dr. Olivier Elemento from Cornell Medicine, who will discuss advancements and the future of oncology precision medicine.Champions' Chief Executive Officer, Ronnie Morris said, "As a leading partner for both preclinical and clinical programs, Champions Oncology is proud to host an event that will bring together a renowned group of leaders in the field and enable enlightening and exciting scientific discussions, that will result in the achievement of our shared mission of improving patient's lives".The symposium will feature Champions' Senior Scientific Director, Dr. Stefano Cairo, and the Director of Flow Cytometry, Dr. Brandon Walling, presenting the latest advancement in integrative approaches using patient-derived models and high-complexity flow cytometry in translational research.The event is proudly sponsored by Champions in partnership with BGI Americas and Emulate and is free to attend, with limited seats.Story continuesFor the full agenda and to register for the upcoming symposium, visit our website at: https://www.championsoncology.com/upcoming-events/boston-symposium_2023About Champions OncologyChampions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.Media Contact:Rachel Bunting, MS, MBAVP, Global [email protected]: www.championsoncology.comFacebook: https://www.facebook.com/championsoncology/LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/Twitter: https://twitter.com/ChampionsOncol1Instagram: https://www.instagram.com/championsoncology/SOURCE: Champions Oncology, Inc.View source version on accesswire.com: https://www.accesswire.com/775798/Champions-Oncology-Announces-Remarkable-Lineup-of-Speakers-at-Its-Translational-Oncology-Symposium-in-Boston-in-September-2023

ACCESSWIRE

Champions Oncology Announces Remarkable Lineup of Speakers at Its Translational Oncology Symposium in Boston in September 2023

https://finance.yahoo.com/news/champions-oncology-aannounces-remarkable-lineup-123000919.html

6896d717-6898-3345-b70d-e6e43d0a7c3f

CSCO

When many investors think of tech stocks, they picture growth stocks aggressively reinvesting profits to focus on growing as much as possible, as fast as possible. While that may be true for a lot of tech stocks, it's just one side of the coin. Here are three dividend-paying tech stocks investors should consider this month.Continue reading

Motley Fool

3 Dividend-Paying Tech Stocks to Buy in September

https://finance.yahoo.com/m/ca24dc8f-88d7-3e82-b0eb-c02492c1f42b/3-dividend-paying-tech-stocks.html

ca24dc8f-88d7-3e82-b0eb-c02492c1f42b

CSCO

Cisco (NASDAQ: CSCO) marched 10% higher last month, according to S&P Global Market Intelligence. Cisco's fiscal fourth quarter beat Wall Street's expectations for both revenue and earnings. The company reported 16% revenue growth over the prior year, which the company attributed to several factors.Continue reading

Motley Fool

Here's Why Cisco Stock Climbed 10% in August

https://finance.yahoo.com/m/a99d36ab-082c-3569-8294-119eee295cf7/here-s-why-cisco-stock.html

a99d36ab-082c-3569-8294-119eee295cf7

CSGP

WASHINGTON, September 07, 2023--(BUSINESS WIRE)--Andy Florance, Founder and Chief Executive Officer of CoStar Group (NASDAQ: CSGP), a leading provider of online real estate marketplaces, information and analytics in the property markets, today was honored as one of Washingtonian’s 2023 Tech Titans.The Tech Titans list, published annually, recognizes industry leaders across the D.C. area who make innovative and important contributions to the region’s technology sector. Tech Titan winners include entrepreneurs, government officials, cybersecurity experts, venture capitalists and others who are committed to propelling the tech industry forward and creating new solutions across a variety of industries. Florance’s position on the list reflects his commitment to digitizing both commercial and residential real estate data and providing best-in-class technology capabilities to better serve the entire real estate industry.Founded in 1986, CoStar Group comprises over 5,500 employees across 14 countries. The company has seen consistent revenue growth quarter-over-quarter in 2022 and 2023, and net new bookings growing to $82 million in Q2 2023. In June 2023, traffic to all of CoStar Group’s web sites reached a new high of 105 million unique visitors, according to Google Analytics."We’re proud to have such a strong presence in the D.C. area and it’s an honor to be named a Tech Titan amongst other industry leaders in the community," said Andy Florance. "Since CoStar Group’s inception, finding innovative solutions and creating best-in-class technology for more seamless user experiences has been at the forefront of our success. We are committed to being a leading provider of real estate data, analytics and online marketplaces and will continue to introduce new opportunities that benefit our clients and communities."About CoStar GroupCoStar Group (NASDAQ: CSGP) is a leading provider of online real estate marketplaces, information, and analytics in the property markets. Founded in 1987, CoStar Group conducts expansive, ongoing research to produce and maintain the largest and most comprehensive database of real estate information. CoStar is the global leader in commercial real estate information, analytics, and news, enabling clients to analyze, interpret and gain unmatched insight on property values, market conditions and availabilities. Apartments.com is the leading online marketplace for renters seeking great apartment homes, providing property managers and owners a proven platform for marketing their properties. LoopNet is the most heavily trafficked online commercial real estate marketplace with over twelve million monthly global unique visitors. STR provides premium data benchmarking, analytics, and marketplace insights for the global hospitality industry. Ten-X offers a leading platform for conducting commercial real estate online auctions and negotiated bids. Homes.com is the fastest growing online residential marketplace that connects agents, buyers, and sellers. BureauxLocaux is one of the largest specialized property portals for buying and leasing commercial real estate in France. Business Immo is France’s leading commercial real estate news service. Thomas Daily is Germany’s largest online data pool in the real estate industry. Belbex is the premier source of commercial space available to let and for sale in Spain. CoStar Group’s websites attract nearly 100 million unique monthly visitors. Headquartered in Washington, DC, CoStar Group maintains offices throughout the U.S., Europe, Canada, and Asia. From time to time, we plan to utilize our corporate website, CoStarGroup.com, as a channel of distribution for material company information. For more information, visit CoStarGroup.com.Story continuesView source version on businesswire.com: https://www.businesswire.com/news/home/20230907626734/en/ContactsNews Media Contact Matthew BlocherCoStar Group(202) [email protected]

Business Wire

Andy Florance Named 2023 Tech Titan By Washingtonian Magazine

https://finance.yahoo.com/news/andy-florance-named-2023-tech-150000577.html

6abe83fc-1b0c-3cb1-9941-e8e3a852032d

CSGP

CoStar Group, Inc. (NASDAQ:CSGP) received a lot of attention from a substantial price movement on the NASDAQGS over the last few months, increasing to US$91.80 at one point, and dropping to the lows of US$77.88. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether CoStar Group's current trading price of US$82.57 reflective of the actual value of the large-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at CoStar Group’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change. Check out our latest analysis for CoStar Group What Is CoStar Group Worth?The stock is currently trading at US$82.57 on the share market, which means it is overvalued by 31% compared to my intrinsic value of $62.90. This means that the opportunity to buy CoStar Group at a good price has disappeared! In addition to this, it seems like CoStar Group’s share price is quite stable, which could mean two things: firstly, it may take the share price a while to fall back down to an attractive buying range, and secondly, there may be less chances to buy low in the future once it reaches that value. This is because the stock is less volatile than the wider market given its low beta.Can we expect growth from CoStar Group?earnings-and-revenue-growthFuture outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. With profit expected to grow by 75% over the next couple of years, the future seems bright for CoStar Group. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.What This Means For YouAre you a shareholder? It seems like the market has well and truly priced in CSGP’s positive outlook, with shares trading above its fair value. At this current price, shareholders may be asking a different question – should I sell? If you believe CSGP should trade below its current price, selling high and buying it back up again when its price falls towards its real value can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.Story continuesAre you a potential investor? If you’ve been keeping an eye on CSGP for a while, now may not be the best time to enter into the stock. The price has surpassed its true value, which means there’s no upside from mispricing. However, the optimistic prospect is encouraging for CSGP, which means it’s worth diving deeper into other factors in order to take advantage of the next price drop.Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. In terms of investment risks, we've identified 2 warning signs with CoStar Group, and understanding them should be part of your investment process.If you are no longer interested in CoStar Group, you can use our free platform to see our list of over 50 other stocks with a high growth potential.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

At US$82.57, Is CoStar Group, Inc. (NASDAQ:CSGP) Worth Looking At Closely?

https://finance.yahoo.com/news/us-82-57-costar-group-130015522.html

92c7e910-395f-32fc-af63-93949db4e251

CSPI

It looks like CSP Inc. (NASDAQ:CSPI) is about to go ex-dividend in the next four days. Typically, the ex-dividend date is one business day before the record date which is the date on which a company determines the shareholders eligible to receive a dividend. The ex-dividend date is of consequence because whenever a stock is bought or sold, the trade takes at least two business day to settle. This means that investors who purchase CSP's shares on or after the 22nd of August will not receive the dividend, which will be paid on the 12th of September.The company's next dividend payment will be US$0.04 per share, and in the last 12 months, the company paid a total of US$0.16 per share. Last year's total dividend payments show that CSP has a trailing yield of 1.1% on the current share price of $14.9. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. So we need to investigate whether CSP can afford its dividend, and if the dividend could grow. View our latest analysis for CSP If a company pays out more in dividends than it earned, then the dividend might become unsustainable - hardly an ideal situation. CSP has a low and conservative payout ratio of just 12% of its income after tax. Yet cash flows are even more important than profits for assessing a dividend, so we need to see if the company generated enough cash to pay its distribution.Click here to see how much of its profit CSP paid out over the last 12 months.historic-dividendHave Earnings And Dividends Been Growing?Companies with consistently growing earnings per share generally make the best dividend stocks, as they usually find it easier to grow dividends per share. If earnings fall far enough, the company could be forced to cut its dividend. Fortunately for readers, CSP's earnings per share have been growing at 13% a year for the past five years.Many investors will assess a company's dividend performance by evaluating how much the dividend payments have changed over time. CSP has seen its dividend decline 2.2% per annum on average over the past 10 years, which is not great to see. It's unusual to see earnings per share increasing at the same time as dividends per share have been in decline. We'd hope it's because the company is reinvesting heavily in its business, but it could also suggest business is lumpy.Story continuesThe Bottom LineIs CSP worth buying for its dividend? We like that CSP has been successfully growing its earnings per share at a nice rate and reinvesting most of its profits in the business. However, we note the high cashflow payout ratio with some concern. Overall we're not hugely bearish on the stock, but there are likely better dividend investments out there.On that note, you'll want to research what risks CSP is facing. For instance, we've identified 3 warning signs for CSP (1 is a bit concerning) you should be aware of.If you're in the market for strong dividend payers, we recommend checking our selection of top dividend stocks.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

There's A Lot To Like About CSP's (NASDAQ:CSPI) Upcoming US$0.04 Dividend

https://finance.yahoo.com/news/theres-lot-csps-nasdaq-cspi-100332721.html

08901d56-5ec4-356d-a35f-b18e80e0996d

CSPI

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. Loss making companies can act like a sponge for capital - so investors should be cautious that they're not throwing good money after bad.So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like CSP (NASDAQ:CSPI). While profit isn't the sole metric that should be considered when investing, it's worth recognising businesses that can consistently produce it. View our latest analysis for CSP CSP's Improving ProfitsInvestors and investment funds chase profits, and that means share prices tend rise with positive earnings per share (EPS) outcomes. So a growing EPS generally brings attention to a company in the eyes of prospective investors. It's an outstanding feat for CSP to have grown EPS from US$0.18 to US$1.04 in just one year. While it's difficult to sustain growth at that level, it bodes well for the company's outlook for the future. But the key is discerning whether something profound has changed, or if this is a just a one-off boost.Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. The music to the ears of CSP shareholders is that EBIT margins have grown from -1.6% to 3.8% in the last 12 months and revenues are on an upwards trend as well. Ticking those two boxes is a good sign of growth, in our book.In the chart below, you can see how the company has grown earnings and revenue, over time. Click on the chart to see the exact numbers.Story continuesearnings-and-revenue-historySince CSP is no giant, with a market capitalisation of US$76m, you should definitely check its cash and debt before getting too excited about its prospects.Are CSP Insiders Aligned With All Shareholders?It's said that there's no smoke without fire. For investors, insider buying is often the smoke that indicates which stocks could set the market alight. Because often, the purchase of stock is a sign that the buyer views it as undervalued. Of course, we can never be sure what insiders are thinking, we can only judge their actions.While there was some insider selling, that pales in comparison to the US$1.4m that the company insider, Joseph Nerges spent acquiring shares. The average price paid was about US$11.51. Insider buying like this is a rare occurrence and should stoke the interest of the market and shareholders alike.On top of the insider buying, it's good to see that CSP insiders have a valuable investment in the business. As a matter of fact, their holding is valued at US$22m. That shows significant buy-in, and may indicate conviction in the business strategy. That amounts to 29% of the company, demonstrating a degree of high-level alignment with shareholders.Is CSP Worth Keeping An Eye On?CSP's earnings per share have been soaring, with growth rates sky high. The cherry on top is that insiders own a bunch of shares, and one has been buying more. These factors seem to indicate the company's potential and that it has reached an inflection point. We'd suggest CSP belongs near the top of your watchlist. Even so, be aware that CSP is showing 3 warning signs in our investment analysis , and 1 of those is potentially serious...The good news is that CSP is not the only growth stock with insider buying. Here's a list of them... with insider buying in the last three months!Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

We Ran A Stock Scan For Earnings Growth And CSP (NASDAQ:CSPI) Passed With Ease

https://finance.yahoo.com/news/ran-stock-scan-earnings-growth-145614906.html

7b9e5483-0cdc-3260-8f50-fa1c1e1e9522

CSR

MINNEAPOLIS, Aug. 24, 2023 /PRNewswire/ -- Centerspace (NYSE: CSR) published its 2022 Environmental, Social, and Governance (ESG) Report, highlighting the company's commitment to sustainable business practices in the multifamily industry. This is the company's fourth annual report following its 2019 formation of an Environmental, Social, and Governance Committee established to lead the charge in identifying, implementing, and tracking the progress of various sustainability initiatives.In 2022, Centerspace focused on setting formal ESG targets to guide the company's ESG strategy over the next five to eight years. Other key accomplishments throughout the year include completion of the company's initial GRESB (formerly known as the Global Real Estate Sustainability Benchmark) submission, enhancing resident engagement and reputation management efforts, and being named the National Apartment Association's Leading Organization in Diversity, Equity, and Inclusion."We are in a position where we can easily identify the investments that we need to make to enhance our commitment to ESG, and I am looking forward to our continued execution of these important initiatives," said Anne Olson, Centerspace President and CEO.Centerspace is committed to exploring and implementing common-sense business practices that further its ability to operate in an environmentally responsible manner. This includes being good stewards of resources, pursuing opportunities to minimize consumption, managing and reducing waste, and conserving energy and water.The full report can be accessed on the Centerspace website at:https://ir.centerspacehomes.com/corporate-overview/corporate-governance/default.aspxAbout CenterspaceCenterspace is an owner and operator of apartment communities committed to providing great homes by focusing on integrity and serving others. Founded in 1970, as of June 30, 2023, Centerspace owned interests in 75 apartment communities consisting of 13,497 apartment homes located in Colorado, Minnesota, Montana, Nebraska, North Dakota, and South Dakota. In 2022, Centerspace was named the National Apartment Association's Leading Organization in Diversity, Equity, and Inclusion. For more information, please visit www.centerspacehomes.com.Story continuesIf you would like more information about this topic, please contact Josh Klaetsch, Director of Investor Relations, at 701-837-7104, or [email protected] InformationJosh KlaetschPhone: 701-837-7104Email: [email protected](PRNewsfoto/Centerspace)CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/centerspace-announces-fourth-annual-environmental-social-and-governance-report-301909506.htmlSOURCE Centerspace

PR Newswire

CENTERSPACE ANNOUNCES FOURTH ANNUAL ENVIRONMENTAL, SOCIAL, AND GOVERNANCE REPORT

https://finance.yahoo.com/news/centerspace-announces-fourth-annual-environmental-203000294.html

8f837c17-00c2-32af-adb3-fa0d1f1f1981

CSR

MINNEAPOLIS, Sept. 1, 2023 /PRNewswire/ -- NYSE: CSR. Centerspace's Board of Trustees announced today that it has declared a regular quarterly distribution of $0.73 per share/unit, payable on October 10, 2023, to common shareholders and unitholders of record at the close of business on September 29, 2023.The Board of Trustees also declared a distribution of $0.4140625 per share on the 6.625% Series C Cumulative Redeemable Preferred Shares (NYSE: CSR PRC), payable on September 29, 2023, to holders of record at the close of business on September 15, 2023. Series C preferred share distributions are cumulative and payable quarterly in arrears at an annual rate of $1.65625 per share.About CenterspaceCenterspace is an owner and operator of apartment communities committed to providing great homes by focusing on integrity and serving others. Founded in 1970, the company currently owns 75 apartment communities consisting of 13,497 homes located in Colorado, Minnesota, Montana, Nebraska, North Dakota, and South Dakota. In 2022, Centerspace was named the National Apartment Association's Leading Organization in Diversity, Equity, and Inclusion. For more information, please visit www.centerspacehomes.com.If you would like more information about this topic, please contact Josh Klaetsch, Investor Relations, at (701) 837-7104 or [email protected].(PRNewsfoto/Centerspace) CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/centerspace-announces-quarterly-dividend-301916238.htmlSOURCE Centerspace

PR Newswire

CENTERSPACE ANNOUNCES QUARTERLY DIVIDEND

https://finance.yahoo.com/news/centerspace-announces-quarterly-dividend-210000540.html

c2c36b52-6df4-3de0-8f63-d77f16f82f86

CSWC

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away.Despite being in the age of tech-stock blue-sky investing, many investors still adopt a more traditional strategy; buying shares in profitable companies like Capital Southwest (NASDAQ:CSWC). Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Capital Southwest with the means to add long-term value to shareholders. View our latest analysis for Capital Southwest Capital Southwest's Earnings Per Share Are GrowingThe market is a voting machine in the short term, but a weighing machine in the long term, so you'd expect share price to follow earnings per share (EPS) outcomes eventually. So it makes sense that experienced investors pay close attention to company EPS when undertaking investment research. Impressively, Capital Southwest has grown EPS by 28% per year, compound, in the last three years. If the company can sustain that sort of growth, we'd expect shareholders to come away satisfied.Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. It's noted that Capital Southwest's revenue from operations was lower than its revenue in the last twelve months, so that could distort our analysis of its margins. Capital Southwest shareholders can take confidence from the fact that EBIT margins are up from 78% to 83%, and revenue is growing. Both of which are great metrics to check off for potential growth.Story continuesThe chart below shows how the company's bottom and top lines have progressed over time. For finer detail, click on the image.earnings-and-revenue-historyOf course the knack is to find stocks that have their best days in the future, not in the past. You could base your opinion on past performance, of course, but you may also want to check this interactive graph of professional analyst EPS forecasts for Capital Southwest.Are Capital Southwest Insiders Aligned With All Shareholders?Insider interest in a company always sparks a bit of intrigue and many investors are on the lookout for companies where insiders are putting their money where their mouth is. That's because insider buying often indicates that those closest to the company have confidence that the share price will perform well. However, insiders are sometimes wrong, and we don't know the exact thinking behind their acquisitions.In the last twelve months Capital Southwest insiders spent US$29k on stock; good news for shareholders. While this investment may be modest, it is great considering the lack of insider selling.The good news, alongside the insider buying, for Capital Southwest bulls is that insiders (collectively) have a meaningful investment in the stock. To be specific, they have US$42m worth of shares. That shows significant buy-in, and may indicate conviction in the business strategy. Even though that's only about 4.8% of the company, it's enough money to indicate alignment between the leaders of the business and ordinary shareholders.Is Capital Southwest Worth Keeping An Eye On?You can't deny that Capital Southwest has grown its earnings per share at a very impressive rate. That's attractive. Furthermore, company insiders have been adding to their significant stake in the company. These things considered, this is one stock worth watching. However, before you get too excited we've discovered 4 warning signs for Capital Southwest (3 are a bit concerning!) that you should be aware of.Keen growth investors love to see insider buying. Thankfully, Capital Southwest isn't the only one. You can see a a free list of them here.Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

With EPS Growth And More, Capital Southwest (NASDAQ:CSWC) Makes An Interesting Case

https://finance.yahoo.com/news/eps-growth-more-capital-southwest-114730869.html

6fd53766-cf9d-3a49-94bc-0c57959e1f67

CSWC

Capital Southwest CorporationSpecial Meeting to be held on October 11, 2023DALLAS, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (the “Company” or “Capital Southwest”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, today announced an upcoming Special Meeting of Shareholders (the “Special Meeting”) to be held virtually on October 11, 2023.Shareholders will soon be receiving a formal notice of the Special Meeting and a proxy statement outlining the proposals being considered for a shareholder vote. These matters are of utmost importance and relate to a proposed amendment to the Company’s Charter to increase the number of authorized shares of common stock from 40,000,000 to 75,000,000 shares. The additional authorized shares of common stock will allow the Company to continue its strong track record of growing the asset base by pursuing attractive investment opportunities consistent with the Company’s investment strategy. If the Company were unable to access the equity capital markets by issuing additional common shares, the Company’s ability to grow the balance sheet could be adversely affected.It is important that all shares be represented at the Special Meeting. The Company has hired a proxy solicitor who may be contacting shareholders prior to the Special Meeting to assist in the voting process. Every vote is very important to the Company, regardless of the number of shares held. About Capital SouthwestCapital Southwest Corporation (Nasdaq: CSWC) is a Dallas, Texas-based, internally managed business development company with approximately $1.3 billion in investments at fair value as of June 30, 2023. Capital Southwest is a middle market lending firm focused on supporting the acquisition and growth of middle market businesses with $5 million to $35 million investments across the capital structure, including first lien, second lien and non-control equity co-investments. As a public company with a permanent capital base, Capital Southwest has the flexibility to be creative in its financing solutions and to invest to support the growth of its portfolio companies over long periods of time.Story continuesAdditional Information and Where to Find ItIn connection with the Special Meeting the Company intends to file with the Securities and Exchange Commission (the “SEC”) and mail to its shareholders a proxy statement on Schedule 14A (the “Proxy Statement”). SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT CAREFULLY AND, IN ITS ENTIRETY, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE SPECIAL MEETING. When available, shareholders will be able to obtain the Proxy Statement filed with the SEC by the Company, free of charge, from the SEC’s web site at www.sec.gov and from the Company’s website (www.capitalsouthwest.com). Participants in the SolicitationThe Company and its directors, executive officers, employees and other persons may be deemed to be participants in the anticipated solicitation of proxies in connection with the Special Meeting. Information regarding the Company’s directors and executive officers is available in its definitive proxy statement for its 2023 annual meeting of shareholders filed with the SEC on June 2, 2023 (the “Annual Meeting Proxy Statement”). To the extent holdings of securities by such directors or executive officers have changed since the amounts disclosed in the Annual Meeting Proxy Statement, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed by such directors or executive officers, as the case may be, with the SEC. More detailed information regarding the identity of potential participants, and their direct or indirect interests, by security holdings or otherwise, will be set forth in the Proxy Statement when such documents become available and in other relevant materials to be filed with the SEC. These documents may be obtained free of charge from the sources indicated above.Forward-Looking StatementsThis press release contains forward-looking statements with respect to the Company’s business, including, but not limited to, the statements about the Company's future performance and financial performance, such as the Company’s ability to maintain its track record and ability to access the equity capital in the future. Forward-looking statements are statements that are not historical statements and can often be identified by words such as "will," "believe," "expect" and similar expressions and variations or negatives of these words. These statements are based on management's current expectations, assumptions and beliefs. They are not guarantees of future results and are subject to numerous risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statement. These risks include risks related to: changes in the markets in which the Company invests; changes in the financial, capital, and lending markets; the Company’s ability to access equity capital and the Company’s ability to manage its capital resources effectively; changes in the interest rate environment and its impact on the Company’s business and its portfolio companies; an economic downturn and its impact on the ability of our portfolio companies to operate and the investment opportunities available to us; the impact of supply chain constraints and labor shortages on our portfolio companies; and the elevated levels of inflation and its impact on our portfolio companies and the industries in which the Company invests. Readers should not place undue reliance on any forward-looking statements and are encouraged to review the Company's Annual Report on Form 10-K for the year ended March 31, 2023 and any subsequent filings, including the "Risk Factors" sections therein, with the Securities and Exchange Commission for a more complete discussion of the risks and other factors that could affect any forward-looking statements. Except as required by the federal securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changing circumstances or any other reason after the date of this press release.Investor Relations Contact:Michael S. Sarner, Chief Financial Officer214-884-3829

GlobeNewswire

Capital Southwest Announces Special Meeting of Shareholders

https://finance.yahoo.com/news/capital-southwest-announces-special-meeting-212200436.html

981d66ac-13ec-336d-9111-3645d91e8d34

CSX

CSX LogoCSX Appoints Rail Industry Veteran as Chief Operating OfficerMike Cory, a seasoned railroad executive with more than 40 years of operations experience, named executive vice president and chief operating officer at CSX.JACKSONVILLE, Fla., Sept. 08, 2023 (GLOBE NEWSWIRE) -- CSX Corp. (NASDAQ: CSX) announced today the appointment of Mike Cory, a seasoned railroad executive with more than 40 years of operations experience, as the company’s executive vice president and chief operating officer.Formerly executive vice president and chief operating officer for the Canadian National (CN) Railway, Cory has provided transportation consulting services since retiring from the CN in 2019.“Mike Cory is one of the rail industry’s leading operations executives, respected for his wealth of operations knowledge and his success as a leader who understands the customers we serve and has a deep appreciation for the employees who provide that service,” said Joe Hinrichs, president and chief executive officer. “Mike’s reputation as a career railroader, devoted to process improvement, team building and employee development within the principles of scheduled railroading will help CSX continue to achieve new levels of safety, service and operating efficiency.”Cory began his railroad career in 1981 as a laborer in the CN locomotive shops in Winnipeg, Canada. Over the years, he rose through the ranks as a superintendent, general superintendent, director of service design, network operations superintendent and general manager of operations for the Michigan sub-region. He also broadened his business perspective by holding customer service and marketing positions. In 2006, he began his ascent through a series of senior leadership roles, including vice president of network operations, senior vice president of the Eastern region and senior vice president for the Western region. He was named executive vice president and chief operating officer in 2016.At CSX, Cory will lead a strong team of operations professionals – led by Ricky Johnson, Senior Vice President of Operations, and Casey Albright, Senior Vice President of Network Operations and Service Design – who have helped transform the company into a safety and service leader among North American Class I railroads. He will continue to strengthen the company’s operating model across the network while fostering a ONE CSX culture that values and engages front-line employees.Story continuesCSX also today announced that Kevin Boone, previously executive vice president of Sales and Marketing, is named executive vice president and chief commercial officer. The new title recognizes Boone’s breadth of existing responsibilities across CSX’s broad customer base and growing offering of supply chain solutions. Boone previously led the company’s finance organization before transitioning to sales and marketing in 2021. He joined CSX in 2017, following a successful 17-year career in the investment industry.“With our great team of talented leaders, I am confident that CSX will continue its momentum toward providing an industry-leading experience for our employees, customers, communities and shareholders,” said Hinrichs.About CSX CSX, based in Jacksonville, Florida, is a premier transportation company. It provides rail, intermodal and rail-to-truck transload services and solutions to customers across a broad array of markets, including energy, industrial, construction, agricultural, and consumer products. For nearly 200 years, CSX has played a critical role in the nation's economic expansion and industrial development. Its network connects every major metropolitan area in the eastern United States, where nearly two-thirds of the nation's population resides. It also links more than 240 short-line railroads and more than 70 ocean, river and lake ports with major population centers and farming towns alike.Contact:Matthew Korn, CFA, Investor Relations904-366-4515Bryan Tucker, Corporate Communications855-955-6397A photo accompanying this announcement is available at:https://www.globenewswire.com/NewsRoom/AttachmentNg/5d315f37-c04b-454a-a020-d12ffda530c2

GlobeNewswire

CSX Names Rail Industry Veteran Mike Cory Chief Operating Officer

https://finance.yahoo.com/news/csx-names-rail-industry-veteran-123000259.html

d4767515-7f15-3b2a-85e1-fc550ac38819

CSX

CSX has hired MIke Cory to be its next COO. (Photo: Jim Allen/FreightWaves)CSX has named Mike Cory, CN’s former chief operating officer, as its new COO, according to a Friday announcement from the Eastern U.S. Class I railroad.Cory, who has more than 40 years of operational experience, joined CN in 1981 as a laborer working in the Canadian railroad’s Winnipeg, Manitoba, locomotive shop and held various positions of increasing responsibility in both operations and sales and marketing before becoming COO in 2016.Prior to becoming COO, other leadership roles at CN included vice president of network operations, senior vice president of the Eastern region and senior vice president for the Western region. Cory retired from CN in 2019 and then worked as a consultant before becoming president of Pacific National, Australia’s largest private railroad, in 2021.At CSX (NASDAQ: CSX), Cory will work with the operations team, including Ricky Johnson, senior vice president of operations, and Casey Albright, senior vice president of network operations and service design. Johnson and Albright have been overseeing operations following former CSX COO Jamie Boychuk’s departure in August.CSX’s new COO Mike Cory. (Photo: CSX)“Mike Cory is one of the rail industry’s leading operations executives, respected for his wealth of operations knowledge and his success as a leader who understands the customers we serve and has a deep appreciation for the employees who provide that service,” CSX President and CEO Joe Hinrichs said in Friday’s announcement. “Mike’s reputation as a career railroader, devoted to process improvement, team building and employee development within the principles of scheduled railroading will help CSX continue to achieve new levels of safety, service and operating efficiency.”In addition to announcing Cory’s appointment, CSX said it promoted Kevin Boone to chief commercial officer. Boone had been serving as executive vice president of sales and marketing.“The new title recognizes Boone’s breadth of existing responsibilities across CSX’s broad customer base and growing offering of supply chain solutions,” CSX said.Story continuesSubscribe to FreightWaves’ e-newsletters and get the latest insights on freight right in your inbox.Click here for more FreightWaves articles by Joanna Marsh.Related links:CSX exec to depart; rail shippers urge renomination of STB membersCSX and Georgia Ports Authority offering new intermodal serviceCross-border traffic, West Coast port activity benefit Eastern railroadsThe post CSX hires ‘career railroader’ Cory as chief operating officer appeared first on FreightWaves.

FreightWaves

CSX hires ‘career railroader’ Cory as chief operating officer

https://finance.yahoo.com/news/csx-hires-career-railroader-cory-152721370.html

657adff4-ffd9-37dc-b326-4005accd11d9

CTAS

For Immediate ReleaseChicago, IL – September 8, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Humana Inc. HUM, Cintas Corp. CTAS, Biogen Inc. BIIB, Royal Caribbean Cruises Ltd. RCL and Markel Group Inc. MKL.Here are highlights from Thursday’s Analyst Blog:Top Analyst Reports for Humana, Cintas and BiogenThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Humana Inc., Cintas Corp. and Biogen Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today's research reports here >>>Shares of Humana have declined -8.9% over the year-to-date period against the Medical - HMOs industry's decline of -10.8%. The companies escalating operating costs are affecting profits. A debt-laden balance sheet induces a rise in interest expenses. As such, the stock warrants a cautious stance.Nevertheless, Humana's Medicaid business benefits from several contract wins and renewals thereby contributing to the top line. Strategic buyouts and alliances place it well for growth in the future.Solid contributions from the Insurance and CenterWell segments bode well. Management estimates adjusted 2023 EPS to be at least $28.25, reflecting minimum growth of 12% year over year. It has been deploying excess capital through share buybacks and dividend payments on balance sheet strength.(You can read the full research report on Humana here >>>)Cintas' shares have outperformed the Zacks Uniform and Related industry over the year-to-date period (+10.6% vs. +9.2%). Strong segmental performances have been aiding the company. Increased productivity level and new product launches are boosting the Uniform Rental and Facility Services segment's performances.Strength in the health and wellness businesses and high customer retention levels are driving the growth of the First Aid and Safety Services segment. The company's focus on enhancement of its product portfolio holds promise. Cintas' efforts to reward shareholders are impressive.However, the rising cost of sales, and increasing selling and administrative expenses pose a threat to the company's bottom line. High tax rate is an added concern for Cintas. Also, foreign currency headwinds are weighing on the company's top line.(You can read the full research report on Cintas here >>>)Shares of Biogen have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+26.8% vs. -10.8%). The company's potential new products like Leqembi in Alzheimer's disease, Qalsody in ALS and zuranolone in depression can help revive growth. With Leqembi receiving traditional approval and broader CMS coverage in the United States, it has the potential to generate blockbuster sales.Biogen is exploring both early to mid-stage assets and late-stage assets to build its pipeline. However, Biogen's has a high-risk pipeline. Sales of Leqembi are expected to be slow in 2023.  It is also facing multiple challenges at present like the generic erosion of Tecfidera, competitive pressure for Spinraza, declining profit share of Rituxan in the United States and the failure of Aduhelm. Most of its key drugs are facing declining sales.(You can read the full research report on Biogen here >>>)Other noteworthy reports we are featuring today include Royal Caribbean Cruises Ltd. and Markel Group Inc.Story continuesWhy Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.See Stocks Free >>Media ContactZacks Investment Research800-767-3771 ext. [email protected]                        https://www.zacks.comPast performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportBiogen Inc. (BIIB) : Free Stock Analysis ReportRoyal Caribbean Cruises Ltd. (RCL) : Free Stock Analysis ReportHumana Inc. (HUM) : Free Stock Analysis ReportCintas Corporation (CTAS) : Free Stock Analysis ReportMarkel Group Inc. (MKL) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

The Zacks Analyst Blog Highlights Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group

https://finance.yahoo.com/news/zacks-analyst-blog-highlights-humana-132400832.html

d827b702-a3a1-3102-be33-a91e6d786ec4

CTAS

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum.Is This 1 Momentum Stock a Screaming Buy Right Now?Different than value or growth investors, momentum-oriented investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.Cintas (CTAS)Founded in 1968 and headquartered in Cincinnati, OH, Cintas Corporation provides specialized services to businesses of all types throughout North America. It also operates in Europe, Asia and Latin America. The company designs, manufactures, implements corporate identity uniform programs, and provides entrance mats, restroom supplies, promotional products and first aid and safety products for diversified businesses.CTAS sits at a Zacks Rank #3 (Hold), holds a Momentum Style Score of A, and has a VGM Score of B. The stock is down 1.3% and up 1.5% over the past one-week and four-week period, respectively, and Cintas has gained 15.9% in the last one-year period as well. Additionally, an average of 286,232.09 shares were traded over the last 20 trading sessions.Momentum investors don't just pay attention to price changes; positive earnings play a crucial role, too. Four analysts revised their earnings estimate upwards in the last 60 days for fiscal 2024. The Zacks Consensus Estimate has increased $0.17 to $14.18 per share. CTAS boasts an average earnings surprise of 4.8%.Story continuesInvestors should take the time to consider CTAS for their portfolios due to its solid Zacks Ranks, notable earnings metrics, and impressive Momentum and VGM Style Scores.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportCintas Corporation (CTAS) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

https://finance.yahoo.com/news/why-1-momentum-stock-could-135007000.html

a9ff9b6a-8a6b-382e-acad-df0c0b583581

CTBI

Community Trust Bancorp, Inc. (NASDAQ:CTBI) will increase its dividend from last year's comparable payment on the 1st of October to $0.46. This takes the dividend yield to 4.7%, which shareholders will be pleased with. Check out our latest analysis for Community Trust Bancorp Community Trust Bancorp's Dividend Forecasted To Be Well Covered By EarningsWe like to see robust dividend yields, but that doesn't matter if the payment isn't sustainable.Community Trust Bancorp has a long history of paying out dividends, with its current track record at a minimum of 10 years. Past distributions do not necessarily guarantee future ones, but Community Trust Bancorp's payout ratio of 39% is a good sign as this means that earnings decently cover dividends.Over the next year, EPS is forecast to fall by 10.7%. But assuming the dividend continues along recent trends, we believe the future payout ratio could be 46%, which we are pretty comfortable with and we think would be feasible on an earnings basis.historic-dividendCommunity Trust Bancorp Has A Solid Track RecordThe company has a sustained record of paying dividends with very little fluctuation. The dividend has gone from an annual total of $1.15 in 2013 to the most recent total annual payment of $1.84. This means that it has been growing its distributions at 4.9% per annum over that time. Although we can't deny that the dividend has been remarkably stable in the past, the growth has been pretty muted.We Could See Community Trust Bancorp's Dividend GrowingSome investors will be chomping at the bit to buy some of the company's stock based on its dividend history. Community Trust Bancorp has impressed us by growing EPS at 7.1% per year over the past five years. Growth in EPS bodes well for the dividend, as does the low payout ratio that the company is currently reporting.We Really Like Community Trust Bancorp's DividendOverall, we think this could be an attractive income stock, and it is only getting better by paying a higher dividend this year. The distributions are easily covered by earnings, and there is plenty of cash being generated as well. We should point out that the earnings are expected to fall over the next 12 months, which won't be a problem if this doesn't become a trend, but could cause some turbulence in the next year. All of these factors considered, we think this has solid potential as a dividend stock.It's important to note that companies having a consistent dividend policy will generate greater investor confidence than those having an erratic one. Still, investors need to consider a host of other factors, apart from dividend payments, when analysing a company. Taking the debate a bit further, we've identified 1 warning sign for Community Trust Bancorp that investors need to be conscious of moving forward. If you are a dividend investor, you might also want to look at our curated list of high yield dividend stocks.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Community Trust Bancorp (NASDAQ:CTBI) Will Pay A Larger Dividend Than Last Year At $0.46

https://finance.yahoo.com/news/community-trust-bancorp-nasdaq-ctbi-123248527.html

d3afbffe-b3a4-34d0-ab35-f5340bce7cba

CTBI

Community Trust Bancorp, Inc.'s (NASDAQ:CTBI) dividend will be increasing from last year's payment of the same period to $0.46 on 1st of October. This takes the dividend yield to 5.2%, which shareholders will be pleased with. See our latest analysis for Community Trust Bancorp Community Trust Bancorp's Dividend Forecasted To Be Well Covered By EarningsIf the payments aren't sustainable, a high yield for a few years won't matter that much.Having distributed dividends for at least 10 years, Community Trust Bancorp has a long history of paying out a part of its earnings to shareholders. Past distributions do not necessarily guarantee future ones, but Community Trust Bancorp's payout ratio of 39% is a good sign as this means that earnings decently cover dividends.Over the next year, EPS is forecast to fall by 10.7%. But assuming the dividend continues along recent trends, we believe the future payout ratio could be 46%, which we are pretty comfortable with and we think would be feasible on an earnings basis.historic-dividendCommunity Trust Bancorp Has A Solid Track RecordThe company has a sustained record of paying dividends with very little fluctuation. Since 2013, the annual payment back then was $1.15, compared to the most recent full-year payment of $1.84. This works out to be a compound annual growth rate (CAGR) of approximately 4.9% a year over that time. While the consistency in the dividend payments is impressive, we think the relatively slow rate of growth is less attractive.The Dividend Has Growth PotentialInvestors could be attracted to the stock based on the quality of its payment history. It's encouraging to see that Community Trust Bancorp has been growing its earnings per share at 7.1% a year over the past five years. Growth in EPS bodes well for the dividend, as does the low payout ratio that the company is currently reporting.Community Trust Bancorp Looks Like A Great Dividend StockIn summary, it is always positive to see the dividend being increased, and we are particularly pleased with its overall sustainability. The distributions are easily covered by earnings, and there is plenty of cash being generated as well. If earnings do fall over the next 12 months, the dividend could be buffeted a little bit, but we don't think it should cause too much of a problem in the long term. All of these factors considered, we think this has solid potential as a dividend stock.Companies possessing a stable dividend policy will likely enjoy greater investor interest than those suffering from a more inconsistent approach. Still, investors need to consider a host of other factors, apart from dividend payments, when analysing a company. As an example, we've identified 1 warning sign for Community Trust Bancorp that you should be aware of before investing. Is Community Trust Bancorp not quite the opportunity you were looking for? Why not check out our selection of top dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Community Trust Bancorp (NASDAQ:CTBI) Is Increasing Its Dividend To $0.46

https://finance.yahoo.com/news/community-trust-bancorp-nasdaq-ctbi-100408680.html

6849acbd-ae0b-3580-abb9-d2c83fb4895a

CTCX

PITTSBURGH & FLAGSTAFF, Ariz., August 09, 2023--(BUSINESS WIRE)--Carmell Corporation (Nasdaq: CTCX) ("Carmell"), a regenerative care company today announced the successful closing of the previously announced merger with Flagstaff-based Axolotl Biologix, a profitable regenerative medicine company developing products for active soft tissue repair, aesthetics and orthopedic indications ("Axolotl").As previously indicated, the initial merger consideration consists of $8 million in cash and $57 million in CTCX common and preferred shares. The number of CTCX common shares was calculated based on a 30-day average of daily volume-weighted average price of the CTCX common shares, which was $7.05 per common share as of Closing. The $8 million in initial cash consideration is due on completion of certain Conditions Subsequent to Closing. Additionally, the following milestone payments are due:$10 million on achievement of $60 million in FY23 audited revenue$10 million on achievement of $80 million in FY23 audited revenue$10 million on achievement of 10% penetration or at least $10 million in booked TTM sales within 3 years of Closing for the Group Purchasing contract executed in Q2 FY23$5 million on execution of a National Purchasing Contract within 18 months of Closing$40 million on achievement of certain clinical milestones.Carmell also announced a change in its corporate identity from "Carmell Therapeutics Corporation" to "Carmell Corporation" and a new brand logo to reflect its broader focus on non-therapeutic indications in aesthetics.Said Mr. Josh Sandberg, CEO of Axolotl, "I am impressed with continued synergy and experienced leadership we have seen throughout this process. Being a part of a decisive and calculated team is going to lead to great combined success. Personally, I am extremely excited to work with Rajiv as we continue to build out the platform through organic as well as M&A strategies."Story continuesSaid Mr. Rajiv Shukla, Executive Chairman of Carmell, "With the closing of the Axolotl Biologix transaction, Carmell is well positioned to meet our goal of profitably achieving $100 million in FY24 revenue. In addition to exploring acquisitions of other commercial businesses, we are also working actively towards launching our first cosmeceutical product for skin rejuvenation by FY24."About AxolotlAxolotl has a portfolio of commercial products based on human amnion grafts for use in diabetic foot ulcers, venous foot ulcers and burns. Axolotl is also developing regenerative products for Foot/Ankle osteoarthritis, Androgenetic Alopecia and Skin rejuvenation. For more information, visit www.axobio.comAbout Carmell Carmell is developing allogeneic plasma-based biomaterials designed to boost innate regenerative pathways across a variety of skin and bone healing indications. Carmell received FDA clearance for a Phase 2-stage clinical trial designed to study accelerated healing and reduced infections in open tibia (shinbone) fractures with intramedullary rodding and is planning a Phase 2 trial for Foot/Ankle Fusion. Pre-clinical development is also underway in Spinal Fusion, Dental Bone Graft Substitute, Androgenetic Alopecia, Active Soft Tissue Repair and Cosmetic Skin Rejuvenation. For more information, visit www.carmellrx.comForward-Looking StatementsThis press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the proceeds of the business combination, the leadership of the combined company, the benefits of the transaction, as well as statements about the potential attributes and benefits of Axolotl’s product candidates and the format and timing of Axolotl’s product development activities and clinical trials. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, the ability to recognize the anticipated benefits of the transaction, the outcome of any legal proceedings that may be instituted against Carmell following completion of the transaction, the impact of COVID-19 on Axolotl’s business, costs related to the proposed transaction, changes in applicable laws or regulations, the possibility that CTCX or Axolotl may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those to be included under the header "Risk Factors" in the registration statement on Form S-4 filed by ALPA with the SEC, as amended (File No. 333-269733). Most of these factors are outside of Carmell’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.View source version on businesswire.com: https://www.businesswire.com/news/home/20230809916251/en/ContactsCarmell Investors:Rajiv ShuklaExecutive [email protected]

Business Wire

Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity

https://finance.yahoo.com/news/carmell-announces-successful-closing-merger-194100982.html

186bf5ab-f351-3320-b41e-2b359c2295e5

CTCX

Carmell Therapeutics CorporationPITTSBURGH, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX) (“Carmell”), a regenerative care company, today announced the completion of post-merger integration with Flagstaff-based Axolotl Biologix, a profitable regenerative medicine company (“Axolotl”).As part of the post-merger planning process, Carmell announced the following changes effective September 1, 2023:Rajiv Shukla, Executive Chairman of Carmell to serve as Chairman & CEO of Carmell.Randy Hubbell to step down as CEO and serve as Advisor to the Chairman & CEO in addition to Josh Sandberg, former CEO of Axolotl who is serving in a similar role.Changes to Carmell’s Board of Directors underway with three board members to step down and candidates with a background in aesthetics being recruited.Milestone payment of $8 million to Axolotl Biologix rescheduled to Aug 31, 2024.Projected post-merger savings anticipated to be nearly $3 million per annum, including from the termination of certain executives serving as part-time consultants and full-time employees in non-core areas or overlapping business functions.Focus on programs in aesthetics that have shorter paths to commercialization, specifically in skin rejuvenation and dental bone healing.“On behalf of Carmell Corp., I would like to thank Randy for his many years of service to the Team. I look forward to working with him as an advisor on commercial strategy,” said Mr. Shukla.Mr. Hubbell said, “I am proud of what we accomplished at Carmell over the years and look forward to continuing to work with Carmell as an advisor.”About Carmell Carmell is a commercial stage regenerative care company with a focus on using human biomaterials for aesthetics (skin and dental) and skin healing. Their commercial product is human amnion allograft that can be used for the healing of diabetic foot ulcers, venous ulcers, recovery from MOHS surgery, conjunctival and corneal healing, and dental, endodontic, oral maxillofacial, and periodontal regenerative procedures. Carmell’s R&D pipeline includes cosmetic and dental products under development. For more information, visit www.carmellrx.comStory continuesForward-Looking Statements This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, the leadership of the company, the savings from the post-merger integration, as well as statements about the potential attributes and benefits of Carmell’s product candidates and the format and timing of Carmell’s product development activities and clinical trials. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, the ability to recognize the anticipated benefits of the transaction, the outcome of any legal proceedings that may be instituted against Carmell, the impact of COVID-19 on Carmell’s business, changes in applicable laws or regulations, the possibility that Carmell may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those to be included under the header “Risk Factors” in the registration statement on Form S-4 filed by ALPA with the SEC, as amended (File No. 333-269733). Most of these factors are outside of Carmell’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.Contacts:Rajiv Shukla Chairman & [email protected]

GlobeNewswire

Carmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organizational Structure Aligned with Focus on Aesthetics

https://finance.yahoo.com/news/carmell-corporation-announces-completion-post-220300950.html

ca6383bc-e5b5-3192-ba1e-fa0dd9ad9620

CTKB

Cytek Biosciences, Inc.FREMONT, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference in New York, New York.Cytek management is scheduled to participate in a fireside chat on Wednesday, September 13th at 4:15 p.m. Eastern Time / 1:15 p.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: investors.cytekbio.com.About Cytek Biosciences, Inc.Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s FSP platform includes its core instruments, the Aurora and Northern Lights™ systems; its cell sorter, the Aurora CS; the flow cytometer and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.Other than Cytek’s Northern Lights CLC system and certain reagents for use therewith, which are available for clinical use in countries where the regulatory approval has been obtained from the local regulatory authorities, including China and the European Union, Cytek’s products are for research use only and not for use in diagnostic procedures.Cytek, Full Spectrum Profiling, FSP, Northern Lights, Amnis and Guava are trademarks of Cytek Biosciences, Inc.Story continuesIn addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and corporate “X” (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.Media Contact:Stephanie OlsenLages & Associates(949) [email protected] Relations Contact:Paul D. GoodsonHead of Investor [email protected]

GlobeNewswire

Cytek Biosciences to participate in the Morgan Stanley 21st Annual Global Healthcare Conference

https://finance.yahoo.com/news/cytek-biosciences-participate-morgan-stanley-201000151.html

76a95630-2f16-347b-9a31-b424506780ec

CTKB

On September 7, 2023, President and CEO Wenbin Jiang of Cytek Biosciences Inc (NASDAQ:CTKB) sold 20,000 shares of the company's stock. This move is part of a larger trend of insider selling at the company, which we will explore in more detail below.Who is Wenbin Jiang?Warning! GuruFocus has detected 4 Warning Signs with CTKB. Click here to check it out. CTKB 30-Year Financial DataThe intrinsic value of CTKBWenbin Jiang is the President and CEO of Cytek Biosciences Inc. He has been with the company for several years and has played a significant role in its growth and development. His insider trades provide valuable insight into the company's financial health and future prospects.About Cytek Biosciences IncCytek Biosciences Inc is a leading biotechnology company that specializes in the development and manufacturing of advanced flow cytometry systems. The company's innovative solutions are used in a wide range of applications, including clinical diagnostics, drug discovery, and biomedical research. With a market cap of $936.795 million, Cytek Biosciences Inc is a significant player in the biotech industry.Insider Sell AnalysisOver the past year, the insider has sold a total of 240,000 shares and purchased 0 shares. This recent sale of 20,000 shares is part of this larger trend. The insider's selling activity can often be an indicator of their confidence in the company's future performance. In this case, the consistent selling could suggest that the insider may have concerns about the company's future prospects.On the day of the insider's recent sale, shares of Cytek Biosciences Inc were trading for $6.83 apiece. This gives the stock a market cap of $936.795 million. The insider's sale at this price could suggest that they believe the stock is currently overvalued.The insider transaction history for Cytek Biosciences Inc shows that there have been 0 insider buys in total over the past year. Meanwhile, there have been 39 insider sells over the same timeframe. This trend of more sells than buys could be a bearish signal for the stock.Story continuesInsider Sell: Cytek Biosciences Inc CEO Wenbin Jiang Sells 20,000 SharesThe above image shows the trend of insider transactions at Cytek Biosciences Inc. As can be seen, the number of sells has been consistently higher than the number of buys over the past year. This could be a sign that insiders at the company are not confident in its future performance.ConclusionInsider selling can often be a bearish signal for a stock. In the case of Cytek Biosciences Inc, the consistent selling by the insider, including the recent sale of 20,000 shares, could suggest that the insider is not confident in the company's future prospects. However, it's important to note that insider selling can be influenced by a variety of factors, and it's just one piece of the puzzle when evaluating a stock. Investors should always conduct their own thorough research before making investment decisions.This article first appeared on GuruFocus.

GuruFocus.com

Insider Sell: Cytek Biosciences Inc CEO Wenbin Jiang Sells 20,000 Shares

https://finance.yahoo.com/news/insider-sell-cytek-biosciences-inc-170207057.html

5f588211-21e3-34f6-8b92-c15d855a9262

CTLT

Value-focused investors are always on the hunt for stocks that are priced below their intrinsic value. One such stock that merits attention is Catalent Inc (NYSE:CTLT). The stock, which is currently priced at $51.4, recorded a gain of 2.39% in a day and a 3-month increase of 35.82%. The stock's fair valuation is $98.47, as indicated by its GF Value.Understanding GF ValueWarning! GuruFocus has detected 6 Warning Signs with CTLT. Click here to check it out. CTLT 30-Year Financial DataThe intrinsic value of CTLTThe GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors: Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at, GuruFocus adjustment factor based on the company's past returns and growth, and future estimates of the business performance.We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.Is Catalent (CTLT) Too Good to Be True? A Comprehensive Analysis of a Potential Value TrapInvesting in Catalent: A Closer LookHowever, investors need to consider a more in-depth analysis before making an investment decision. Despite its seemingly attractive valuation, certain risk factors associated with Catalent should not be ignored. These risks are primarily reflected through its low Altman Z-score of 1.37. These indicators suggest that Catalent, despite its apparent undervaluation, might be a potential value trap. This complexity underlines the importance of thorough due diligence in investment decision-making.Altman Z-score: A Brief OverviewBefore delving into the details, let's understand what the Altman Z-score entails. Invented by New York University Professor Edward I. Altman in 1968, the Z-Score is a financial model that predicts the probability of a company entering bankruptcy within a two-year time frame. The Altman Z-Score combines five different financial ratios, each weighted to create a final score. A score below 1.8 suggests a high likelihood of financial distress, while a score above 3 indicates a low risk.Story continuesCompany Profile: CatalentCatalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.Is Catalent (CTLT) Too Good to Be True? A Comprehensive Analysis of a Potential Value TrapCatalent's Low Altman Z-Score: A Breakdown of Key DriversA dissection of Catalent's Altman Z-score reveals Catalent's financial health may be weak, suggesting possible financial distress:The Retained Earnings to Total Assets ratio provides insights into a company's capability to reinvest its profits or manage debt. Evaluating Catalent's historical data, 2021: 0.00; 2022: 0.05; 2023: 0, we observe a recent decline following an initial increase in this ratio. This downward movement indicates Catalent's diminishing ability to reinvest in its business or effectively manage its debt. Consequently, it exerts a negative impact on its Z-Score.The EBIT to Total Assets ratio serves as a crucial barometer of a company's operational effectiveness, correlating earnings before interest and taxes (EBIT) to total assets. An analysis of Catalent's EBIT to Total Assets ratio from historical data (2021: 0.09; 2022: 0.07; 2023: -0.01) indicates a descending trend. This reduction suggests that Catalent might not be utilizing its assets to their full potential to generate operational profits, which could be negatively affecting the company's overall Z-score.When it comes to operational efficiency, a vital indicator for Catalent is its asset turnover. The data: 2021: 0.48; 2022: 0.48; 2023: 0.40 from the past three years suggests a decreasing trend in this ratio. The asset turnover ratio reflects how effectively a company is using its assets to generate sales. Therefore, a drop in this ratio can signify reduced operational efficiency, potentially due to underutilization of assets or decreased market demand for the company's products or services. This shift in Catalent's asset turnover underlines the need for the company to reassess its operational strategies to optimize asset usage and boost sales.Conclusion: Catalent as a Value TrapGiven the analysis above, it becomes evident that despite its seemingly attractive valuation, Catalent (NYSE:CTLT) carries significant risks that might render it a potential value trap. The company's declining ratios and low Altman Z-Score suggest possible financial distress and operational inefficiencies, which investors must thoroughly evaluate before making an investment decision. This case underscores the importance of comprehensive due diligence in identifying value traps and making informed investment choices.GuruFocus Premium members can find stocks with high Altman Z-Score using the following Screener: Walter Schloss Screen .This article first appeared on GuruFocus.

GuruFocus.com

Is Catalent (CTLT) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap

https://finance.yahoo.com/news/catalent-ctlt-too-good-true-153325292.html

2d25f328-9427-3fa5-881c-504762df05ab

CTLT

SOMERSET, N.J., September 07, 2023--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that members of its executive leadership team will participate at two upcoming investor conferences.On September 12, 2023, at 10:50 a.m. ET, the Company will present at the Morgan Stanley 21st Annual Global Healthcare Conference.On September 13, 2023, at 7:55 a.m. ET, the Company will present at Baird’s 2023 Global Healthcare Conference.A live webcast of the presentation will be accessible at http://investor.catalent.com and will be available for replay following the event.About CatalentCatalent, Inc. (NYSE: CTLT), is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $4.3 billion in revenue in its 2023 fiscal year. For more information, visit www.catalent.com.View source version on businesswire.com: https://www.businesswire.com/news/home/20230907831392/en/ContactsInvestor:Paul Surdez, Catalent, Inc.(732) [email protected]

Business Wire

Catalent, Inc. to Present at September Investor Conferences

https://finance.yahoo.com/news/catalent-inc-present-september-investor-131100224.html

51ba18ef-402a-3d00-b1b9-b6e357890789

CTMX

A downtrend has been apparent in CytomX Therapeutics (CTMX) lately with too much selling pressure. The stock has declined 13.5% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.Here's Why CTMX Could Experience a TurnaroundThe heavy selling of CTMX shares appears to be in the process of exhausting itself, as indicated by its RSI reading of 28.13. So, the trend for the stock could reverse soon for reaching the old equilibrium of supply and demand.The RSI value is not the only factor that indicates a potential turnaround for the stock in the near term. On the fundamental side, there has been strong agreement among the sell-side analysts covering the stock in raising earnings estimates for the current year. Over the last 30 days, the consensus EPS estimate for CTMX has increased 38.9%. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.Story continuesMoreover, CTMX currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportCytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

CytomX Therapeutics (CTMX) Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

https://finance.yahoo.com/news/cytomx-therapeutics-ctmx-loses-13-133505061.html

f89c67ab-118f-302e-9c0d-e672a46cddc1

CTMX

CytomX Therapeutics Inc.SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that management will participate in the following investor conferences in September.H.C. Wainwright 25th Annual Global Investment Conference Date: Tuesday, September 12, 2023 Company Presentation: 11:30 a.m. ET Location: New York, NYCantor Global Healthcare Conference Date: Tuesday, September 26, 2023 Fireside Chat: 8:10 a.m. ET Location: New York, NYLive webcasts of the H.C. Wainwright presentation and Cantor fireside chat will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.About CytomX TherapeuticsCytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engaging bispecific antibodies, and immune modulators such as cytokines and checkpoint inhibitors. CX-904 is a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells, which is partnered with Amgen. CytomX’s clinical pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probody therapeutic BMS-986288, partnered with Bristol Myers Squibb. In addition, CytomX has a diverse preclinical portfolio of wholly-owned assets including CX-2051, a conditionally activated ADC directed toward EpCAM, with potential applicability across multiple EpCAM-expressing epithelial cancers, and CX-801, an interferon alpha-2b Probody cytokine that has broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has also established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and Twitter.Story continuesProbody is a U.S. registered trademark of CytomX Therapeutics, Inc.CytomX Contact:Chris OgdenSVP, Finance and Accounting [email protected] (317) 767-4764Investor and Media Contact:Stern Investor RelationsStephanie [email protected]

GlobeNewswire

CytomX Therapeutics to Present at Upcoming September Investor Conferences

https://finance.yahoo.com/news/cytomx-therapeutics-present-upcoming-september-200500440.html

9175a504-54cb-365d-a6b9-8dd19a6d2f27

CTRA

Marriott downgraded, Okta upgraded: Wall Street's top analyst callsThe most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: Goldman Sachs double upgraded Okta (OKTA) to Buy from Sell with a price target of $91, up from $77. The shares can outperform over the next 12 months, driven by remaining performance obligations and annual recurring revenue acceleration back to 15%-20%, the firm argues. [Read more]Goldman Sachs upgraded Teledyne (TDY) to Buy from Neutral with a price target of $495, up from $423. Teledyne is one of the "highest quality, most consistent, best managed companies" in the sector that compounds cash flow over time, the firm says. [Read more]BofA double upgraded Parsons (PSN) to Buy from Underperform with a price target of $65, up from $46. The firm cites stronger than expected growth from both the company's organic and inorganic opportunities for the upgrade. [Read more]Barrington upgraded Anika Therapeutics (ANIK) to Outperform from Market Perform with a $24 price target. The risk/reward at current levels for Anika "strongly favors investment," Barrington contends. [Read more]Piper Sandler upgraded Coterra Energy (CTRA) to Overweight from Neutral with a price target of $35, up from $30. The company's Q2 print and updated long-term guidance demonstrate expectations from continued strong execution across the portfolio, the firm tells investors in a research note. [Read more]Top 5 Downgrades:Bernstein downgraded Marriott (MAR) to Market Perform from Outperform with a price target of $218, up from $204. The firm cites valuation for the downgrade of Marriott with the shares up 42% year-to-date. [Read more]Citi downgraded Urban Outfitters (URBN) to Neutral from Buy with a price target of $40, up from $36. The firm anticipates a Q2 earnings beat when the company reports on August 22, but believes market expectations are high into the print. [Read more]BMO Capital downgraded Capri Holdings (CPRI) to Market Perform from Outperform with a price target of $57, down from $68, after the company entered into an agreement to be acquired by Tapestry (TPR) for $57 per share in cash. [Read more]BofA downgraded Keysight Technologies (KEYS) to Underperform from Neutral with a price target of $148, down from $163. The firm expects the company's July quarter orders to decline more than consensus expectations and sees downside risk to fiscal 2024 estimates. [Read more]Argus downgraded Boston Properties (BXP) to Hold from Buy. The REIT is being hurt by rising office vacancies, weak "return-to-office" trends, and high interest expense, and while the management has raised its 2023 FFO guidance, it still projects a 4% decrease in FFO at the midpoint of the range, the firm says. [Read more]Top 5 Initiations: HSBC initiated coverage of Monster Beverage (MNST) with a Buy rating and $72 price target. Monster's purchase of Bang "addresses a missing growth driver," which is recruiting women into a category that typically skews male 60%-40%, the firm says. [Read more]Telsey Advisory initiated coverage of Academy Sports (ASO) with an Outperform rating and $72 price target. The firm views Academy Sports as a unit and sales growth story driven by market share gains as the company expands in existing markets and enters new markets with a better assortment, customer service, and go-to-market strategy. [Read more]Morgan Stanley initiated coverage of Oddity (ODD) with an Equal Weight rating and $57 price target. The firm sees strong long-term revenue growth prospects for the company but believes the stock's valuation already reflects the positives. [Read more] BofA also initiated coverage of Oddity with a Neutral rating and $60 price target, [Read more] while Truist started the name with a Hold rating and $54 price target. [Read more] Needham initiated coverage of Agilysys (AGYS) with a Buy rating and $92 price target. The firm believes the company's market leadership in the hospitality industry and its "steadily growing" subscription revenue base balanced with steady profitability support the stock's premium valuation. [Read more]BTIG initiated coverage of Playstudios (MYPS) with a Neutral rating and no price target. The firm sees a number of potential near- and medium-term catalysts for growth and "substantial runway" for margin improvement, but lateral reads on the mobile gaming industry have been "mixed to negative lately." [Read more]

The Fly

Marriott downgraded, Okta upgraded: Wall Street's top analyst calls

https://finance.yahoo.com/news/marriott-downgraded-okta-upgraded-wall-135921761.html

c5e051b4-9910-3004-a2c7-d12fce0ea033

CTRA

HOUSTON, August 30, 2023--(BUSINESS WIRE)--Coterra Energy Inc. (NYSE: CTRA) ("Coterra" or the "Company") today announced that Thomas E. Jorden, Chairman, Chief Executive Officer and President, will participate in a fireside chat at the Barclays CEO Energy-Power Conference. The fireside chat will begin at 12:40 PM ET on Wednesday, September 6, 2023.A live webcast of the presentation will be available on the "Events & Presentations" page under the "Investors" section of the Company’s website at www.coterra.com. The webcast will be archived and available for 180 days at the same location after the conclusion of the live event.About Coterra EnergyCoterra is a premier exploration and production company based in Houston, Texas with focused operations in the Permian Basin, Marcellus Shale, and Anadarko Basin. We strive to be a leading energy producer, delivering sustainable returns through the efficient and responsible development of our diversified asset base. Learn more about us at www.coterra.com.View source version on businesswire.com: https://www.businesswire.com/news/home/20230830102030/en/ContactsInvestor Relations Contacts Daniel Guffey – Vice President of Finance, Planning & Analysis and Investor Relations 281.589.4875Hannah Stuckey – Investor Relations Manager 281.589.4983

Business Wire

Coterra Energy to Participate at Upcoming Conference

https://finance.yahoo.com/news/coterra-energy-participate-upcoming-conference-213300163.html

f79868df-c0f0-3ee5-89f9-5bfda08736fc

CTSH

It has been about a month since the last earnings report for Cognizant (CTSH). Shares have added about 1.6% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Cognizant due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.Cognizant Q2 Earnings Beat Estimates, Revenues Down Y/YCognizant Technology Solutions reported second-quarter 2023 non-GAAP earnings of $1.10 per share, which beat the Zacks Consensus Estimate by 13.4% but decreased 3.5% year over year.Revenues of $4.89 billion beat the consensus mark by 1.5%. However, the top line decreased 0.4% year over year and 0.1% at constant currency (cc). On a sequential basis, revenues increased more than 1%.Acquisitions contributed 130 basis points (bps) to top-line growth.Bookings increased 17% year over year, which benefited from mix-shift towards larger deals. Cognizant continued to witness weakness in smaller, shorter-duration contracts, primarily due to sluggish discretionary spending.On a trailing twelve-month basis, bookings increased 14% year over year to $26.4 billion, which represented a book-to-bill of approximately 1.4 times.Top-Line DetailsFinancial services revenues (29.9% of revenues) decreased 4.8% year over year at cc to $1.46 billion. The decline was attributed to a challenging demand environment and weakness in discretionary spending.Financial services revenues missed the Zacks Consensus Estimate by 1.41%.Health Sciences revenues (29.5% of revenues) increased 2.1% year over year at cc to $1.44 billion. Strong demand for integrated software solutions (up mid-teens year over year) drove growth.Health Sciences revenues beat the consensus mark by 0.61%.Products and Resources revenues (24.1% of revenues) increased 3.7% year over year at cc to $1.18 billion and beat the Zacks Consensus Estimate by 4.05%. Continued strength among automotive, travel and hospitality customers benefited the segment’s top-line growth.Communications, Media and Technology revenues (16.5% of revenues) were $806 million, which declined 0.4% from the year-ago quarter at cc but beat the consensus mark by 0.51%.Region-wise, revenues from North America decreased 1.7% year over year at cc and accounted for 73.5% of total revenues. The decline was primarily attributed to weakness in Financial Services, as well as the Communications, Media and Technology segment.Revenues from Europe increased 6.3% from the year-ago quarter at cc and made up 19.8% of total revenues. Revenues from the U.K. and Continental Europe increased 3.3% and 9.5% year over year at cc, respectively.The Rest of the World revenues were flat at cc and represented 6.8% of total revenues.Story continuesOperating DetailsSelling, general & administrative expenses, as a percentage of revenues, decreased 100 bps year over year to 17%.Total headcount at the end of the second quarter was 345,600, down 5,900 sequentially but up 4,300 year over year.Voluntary attrition – Tech Services, on a trailing 12-month basis, declined to 19.9% from 23.1% in the first quarter of 2023 and 31.1% in the second quarter of 2022.Cognizant reported a non-GAAP operating margin of 14.2%, which contracted 130 bps year over year.The company incurred $117 million in costs related to the NextGen program, negatively impacting GAAP operating margin by 240 bps.Key Q2 DevelopmentsCognizant strengthened its partner base in the reported quarter. It expanded its partnership with Gilead Sciences, ServiceNow, Alphabet’s division Google Cloud, AT&T and Orkla. Cognizant also inked new partnerships with Microsoft subsidiary Nuance Communications and Accuray.The partnership with Gilead Sciences is valued at $800 million over the next five years. Per the renewed and expanded partnership, Cognizant will manage Gilead’s global IT infrastructure, platforms, applications and advanced analytics, and lead initiatives designed to accelerate its digital transformation, leveraging the power of generative AI.The expanded partnership with ServiceNow aims to improve AI-driven automation across industries. Cognizant’s newly formed ServiceNow Business Group will offer AI-based solutions that will solve complex problems, automate operations, and enhance employee and end-customer experiences.Moreover, as a part of its expanding alliance with Google Cloud, Cognizant will open new Google Cloud AI innovation centers in Bangalore, London and San Francisco to support a new Cognizant Google Cloud AI University to train 25,000 Cognizant associates and clients.Cognizant will help the Microsoft subsidiary Nuance to develop Dragon Ambient eXperience Operations. For Accuray, the company will support its deployment of SAP S/4HANA to obtain better data and analytics and achieve greater business efficiencies.Moreover, Cognizant launched a new business group, Cognizant Ocean, to help support ocean industries or the “Blue Economy,” leveraging digital technologies, including AI and data analytics.Blue Economy companies encompass a broad range of sectors, including shipping, marine transportation, offshore oil and gas, marine renewables, aquaculture and marine conservation. These companies are facing challenges related to sustainability, environmental impact and climate change.Cognizant Ocean will help Blue Economy companies to be more sustainable and efficient. Apart from improving business outcomes, Cognizant will help reduce their carbon output and decarbonize the oceans.The company also announced a partnership with Tidal, a project inside X, Alphabet’s Moonshot Factory. Under the collaboration, Tidal’s ocean information platform will be widely available to the aquaculture market. Tidal leverages innovation in underwater perception, machine learning, AI and automation to gather and analyze data.Balance SheetCognizant had cash and short-term investments of $2.1 billion as of Jun 30, 2023 compared with $2.48 billion as of Mar 31, 2023.As of Jun 30, 2023, the company had a total debt of $793 million, up from $646 million reported as of Mar 31, 2023.It generated $36 million in cash from operations compared with $729 million in the previous quarter.Free cash outflow was $32 million against free cash flow of $631 million reported in the prior quarter. Free cash flow was negatively impacted by tax payments of approximately $300 million related to 2022.In the second quarter of 2023, the company returned $200 million through share repurchases. As of Jun 30, 2023, it had $2.4 billion remaining under the current share repurchase program.GuidanceCognizant expects third-quarter 2023 revenues between $4.89 billion and $4.94 billion, indicating a decline of 0.5% to an increase of 0.5% on a cc basis. Favorable forex is expected to aid the top line by 110 bps while acquisitions are expected to contribute 100 bps.In the Financial Services segment, Cognizant continues to expect the challenging macro environment to hurt spending rates, thereby negatively impacting top-line growth.Cognizant expects the Communications, Media and Technology segment to improve in the third quarter of 2023, due to ramping up of new bookings.However, it expects a softer fourth quarter than usual due to weak and sluggish discretionary spending.For 2023, revenues are expected to be $19.2-$19.6 billion, indicating a decline of 1% to growth of 1% at cc. Adjusted operating margin for 2023 is expected between 14.2% and 14.7%. Adjusted earnings for 2023 are expected between $4.25 and $4.44 per share.The company anticipates interest income of $115 million in 2023. Moreover, Cognizant now expects to incur $350 million in NextGen charges, out of which, $250 million will be recognized in 2023.Cognizant still expects to return $1.4 billion to shareholders through share repurchases and regular quarterly dividends.How Have Estimates Been Moving Since Then?It turns out, fresh estimates have trended downward during the past month.VGM ScoresAt this time, Cognizant has a subpar Growth Score of D, however its Momentum Score is doing a lot better with a B. Following the exact same course, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions looks promising. Notably, Cognizant has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.Performance of an Industry PlayerCognizant is part of the Zacks Business - Software Services industry. Over the past month, Tyler Technologies (TYL), a stock from the same industry, has gained 4.1%. The company reported its results for the quarter ended June 2023 more than a month ago.Tyler Technologies reported revenues of $504.28 million in the last reported quarter, representing a year-over-year change of +7.6%. EPS of $2.01 for the same period compares with $1.88 a year ago.For the current quarter, Tyler Technologies is expected to post earnings of $1.97 per share, indicating a change of -4.4% from the year-ago quarter. The Zacks Consensus Estimate has changed -0.3% over the last 30 days.Tyler Technologies has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportCognizant Technology Solutions Corporation (CTSH) : Free Stock Analysis ReportTyler Technologies, Inc. (TYL) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Cognizant (CTSH) Up 1.6% Since Last Earnings Report: Can It Continue?

https://finance.yahoo.com/news/cognizant-ctsh-1-6-since-153139159.html

84b7cbfe-0bee-37be-a5fe-6ad555f1daa7

CTSH

Cognizant Technology Solutions' (NASDAQ:CTSH) stock is up by a considerable 13% over the past three months. Given the company's impressive performance, we decided to study its financial indicators more closely as a company's financial health over the long-term usually dictates market outcomes. In this article, we decided to focus on Cognizant Technology Solutions' ROE.ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In short, ROE shows the profit each dollar generates with respect to its shareholder investments. Check out our latest analysis for Cognizant Technology Solutions How Do You Calculate Return On Equity?The formula for return on equity is:Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' EquitySo, based on the above formula, the ROE for Cognizant Technology Solutions is:17% = US$2.2b ÷ US$13b (Based on the trailing twelve months to June 2023).The 'return' refers to a company's earnings over the last year. Another way to think of that is that for every $1 worth of equity, the company was able to earn $0.17 in profit.What Is The Relationship Between ROE And Earnings Growth?Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company’s earnings growth potential. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.A Side By Side comparison of Cognizant Technology Solutions' Earnings Growth And 17% ROETo start with, Cognizant Technology Solutions' ROE looks acceptable. Even when compared to the industry average of 16% the company's ROE looks quite decent. This certainly adds some context to Cognizant Technology Solutions' moderate 6.1% net income growth seen over the past five years.Story continuesNext, on comparing with the industry net income growth, we found that Cognizant Technology Solutions' reported growth was lower than the industry growth of 23% over the last few years, which is not something we like to see.past-earnings-growthEarnings growth is an important metric to consider when valuing a stock. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. Doing so will help them establish if the stock's future looks promising or ominous. Is CTSH fairly valued? This infographic on the company's intrinsic value has everything you need to know.Is Cognizant Technology Solutions Making Efficient Use Of Its Profits?With a three-year median payout ratio of 26% (implying that the company retains 74% of its profits), it seems that Cognizant Technology Solutions is reinvesting efficiently in a way that it sees respectable amount growth in its earnings and pays a dividend that's well covered.Additionally, Cognizant Technology Solutions has paid dividends over a period of six years which means that the company is pretty serious about sharing its profits with shareholders. Based on the latest analysts' estimates, we found that the company's future payout ratio over the next three years is expected to hold steady at 25%. As a result, Cognizant Technology Solutions' ROE is not expected to change by much either, which we inferred from the analyst estimate of 18% for future ROE.SummaryOn the whole, we feel that Cognizant Technology Solutions' performance has been quite good. Particularly, we like that the company is reinvesting heavily into its business, and at a high rate of return. As a result, the decent growth in its earnings is not surprising. That being so, the latest analyst forecasts show that the company will continue to see an expansion in its earnings. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Are Strong Financial Prospects The Force That Is Driving The Momentum In Cognizant Technology Solutions Corporation's NASDAQ:CTSH) Stock?

https://finance.yahoo.com/news/strong-financial-prospects-force-driving-110045577.html

5192a62c-91c7-3c5e-a736-3046a77c22d7

CTVA

INDIANAPOLIS, Sept. 5, 2023 /PRNewswire/ -- Corteva, Inc. (NYSE: CTVA) announces that Chief Executive Officer, Chuck Magro, and Executive Vice President and Chief Financial Officer, Dave Anderson, will speak at the Morgan Stanley 11th Annual Laguna Conference at 2:40 p.m. Eastern Time on Tuesday, September 12, 2023.(PRNewsfoto/Corteva Agriscience)Remarks will be webcast live. Registration for the webcast can be accessed through the Corteva Investor Relations website. A replay of the presentation will be available 24-hours after the presentation ends and will be accessible until December 12, 2023.About Corteva Corteva, Inc. (NYSE: CTVA) is a publicly traded, global pure-play agriculture company that combines industry-leading innovation, high-touch customer engagement and operational execution to profitably deliver solutions for the world's most pressing agriculture challenges. Corteva generates advantaged market preference through its unique distribution strategy, together with its balanced and globally diverse mix of seed, crop protection, and digital products and services. With some of the most recognized brands in agriculture and a technology pipeline well positioned to drive growth, the company is committed to maximizing productivity for farmers, while working with stakeholders throughout the food system as it fulfills its promise to enrich the lives of those who produce and those who consume, ensuring progress for generations to come. More information can be found at www.corteva.com.Follow Corteva on Facebook, Instagram, LinkedIn, Twitter and YouTube.Cautionary Statement About Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which may be identified by their use of words like "plans," "expects," "will," "anticipates," "believes," "intends," "projects," "targets," "estimates" or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva's financial results or outlook; strategy for growth; product development; regulatory approvals; market position; capital allocation strategy; liquidity; environmental, social and governance targets; the anticipated benefits of acquisitions, restructuring actions, or cost savings initiatives; and the outcome of contingencies, such as litigation and environmental matters, are forward-looking statements.Story continuesForward-looking statements are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond Corteva's control. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Corteva's business, results of operations and financial condition. Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business.Where, in any forward-looking statement, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva's management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the "Risk Factors" section of Corteva's Annual Report on Form 10-K, as modified by subsequent Quarterly Reports on Forms 10-Q and Current Reports on Form 8-K.™ ® Trademarks of Corteva Agriscience and its affiliated companies.CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/corteva-agriscience-to-participate-in-the-morgan-stanley-11th-annual-laguna-conference-301917654.htmlSOURCE Corteva, Inc.

PR Newswire

Corteva Agriscience to Participate in the Morgan Stanley 11th Annual Laguna Conference

https://finance.yahoo.com/news/corteva-agriscience-participate-morgan-stanley-130000474.html

884be6c4-6152-3ddb-a534-9284bb4e183a

CTVA

In the latest trading session, Corteva, Inc. (CTVA) closed at $49.58, marking a +0.04% move from the previous day. This change lagged the S&P 500's 0.14% gain on the day. Meanwhile, the Dow gained 0.22%, and the Nasdaq, a tech-heavy index, added 0.09%.Coming into today, shares of the agriculture had lost 5.08% in the past month. In that same time, the Consumer Staples sector lost 4.48%, while the S&P 500 lost 1.27%.Wall Street will be looking for positivity from Corteva, Inc. as it approaches its next earnings report date. In that report, analysts expect Corteva, Inc. to post earnings of -$0.19 per share. This would mark a year-over-year decline of 58.33%. Our most recent consensus estimate is calling for quarterly revenue of $2.79 billion, up 0.46% from the year-ago period.Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $2.84 per share and revenue of $18.01 billion. These totals would mark changes of +6.37% and +3.15%, respectively, from last year.It is also important to note the recent changes to analyst estimates for Corteva, Inc.These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Corteva, Inc. is currently sporting a Zacks Rank of #4 (Sell).Valuation is also important, so investors should note that Corteva, Inc. has a Forward P/E ratio of 17.47 right now. Its industry sports an average Forward P/E of 16.54, so we one might conclude that Corteva, Inc. is trading at a premium comparatively.Story continuesMeanwhile, CTVA's PEG ratio is currently 1.32. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. CTVA's industry had an average PEG ratio of 1.16 as of yesterday's close.The Agriculture - Operations industry is part of the Consumer Staples sector. This group has a Zacks Industry Rank of 103, putting it in the top 41% of all 250+ industries.The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportCorteva, Inc. (CTVA) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

Corteva, Inc. (CTVA) Gains But Lags Market: What You Should Know

https://finance.yahoo.com/news/corteva-inc-ctva-gains-lags-221521011.html

7b4fda42-9fe4-3c76-8a20-c8d02484b331

CULL

CULLMAN, Ala., October 19, 2022--(BUSINESS WIRE)--Cullman Bancorp, Inc. (the "Company") (Nasdaq:CULL), the holding company for Cullman Savings Bank, announced that its Board of Directors has adopted a stock repurchase program. Under the repurchase program, the Company may repurchase up to 550,000 shares of its common stock, or approximately 7.5% of the current outstanding shares.Repurchases will be made no sooner than the termination of the Company’s regular trading blackout period, and consistent with the Company’s trading policies.The repurchase program permits shares to be repurchased in open market or private transactions, through block trades, and pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission.Repurchases will be made at management’s discretion at prices management considers to be attractive and in the best interests of both the Company and its stockholders, subject to the availability of stock, general market conditions, the trading price of the stock, alternative uses for capital, and the Company’s financial performance. Open market purchases will be conducted in accordance with the limitations set forth in Rule 10b-18 of the Securities and Exchange Commission and other applicable legal requirements.The repurchase program may be suspended, terminated or modified at any time for any reason, including market conditions, the cost of repurchasing shares, the availability of alternative investment opportunities, liquidity, and other factors deemed appropriate. These factors may also affect the timing and amount of share repurchases. The repurchase program does not obligate the Company to purchase any particular number of shares.About Cullman Bancorp, Inc.The Company is a Maryland corporation based in Cullman, Alabama. The Company’s banking subsidiary, Cullman Savings Bank, opened in 1887 and currently operates three full-service offices in Cullman, Alabama and one full-service office in Hanceville, Alabama.Story continuesForward-Looking StatementsCertain statements contained herein constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by words such as "may," "will," "would," "intend," "believe," "expect," "plan," "estimate," "anticipate," "continue," or similar terms or variations on those terms, or the negative of those terms. These statements are based upon the current beliefs and expectations of Company management and are subject to significant risks and uncertainties. Actual results may differ materially from those set forth in the forward-looking statements as a result of numerous factors. Factors that could cause such differences to exist include, but are not limited to: the effects of any pandemic disease, natural disaster, war, act of terrorism, accident, or similar action or event; those related to the real estate and economic environment, particularly in the market areas in which the Company operates; fiscal and monetary policies of the U.S. Government; inflationary matters; changes in government regulations affecting financial institutions, including regulatory compliance costs and capital requirements; fluctuations in the adequacy of loan loss reserves; decreases in deposit levels necessitating increased borrowing to fund loans and investments; operational risks including, but not limited to, cybersecurity, fraud and natural disasters; the risk that the Company may not be successful in the implementation of its business strategy; changes in prevailing interest rates; credit risk management; asset-liability management; and other risks described in the Company’s filings with the Securities and Exchange Commission, which are available at the SEC’s website, www.sec.gov.The Company wishes to caution readers not to place undue reliance on any such forward looking statements, which speak only as of the date made. The Company wishes to advise readers that the factors listed above or other factors could affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods in any current statements. The Company does not undertake and specifically disclaims any obligation to publicly release the results of any revisions, which may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.View source version on businesswire.com: https://www.businesswire.com/news/home/20221019005679/en/ContactsJohn A. Riley, IIIPresident and Chief Executive Officer(256) 734-1740

Business Wire

Cullman Bancorp, Inc. Adopts Stock Repurchase Program

https://finance.yahoo.com/news/cullman-bancorp-inc-adopts-stock-132000275.html

5aa55281-a968-38e0-a174-6340914c124c

CULL

CULLMAN, Ala., January 18, 2023--(BUSINESS WIRE)--Cullman Bancorp, Inc. (the "Company") (Nasdaq: CULL), the holding company for Cullman Savings Bank, announced that the Company has declared the payment of an annual cash dividend. The dividend of $0.12 per share will be paid on February 22, 2023 to stockholders of record as of February 1, 2023.John A. Riley, III, President and Chief Executive Officer of the Company, stated "This dividend reflects our ongoing commitment to delivering stockholder value. We look forward to continuing to provide such value in the future."Forward-Looking StatementsCertain statements contained herein constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by words such as "may," "will," "would," "intend," "believe," "expect," "plan," "estimate," "anticipate," "continue," or similar terms or variations on those terms, or the negative of those terms. These statements are based upon the current beliefs and expectations of Company management and are subject to significant risks and uncertainties. Actual results may differ materially from those set forth in the forward-looking statements as a result of numerous factors. Factors that could cause such differences to exist include, but are not limited to: the effects of any pandemic disease, natural disaster, war, act of terrorism, accident, or similar action or event; those related to the real estate and economic environment, particularly in the market areas in which the Company operates; inflation; fiscal and monetary policies of the U.S. Government; changes in government regulations affecting financial institutions, including regulatory compliance costs and capital requirements; fluctuations in the adequacy of loan loss reserves; decreases in deposit levels necessitating increased borrowing to fund loans and investments; operational risks including, but not limited to, cybersecurity, fraud and natural disasters; the risk that the Company may not be successful in the implementation of its business strategy; changes in prevailing interest rates; credit risk management; asset-liability management; and other risks described in the Company’s filings with the Securities and Exchange Commission, which are available at the SEC’s website, www.sec.gov.Story continuesThe Company wishes to caution readers not to place undue reliance on any such forward looking statements, which speak only as of the date made. The Company wishes to advise readers that the factors listed above or other factors could affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods in any current statements. The Company does not undertake and specifically disclaims any obligation to publicly release the results of any revisions, which may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.About Cullman Bancorp, Inc.The Company is a Maryland corporation based in Cullman, Alabama. The Company’s banking subsidiary, Cullman Savings Bank, opened in 1887 and currently operates three full-service offices in Cullman, Alabama and one full-service office in Hanceville, Alabama.View source version on businesswire.com: https://www.businesswire.com/news/home/20230118005632/en/ContactsJohn A. Riley, IIIPresident and Chief Executive OfficerTelephone: (256) 734-1740

Business Wire

Cullman Bancorp, Inc. Announces Payment of Annual Cash Dividend of $0.12 Per Share

https://finance.yahoo.com/news/cullman-bancorp-inc-announces-payment-142000199.html

11d58536-1029-3979-bd09-67c19a2c3dd0

CULP

ParticipantsBoyd B. Chumbley; President of Culp Upholstery Fabrics Division; Culp, Inc.Dru L. Anderson; SVP and Principal; Corporate Communications, Inc.Kenneth R. Bowling; Executive VP, CFO & Treasurer; Culp, Inc.Robert G. Culp; President, CEO, President of Culp Home Fashions & Director; Culp, Inc.Tommy Bruno; EVP of Culp Home Fashions; Culp, Inc.Anthony Chester Lebiedzinski; Senior Equity Research Analyst; Sidoti & Company, LLCBeryl Bugatch; Head of Consumer Hardlines; Water Tower Research LLCPresentationOperatorGood morning, and welcome to the Culp, Inc. First Quarter Fiscal 2024 Earnings Conference Call. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference over to Dru Anderson. Please go ahead.Dru L. AndersonThank you. Good morning, and welcome to the Culp conference call to review the company's results for the first quarter of fiscal 2024. As we start, let me state that this morning's call will contain forward-looking statements about the business, financial condition and prospects of the company. Forward-looking statements are statements that include projections, expectations or beliefs about future events or results or otherwise are not statements of historical fact.The actual performance of the company could differ materially from that indicated by the forward-looking statements because of various risks and uncertainties. These risks and uncertainties are described in our regular SEC filings, including the company's most recent filings on Form 10-K and Form 10-Q.Additional risks and uncertainties that we do not presently know about or that we currently consider to be immaterial may also affect our business operations and financial results. You are cautioned not to place undue reliance on forward-looking statements made today, and each such statement speaks only as of today. We undertake no obligation to update or to revise forward-looking statements.In addition, during this call, the company will be discussing non-GAAP financial measurements. A reconciliation of these non-GAAP financial measurements to the most directly comparable GAAP financial measurements is included in the tables to the press release included as an exhibit to the company's 8-K filed yesterday and posted on the company's website at culp.com. I will now turn the call over to Iv Culp, President and Chief Executive Officer of Culp. Please go ahead, Iv.Story continuesRobert G. CulpThank you Dru, and good morning, everyone, and thank you for joining us today. I would like to welcome you to the Culp quarterly conference call with analysts and investors.With me on the call are Ken Bowling, Chief Financial Officer; Boyd Chumbley, President of our upholstery fabrics business; and Tommy Bruno, President of our Mattress Fabrics business. So today, I'll begin the call with some detailed comments, including a discussion of key points and topics for the quarter and for both businesses as well as priorities as we look ahead. After that, Ken will review the financial results for the quarter, and I will then briefly review our business outlook for the second quarter of fiscal '24, and we will then take your questions.Regarding the current state of our business, in the overall furniture and bedding industries. I want to review some overriding themes we discussed last quarter and detail some critical actions we are continuing to execute within both businesses. I will also expand on our comments with a few important points that illustrate where Culp is today.Number one, we are encouraged by our better-than-expected operating improvement for the quarter both sequentially and year-over-year despite the ongoing industry malaise and demand softness within the two industries we service. Number two, we remain excited about the progress of our comprehensive transformation within our CHF mattress fabrics business, and we are pleased to be gaining market position in the face of some contraction in the domestic mattress industry.Number three, although market conditions are also pressuring the residential home furnishings industry, our upholstery fabrics business has remained profitable despite these pressures, and demand remains quite solid in our growing hospitality business. And number four, we are continuing our diligent focus on prudent financial management, including maintaining a strong balance sheet and ensuring a strategic level of working capital.So going to theme #1. Our results for the first quarter reflected better-than-expected operating performance, both sequentially and year-over-year even as industry demand remains soft, especially in residential home furnishings. However, our operating performance improved despite pressure on sales due to internal improvements within both businesses. The strong sequential and year-over-year improvement in our Mattress Fabrics business, a 45% improvement sequentially and a 52% improvement year-over-year was supported by the rollout of new fabric and cover placements during the period.As we have commented for some time now, these new programs are priced in line with current raw material and operational costs and we expect these new programs to grow Culp Home Fashion's market position in fiscal '24.The operating improvement in the CHF business was also driven by our ongoing focus on operational efficiencies and cost reduction initiatives across our locations, and I will expand more on this shortly. I do want to emphasize that Mattress Fabric sales for the quarter were flat compared to the prior year period, which is a solid performance in the face of difficult industry conditions and certainly reflects our growing position in the market.For the Upholstery Fabric segment, we saw operational improvements and fixed cost savings along with solid demand in our hospitality/contract fabric business and improvement for Read window. But as expected, sales within our residential fabrics business were lower as compared to the first quarter of last fiscal year, which notably was a strong quarter due to a lift in sales following pandemic-related shutdowns in China and the quick recovery that the upholstery furniture industry was experiencing at that time.Our sales for residential fabrics this quarter were certainly affected by the ongoing softness in the home furnishings industry and shifting consumer spending trends following the Pandemic stay-at-home surge. While we do understand that the furniture and bedding environment remains challenged, we will continue to manage the aspects of our business we can control, taking necessary steps to withstand current market conditions, and position our business for renewed growth.As detailed in earlier quarters, we have made platform changes to our cut and sew profile on both Mattress Fabrics and Upholstery. And the cost benefits from these adjustments are coming to bear. We are also focused on managing our operational efficiencies across our fabric platforms and therefore, lowering overall costs.Beyond Q1, we believe our continuing recovery will be led by our Mattress Fabrics segment, while our execution of a comprehensive transformation plan is laying the foundation for steady improvement. I'll expand much more on the Mattress Fabrics transformation plan momentarily, but our sequential and year-over-year operating improvement reflects some of these initiatives we have undertaken internally to manage our business.While the challenging industry environment is expected to continue for some time, our market position is strong and improving, and we believe we are poised for a considerably better second half of fiscal '24 and that's November to April by the calendar, with a return to operating profitability in this fiscal year.Regardless of the current demand backdrop, we expect continued progress in improving our operating results, but we understand the speed of our recovery may be affected by overall industry trends. We would like to see some macro tailwinds to allow recovery to happen quicker. We are well prepared for the long term, and our strong leadership teams, innovative product offerings, creative designs and a resilient global manufacturing and sourcing platform will support us into the future, especially when the environment improves.The second important thing to expand on is the business transformation update within Culp Home Fashions, our Mattress Fabrics segment. Under the leadership of Division President, Tommy Bruno, along with his restructured management team.Our transformation plan focuses on long-term improvement in every facet of the business, including quality, sales, marketing and operational processes, supply chain optimization, employee engagement and organizational management structure.As we said, we believe CHF improvement is our best short-term opportunity for recovery and growth from our current levels. Tommy and the CHF management team remains focused on operational excellence as well as balancing our product mix to proper volumes and steady run schedules.Even after our previous cost-saving adjustment to our domestic North Carolina cut and sew capabilities, we continue with a robust global platform featuring manufacturing and sourcing capabilities in six countries: The U.S., Canada, Turkey, Haiti, China and Vietnam. Our combination of onshore, nearshore and offshore options provide our Mattress Fabric and sewn cover customers with the agility and value they need for their business.Combining this platform with our expertise in design and product innovation, we are making excellent progress for sustainable improvement in fiscal '24.Overall, as we've mentioned, the domestic mattress industry is experiencing significant contraction with industry reports showing aggregate reductions of 10% in dollars and 20% in units through the first 6 months of calendar '23. But notably, again, CHF revenue over the same general period has remained flat, indicating that CHF has made gains with customers in a difficult market environment.While the mattress industry slowness may remain for some period, we still expect to improve our performance through new programs and improved operations. Our recovery in CHF is not fully dependent on the industry environment, and assuming our sales volumes in fiscal '24 do not materially fall below the prior year, we expect to see significant progress with steady sustainable improvement in CHF this year and beyond.The third important theme is the continued profitability of Culp Upholstery Fabrics. I've detailed just now a lot of excitement about CHF, but it is equally as important to note the steady performance of CUF. Division President, Boyd Chumbley and his strong leadership team have managed effectively in the most -- in the midst of abnormal tumultuous times.CUF has maintained profitability with a focus on improving operational efficiencies and proactively taking strategic actions to reduce our cost structure to align with demand levels while also always supporting our customers with our flexible global platform. I believe CUF has best-in-class in servicing our customers and our design & product excellence, combined with an effective global platform has led the way.Our improved operating cost within CUF began with the restructuring of our cut and sew upholstery kit platform in China during the second quarter of last fiscal year and then continued with the rationalization of our upholstery cut and sew platform in Haiti near the end of last fiscal year. We took further action in Haiti this quarter to discontinue production of cut and sewn upholstery kits at this location based on demand softness.This step further reduces CUF cost structure and avoids losses that would have otherwise been incurred while allowing this business to continue to support customers through its strong Asian supply chain.Notably through these actions and other improvements in operational efficiencies, CUF has been effective in lowering its overall cost levels to remain profitable in the face of reduced demand.Just want to quick aside, I do want to again reiterate that while we have discontinued production of upholstery, cut and sew kits in Haiti, our Haiti cut and sew platform for mattress covers remains an integral part of our strategic plan.Now turning back to CUF, we are also adjusting our global platform for the fabrics portion of our upholstery fabrics business as we look to provide options within our supply chain in China, Vietnam and multiple other new countries. Customer service is a hallmark for Culp and a diversified platform provides improved risk management and a more stable supply base.Of note, our hospitality contract business accounted for 33% of segment sales for the first quarter. While this percentage is higher than normal due to lower residential sales, it does reflect the ongoing solid performance of our hospitality/contract business as well as its importance to our overall strategy of product diversification for this segment.While the tough demand environment may continue for some time, Culp upholstery fabrics remains well positioned for the long term with a scalable global platform and innovative product offerings, including our popular portfolio of LiveSmart performance products and our new product technologies.We are also beginning to see increases in newly written fabric orders, and we believe we will see the benefit from this in the second half of fiscal '24.Similar to the first quarter, we also expect the upholstery fabric segment will continue to benefit Culp through the remainder of fiscal '24 with improved inventory management, a solid hospitality/contract fabric business, improvement in our Read Window business and a rationalized cut-and-sew platform.And lastly, I'll shift to the fourth theme, which is constant focus on prudent financial management including maintaining a strong balance sheet and ensuring a strategic level of working capital. I am very pleased with the management team for its continued effort in maintaining our cash and total liquidity position.We ended the quarter with $16.8 million in cash and no outstanding borrowings, and we had total liquidity of $42.3 million, consisting of cash and borrowing availability under our domestic credit facility. We are continuing to carefully manage inventory against current demand levels, and we are strategically investing in our business.I have repeatedly through my remarks, mentioned the softness within our industries, and that has been most evident to us by several recent closures within the furniture industry. And remember, this is on the heels of several bankruptcies we witnessed in the last year as well. We are seeing some suppliers, competitors and customers endure financial difficulty and it gives us more appreciation for our financial stability and it's important to our future.We are managing accounts receivable effectively, and we do not have any material exposure with respect to the recent closures. I am grateful to our credit teams and divisional management for how we conduct Culp's business with a lens towards the future and careful partner selection.We fully recognize that the management of Culp's strong balance sheet is a critical initiative, and we believe we are well positioned to focus on investing and optimizing our global manufacturing platform and growing profitable sales.I'll now turn the call over to Ken, who will review the financial results for the quarter, and then I'll briefly review the outlook for the second quarter of this fiscal year. Ken?Kenneth R. BowlingThanks, Iv. Here are the financial highlights for the first quarter. Starting with consolidated results, net sales were $56.7 million, down 9.5% compared with the prior year period, driven almost entirely by a decline in upholstery fabric sales.The company reported a loss from operations of $3.1 million, which included $517,000 in mostly non-cash restructuring and related charges associated with the discontinued production of cut and sewn upholstery kits in Haiti during the quarter, as Iv discussed earlier.Excluding this $517,000, adjusted loss from operations for the quarter was $2.6 million, a better-than-expected improvement as compared with a loss of operations of $4.7 million for the prior year period and a loss from operations of $4 million for the fourth quarter of last fiscal year.Net loss for the first quarter was $3.3 million or $0.27 per diluted share compared with a net loss of $5.7 million or $0.47 per diluted share for the prior year period. Net loss for the quarter included the $517,000 restructuring-related charges I just mentioned.Our overall operating performance for the first quarter as compared to the prior year period was positively affected by improved margins on new products, improvement in operating efficiencies and lower overhead costs in both segments, a higher contribution from hospitality fabrics in the Read window business and a more favorable foreign exchange rate associated with China. This year-over-year improvement in operating performance was partially offset by margin pressures due to lower sales and higher SG&A expense.SG&A expense was higher than last year due to increased compensation expense mostly related to wage inflation and higher incentive compensation pools, higher professional fees and increased sampling expense driven by new product rollouts in both businesses. Importantly, with regard to SG&A expense, as business conditions improve and demand for new products rise, we believe that we'll get significant leverage from the increased sales.Adjusted EBITDA for the period was close to breakeven at negative $416,000 as compared to adjusted EBITDA of negative $2.7 million for the prior year period. The effective income tax rate for the first quarter of this fiscal year was a negative 26.5% compared with a negative 18.7% for the same period a year ago.Our effective income tax rate for the quarter was impacted by the company's mix of earnings between our U.S. and foreign subsidiaries with an operating loss in the U.S. while China and Canada generated income that was packed at higher rate as compared to the U.S.Our cash income tax payments totaled $1.1 million for the first quarter of this fiscal year, and based on current expectations, we currently plan for cash income tax payments of approximately $3.2 million for the entire fiscal '24 year. Importantly, our estimated cash income tax payments for fiscal '24, our management's current projections only and can be affected by a variety of factors over the course of the year.Now let's take a look at our business segments. For the Mattress Fabrics segment, sales for the first quarter were $29.2 million, down 0.5% compared to last year's first quarter, outperforming overall industry trends. Operating loss for the quarter was $1.4 million, a 52% improvement compared to an operating loss of $2.9 million a year ago. This operating improvement was driven by new placements priced in line with current cost, improvements in operating efficiencies and lower costs resulting from the restructuring and rationalization of this segment's mattress cover platform initiated last fiscal year, offset somewhat by higher SG&A expense.For the Upholstery Fabrics Segment, sales for this first quarter were $27.4 million, down 17.4% over the prior year period, which was a strong quarter due to a lift in sales following pandemic-related shutdowns in China.Sales for our residential fabric business for the quarter were affected by ongoing softness in the residential home furnishings industry, however demand remains solid in our upholstery -- in our hospitality contract business during the first quarter with sales for this business accounted for approximately 33% of the upholstery fabric segment's total sales.Operating income and operating margin for the quarter were $1.3 million and 4.8%, 145% and 320 basis point improvement, respectively, compared with the prior year period. This operating performance was positively affected by a higher contribution from hospitality fabrics and Read window business, lower costs resulting from the restructuring of this segment's cut and sew platforms during earlier periods, and a more favorable foreign exchange rate associated with this segment's operations in China as well as other operational improvements. These factors were partially offset by lower residential fabric sales and higher SG&A during the period.Now I'll turn to the balance sheet. We reported $16.8 million in total cash and no outstanding debt as of the end of the first quarter. Cash flow from operations and free cash flow were negative $4.4 million and negative $4.2 million, respectively, for the first three months of this fiscal year. Our cash flow from operations and free cash flow during the period were affected by an operating loss and investments in working capital and capital expenditures mostly related to the Mattress Fabrics transformation plan.Capital expenditures for the first three months of this fiscal year were $513,000. Based on current expectations, capital spending for this fiscal year is projected to be in the range of $5 million to $6 million and will center mostly on maintenance CapEx and quick payback projects focused on improving quality and efficiency in our Mattress Fabrics business. Based on current expectations, depreciation for this fiscal year is expected to be approximately $7 million.With respect to liquidity, as of the end of the first quarter, we had $42.3 million consisting of $16.8 million in total cash and $25.5 million in borrowing availability under our asset-based domestic credit facility. Borrowing availability under this facility is based on a calculation using [1/3] of the company's accounts receivable and inventory determined on a monthly basis.The company did not repurchase any shares during the first quarter of this fiscal year, leaving $3.2 million available under our current share repurchase program. Despite the current share repurchase authorization, we do not expect any activity during the second quarter this fiscal year as we remain focused on preserving liquidity and being positioned to support future growth opportunities.With that, I'll turn the call over to Iv to discuss the general outlook for the second quarter of this fiscal year, and then we'll take your questions. Iv?Robert G. CulpThank you, Ken. Due to the continued volatility in the macro environment, we are providing only limited financial guidance for the second quarter of fiscal '24. We expect consolidated net sales for the second quarter to be comparable to the second quarter of fiscal '23 driven by further improvement in the mattress fabrics segment, but offset by lower residential upholstery fabric sales.We expect consolidated operating loss for the second quarter of fiscal '24, that is in the range of $2.2 million to $2.6 million, a significant improvement compared to the $11.9 million operating loss for the prior year period, which did include approximately $6 million relating to certain inventory impairment charges, losses from inventory close out sales and greater-than-normal inventory markdowns.Again, I will comment that we believe we are poised for a considerably better second half performance, with a return to operating profitability this fiscal year.Finally, we will continue to be laser-focused on prudent financial management with the goal of always maintaining a strong balance sheet especially with regard to ensuring a strategic balance in our working capital. We are optimistic about Culp's future, and we know that financial stability is paramount to our success. So with that, we will now take questions.Question and Answer SessionOperator(Operator Instructions) Our first question comes from Anthony Lebiedzinski with Sidoti & Company.Anthony Chester LebiedzinskiSo first, just a quick comment. Overall, a perfect job of maintaining a strong balance sheet and certainly nice to see a solid gross profit gains here in the quarter. So first question here for CHF, so you mentioned that new placements are in line with current costs and that's great to hear. So I guess for the quarter, can you give us just kind of a rough breakdown between pricing and unit volumes? I would love to hear your thoughts on that.Robert G. CulpKen, can you?Kenneth R. BowlingYes. yes. Anthony, I mean, we -- I think we've mentioned this before. I mean we price new products to capture the cost and that pricing flows throughout the year. I mean, obviously, we were right in line with sales and units were close as well. So really, it wasn't a big difference at all, pretty consistent on both.Robert G. CulpWe were building in the mattress fabrics business, Anthony, and you hopefully hear our excitement as we talk about the business. It's such a strong turnaround that's underway, and we're growing dollars and units. I mean we're a unit-driven company. So we're not going to have success without also growing the units. So we're doing both.Anthony Chester LebiedzinskiSo before COVID, I mean, the gross margin at CHF was in the mid-teens and even higher in prior years. So given the transformation underway, do you think it's reasonable that you could get back to at least double-digit segment margin sometime this fiscal year?Robert G. CulpWell, Anthony, we -- I'll let Tommy make some comments to what he's seeing. The problem won't be as bold to tell you exactly when that's going to happen. But in our -- all the investor information that we're putting out through our new deck, sort of a minimum standard for our expectation in the CHF business is double-digit operating income percent. And we certainly have every intention of being at that in our intermediate future. Now whether we can get all the way to double-digit profitability in this fiscal year, TBD, but we are expecting to return to profitability both in the division and consolidated in this year.Tommy, anything you would add as you're just going through the process?Tommy BrunoNo, I think that's a good representation of the improvement. I think, Anthony, we expect it to be sequentially higher quarter-over-quarter and with the objective of getting back to historical profitability rates.Anthony Chester LebiedzinskiOkay. That sounds good. And then for CUF, the residential, obviously, as you called out, is softer but are you seeing any notable customers moving away from Culp? Or is it just -- is that you're just seeing that customers are just ordering less across the board now?Robert G. CulpI'll let Boyd speak to that question, Anthony.Boyd B. ChumbleyYes, Anthony. No, we're really not seeing any dramatic changes in our customer base. I think this was more just an overall industry demand situation that we're being impacted with. And of course, we have to remember, too, that for this quarter, we were comparing to an abnormally high first quarter of last year due to the pandemic. So the extreme pandemic-induced swings in demand over the last several years have made year-over-year comparisons difficult.So -- but no, to answer your question, don't see that we're having any changes in our customer mix in any significant way. This is more just industry-wide demand depression at the moment.Robert G. CulpAnd Anthony, as Boyd -- Boyd has worked here with Culp for almost 40 years and we have seen our shares of ups and downs in the residential furniture business over many, many times. And we always think and it has typically beared itself out, we gain market position in times like this. And typically, when these times pass, we find ourselves in a better position. And this is no different. We believe on our side, we are actually gaining market position now and we think it's fully driven by just the slowness in the current industry.If supply chains are adjusting, new products are being rolled out on the floor. Remember, we skipped about a year of new intros in that business for a little bit as no one needed to relaunch retail. So as that starts to happen, we're pretty optimistic about where it's going to go. And we noted in our script that we are now starting to see new written orders gradually increase. So we are seeing optimism as we look past -- probably looking past second quarter, but we do see those sales levels starting to pick back up.Anthony Chester LebiedzinskiThat's great to hear. And then last question before I turn the call over to others. I guess probably a question for Ken. So inventory management, that has certainly been a nice source of cash, so a nice job with that. So do you think you can further reduce inventories? How about cash flow? So how should we think about that?Kenneth R. BowlingYes, Anthony, that's -- I mean, as we look to grow the business on both sides, I mean, we -- both teams have done -- if you look over the last six quarters, they've done a remarkable job of getting inventory down and really meeting demand. And so as we proceed ahead into the next quarters, our focus is going to be on growing the business, and as we said in the prepared remarks, balancing inventory with sales, and that's -- that we preach that every day.So is there some opportunity to continue to maximize efficiencies in inventory? Probably some but right now, the we've got to make sure we've got the right amount of inventory on hand to support growth. And so -- but that said, we're going to be very careful about balancing both as we grow the business.OperatorOur next question comes from Bud Bugatch with Water Tower Research.Beryl BugatchFirst, I just want to make a comment that I know it's been a very tumultuous time for everybody. Congratulations on keeping the financial condition of Culp pretty strong, making it through these times.Robert G. CulpThank you.Beryl BugatchYou're welcome. I guess the first question is, you talk about the improvements in CHF. And I guess I would love to get some color on that, maybe anecdotally what you've done, what -- you talked about some of the operational cost efficiencies. Do you have some examples of what that was or maybe put some color to numbers on that?Robert G. CulpYes. And I'll let Tommy speak to that, Bud, because he's living it. He's living -- we're happy to have him here with us in the office and not on the plant floor. We got him, we had to pry him out from that. But Tommy, why don't you touch on anything from your standpoint?Tommy BrunoYes, sure. Bud, it's really, for us, improving our gross profit is really a combination of working on our mix, working on improving previous programs that weren't costed in line with the market conditions through COVID. As it related to operational efficiencies, we continue to really push our supply chain for best cost position on raw materials as well as continuous improvement, quality and manufacturing efficiency initiatives in Stokesdale and in Canada. Other initiatives we're doing is making sure that we're really leveraging our global platform for efficiency and profitability and balancing those together with our manufacturing assets.Beryl BugatchAnd Tommy, can you kind of maybe characterize the importance of that? Was pricing more important than the operational efficiencies? How do you -- what's the relative mix between the two?Tommy BrunoYes. That's a really -- I don't want to take the easy way out of this question. I would say that they're equally important Bud, because we had some programs that weren't profitable that we had to reshift away. But we also have opportunities through a challenging COVID environment to really engage and drive operational improvement as the macro environment and raw materials opportunities have come along. So we're focused equally on both of them.Beryl BugatchAnd so do we think about them as 50-50 kind of improvement? You get 50% of the improved gross margin from pricing and 50% -- from pricing that you can finally get a hold of or get either through new programs or realigning previously unprofitably priced programs and 50% through operational efficiencies?Tommy BrunoYes, sir. I would characterize it as 50-50.Robert G. CulpAnd what I get excited about Bud from what Tommy is working on, I agree. It's both half and half, better pricing and better cost improvement. What makes me excited watching it is the business is gradually picking up. We are -- and we're doing that internally by gaining market position.We've been around this mattress business for some time, and we know our position is strong, and we're going to have periods where demand is going to be really high. We just hope that will start to turn a little bit to our favor. And having all these operational improvements in place will benefit so much more when that happens.And I think something he said is really important to realize, we always want to leverage our strong global options. That's going to always be important, and if we get the right product priced and manufacturing them in the right places, so the right things for U.S., right things for Canada, the right things for Asia, right things for Haiti, that's where we really have the ability when the cylinders start firing to generate strong profit. So really good work being done and being prepared for the turnaround.Beryl BugatchOkay. Turning to CUF, Read is embedded within CUF and that's -- and you said Read for this quarter looks like about 1/3 of the revenue, so somewhere around $9 million for Read. How did that compare to last year for Read in the first quarter. What was that comparison like?Boyd B. ChumbleyYes, Bud, this is Boyd. And last year, first quarter, we were around 25% for that -- that's the total hospitality business. As a [percentage] of our total sales, which is the way we characterize that. So 25% last year versus 33% this year and that percentage was gaining throughout the year last fiscal year.Beryl BugatchI see. And so then on that basis and Read's gross margin, how would you characterize that versus the fleet margin, the average margin in CUF?Kenneth R. BowlingYes, Bud, this is Ken. As we -- the critical point that we made was Read had dramatic improvement year-over-year from last year. In fact, we were at a loss last year, now we're making money. The margin is comparable to the overall margin right now for CUF, Obviously, we want to continue to grow both as we make progress over the coming quarters. But we're just excited that, that business has really improved and really contributing this year.Beryl BugatchOkay. great. And turning a little bit to the future now, and I know that the guidance for the second quarter in the midst of a very uncertain macro environment being tough, and we appreciate what you did give. But Iv, you also did say you're looking to make operating profitability for the second half of the year. And I'm trying to make sure I understand, is that -- do you think you'll be operating profitable for all of the second half of the year? Or you think you'll be operating profitable for the entire year based upon the improvements that you're seeing in the second half of the year? How do we (inaudible) about that?Robert G. CulpYes. Thank you, Bud. Good question. And the way we're talking about that is certainly, we aren't -- because we're coming from the first couple of quarters, we aren't forecasting operating profitability for the entire year. But we do believe somewhere in that back half of our year, we'll have months and a quarter that will turn to consolidated operating profitability. We don't know if it's going to be the end of third, going to fourth, but somewhere in the second half.And a lot of that, we aren't dependent to keep sequentially improving on the macro demand. But if that happens faster, we'll turn faster. But even without -- if demand at current levels, we will have a quarter in the back half that turns profitable, most likely towards the end of the year, Bud.Beryl BugatchAnd so even if it does not sufficiently to make the second half overall profitable, but just in the particular quarter in which you reach operating profitability? Is that (inaudible).Robert G. CulpYes, that's what -- that's -- now we hope your first statement is right. But that's -- today, we're saying, we're not saying for the whole second half. We're saying we'll turn to profitability in the second half.Beryl BugatchIn the second half. Okay. And looking farther down the road. So now going from the near term, intermediate term to a little bit longer term, you continue to exude confidence and comfort longer term. And I think that if I got your message is even stronger now than it might have been even in some of the past calls, can you kind of give us a framing of what that looks like? Tell us what we should think about success when you get to success in the longer term.Robert G. CulpYes, certainly, Bud, thank you for picking up on that. We are -- we certainly understand that we're in a tough period. We're recovering from an even tougher period, but there's a lot of confidence in all of us, its executive management that we see -- we see brighter times for the business. We see where we're positioned. We see our innovative products and the platform we have to service customers and we know that our industry is, generally over our history, been a stable slow growing industry.We haven't been used to these ups and downs that we've had in the last two, three years. That's been -- that's taken a toll on our results. But as we get to some stability and the teams that we have in place operating in both divisions are really confidence inspiring.So when we look out into beyond '24 and to '25, '26, I mean we're back to double-digit operating incomes in mattress fabrics and high single-digit operating income percentages in upholstery fabrics. And we'd like to go past that. But that's our first target to recover to and I guess it depends on your horizon of medium to long term, but we would see that happening in our medium term as we look out forward.Beryl BugatchOkay. So that gets us to the margin side of that. And then in terms of the topline, you think you can match the industry's slow growing low to mid-single-digit kind of growth over time topline?Robert G. CulpYes, sir. I mean ideally, in our best days, and we hope we can grow faster than the industry grows. That's always our goal. And I don't see why we can't, but we certainly will stay with industry pace and see that steady growth.Beryl BugatchAll right. And last for me, the other thing that I noticed in the quarter was SG&A was a little bit heavier than what we were looking for and operating expenses a little bit heavier. Maybe you can give us some color as to what we -- why that might have been and what we should expect as we go down the road.Kenneth R. BowlingYes, Bud, this is Ken. We listed some of the reasons for the higher. Obviously, wage inflation was a part of it. We did have some higher incentive compensation accrual. Keep in mind, we're coming off of a very, very tough year, and our -- the way we're looking at this year is significant improvement. So we've got some opportunity there.We also have some professional fees that -- just various professional fees. And also, and this is something that both divisions had to contend with was sampling expense and people forget about that. But this time last year, we didn't have any hardly any new programs, and now both teams are dealing with new great opportunities and new rollouts, and so the sampling expense was higher.So all those reasons kind of impacted all three, the corporate account, our corporate expense and divisionals. What we're excited about is that we've talked about this in the prepared remarks, as we grow the business, we've got -- our SG&A level right now is supporting our activities in our business models. As we grow sales, we're going to have significant leverage opportunity to bank a lot of that profitability, and so both SG&A and fixed costs. So we've got everything ready to go, we just need that lift in sales to get that leverage.Beryl BugatchAnd is there an order of magnitude on the sampling cost that you're willing to share? And does that go into -- doesn't that go into gross margin? I mean, sampling costs would be fabric you create? Or do you take out those -- that sample cost that you can isolate and then make sure that's showing up in SG&A and operating expense?Tommy BrunoBud, the way that we characterize our sampling cost is really is a part of our launches, so it's really a part of our commercial process of sampling, creating -- doing all the development and design work relative to new programs.Beryl BugatchOkay. So it's not just the cost of the fabric you produce for the samples, you produce or maybe send out to your clients, but it's the wages and the cost inside of there for the team to develop those? There's no (inaudible).Tommy BrunoIt's all the cost from sampling, design and launch preparations.Beryl BugatchAnd that winds up in operating expense. Is that right?Tommy BrunoYes.Beryl BugatchOkay. Again, congratulations on navigating through a challenging period. There are some in the industry that -- well, they're not there anymore to do that.Robert G. CulpThank you, Bud. Have a good weekend.OperatorThis concludes our question-and-answer session. I would like to turn the call back over to Iv Culp for any closing remarks.Robert G. CulpThank you, operator. And again, thank you to everyone for your participation and your interest in Culp. We look forward to updating you on our progress next quarter.OperatorThe conference has now concluded. Thank you for attending today's presentation. You may now disconnect.

Thomson Reuters StreetEvents

Q1 2024 Culp Inc Earnings Call

https://finance.yahoo.com/news/q1-2024-culp-inc-earnings-064138543.html

fcbfbd9c-5132-391f-a62b-663325223930

CULP

Culp, Inc. (NYSE:CULP) Q1 2024 Earnings Call Transcript August 31, 2023Operator: Good morning, and welcome to the Culp, Inc. First Quarter Fiscal 2024 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Dru Anderson. Please go ahead.Dru Anderson: Thank you. Good morning, and welcome to the Culp conference call to review the company's results for the first quarter of fiscal 2024. As we start, let me state that this morning's call will contain forward-looking statements about the business, financial condition and prospects of the company. Forward-looking statements are statements that include projections, expectations or beliefs about future events or results or otherwise are not statements of historical fact. The actual performance of the company could differ materially from that indicated by the forward-looking statements because of various risks and uncertainties. These risks and uncertainties are described in our regular SEC filings, including the company's most recent filings on Form 10-K and Form 10-Q.mattressty-carlson-I8kTKM17Ktc-unsplashAdditional risks and uncertainties that we do not presently know about or that we currently consider to be immaterial may also affect our business operations and financial results. You are cautioned not to place undue reliance on forward-looking statements made today, and each such statement speaks only as of today. We undertake no obligation to update or to revise forward-looking statements. In addition, during this call, the company will be discussing non-GAAP financial measurements. A reconciliation of these non-GAAP financial measurements to the most directly comparable GAAP financial measurements is included in the tables to the press release included as an exhibit to the company's 8-K filed yesterday and posted on the company's website at culp.com.I will now turn the call over to Iv Culp, President and Chief Executive Officer of Culp. Please go ahead, Iv.Story continuesRobert Culp: Thank you, Dru, and good morning, everyone, and thank you for joining us today. I would like to welcome you to the quarterly conference call with analysts and investors. With me on the call are Ken Bowling, Chief Financial Officer; Boyd Chumbley, President of our Upholstery Fabrics business; and Tommy Bruno, President of our Mattress Fabrics business. So today, I'll begin the call with some detailed comments, including a discussion of key points and topics for the quarter and for both businesses as well as priorities as we look ahead. After that, Ken will review the financial results for the quarter, and I will then briefly review our business outlook for the second quarter of fiscal '24, and we will then take your questions.Regarding the current state of our business, in the overall furniture and bedding industries. I want to review some overriding themes we discussed last quarter and detail some critical actions we are continuing to execute within both businesses. I will also expand on our comments with a few important points that illustrate where Culp is today. Number one, we are encouraged by our better-than-expected operating improvement for the quarter both sequentially and year-over-year despite the ongoing industry malaise and demand softness within the two industries we service. Number two, we remain excited about the progress of our comprehensive transformation within our CHF mattress fabrics business, and we are pleased to be gaining market position in the face of some contraction in the domestic mattress industry.Number three, although market conditions are also pressuring the residential home furnishings industry, our upholstery fabrics business has remained profitable despite these pressures, and demand remains quite solid in our growing hospitality business. And number four, we are continuing our diligent focus on prudent financial management, including maintaining a strong balance sheet and ensuring a strategic level of working capital. So going to theme #1. Our results for the first quarter reflected better-than-expected operating performance, both sequentially and year-over-year even as industry demand remains soft, especially in residential home furnishings. However, our operating performance improved despite pressure on sales due to internal improvements within both businesses.The strong sequential and year-over-year improvement in our mattress fabrics business, a 45% improvement sequentially and a 52% improvement year-over-year was supported by the rollout of new fabric and cover placements during the period. As we have commented for some time now, these new programs are priced in line with current raw material and operational costs and we expect these new programs to grow Culp Home Fashion's market position in fiscal '24. The operating improvement in the CHF business was also driven by our ongoing focus on operational efficiencies and cost reduction initiatives across our locations, and I will expand more on this shortly. I do want to emphasize that mattress fabric sales for the quarter were flat compared to the prior year period, which is a solid performance in the face of difficult industry conditions and certainly reflects our growing position in the market.For the Upholstery Fabrics segment, we saw operational improvements and fixed cost savings along with solid demand in our hospitality contract fabric business and improvement for Read Window. But as expected, sales within our residential fabrics business were lower as compared to the first quarter of last fiscal year, which notably was a strong quarter due to a lift in sales following pandemic-related shutdowns in China and the quick recovery that the upholstery furniture industry was experiencing at that time. Our sales for residential fabrics this quarter were certainly affected by the ongoing softness in the home furnishings industry and shifting consumer spending trends following the pandemic stay at home search. While we do understand that the furniture and bedding environment remains challenged, we will continue to manage the aspects of our business we can control, taking necessary steps to withstand current market conditions, and position our business for renewed growth.As detailed in earlier quarters, we have made platform changes to our cut and sew profile on both mattress fabrics and upholstery and the cost benefits from these adjustments are coming to bear. We are also focused on managing our operational efficiencies across our fabric platforms and therefore, lowering overall costs. Beyond Q1, we believe our continuing recovery will be led by our mattress fabrics segment, while our execution of a comprehensive transformation plan is laying the foundation for study improvement. I'll expand much more on the mattress fabrics transformation plan momentarily, but our sequential and year-over-year operating improvement reflects some of these initiatives we have undertaken internally to manage our business. While the challenging industry environment is expected to continue for some time, our market position is strong and improving, and we believe we are poised for a considerably better second half of fiscal '24 and that's November to April by the calendar with a return to operating profitability in this fiscal year.Regardless of the current demand backdrop, we expect continued progress in improving our operating results, but we understand the speed of our recovery may be affected by overall industry trends. We would like to see some macro tailwinds to allow recovery to happen quicker. We are well prepared for the long term, and our strong leadership teams, innovative product offerings creative designs and a resilient global manufacturing and sourcing platform will support us into the future, especially when the environment improves. The second important thing to expand on is the business transformation update within Culp Home Fashions, our Mattress Fabrics segment, under the leadership of Division President, Tommy Bruno, along with his restructured management team.Our transformation plan focuses on long-term improvement in every facet of the business, including quality, sales, marketing and operational processes, supply chain optimization, employee engagement and organizational management structure. As we said, we believe CHF improvement is our best short-term opportunity for recovery and growth from our current levels. Tommy and the CHF management team remains focused on operational excellence as well as balancing our product mix to proper volumes and steady run schedules. Even after our previous cost-saving adjustment to our domestic North Carolina cut and sew capabilities, we continue with a robust global platform, featuring manufacturing and sourcing capabilities in six countries: The U.S., Canada, Turkey, Haiti, China and Vietnam.Our combination of onshore, nearshore and offshore options provide our mattress fabric and sewn cover customers with the agility and value they need for their business. Combining this platform with our expertise in design and product innovation, we are making excellent progress for sustainable improvement in fiscal '24. Overall, as we've mentioned, the domestic mattress industry is experiencing significant contraction with industry reports showing aggregate reductions of 10% in dollars and 20% in units through the first six months of calendar '23. But notably, again, CHF revenue over the same general period has remained flat, indicating that CHF has made gains with customers in a difficult market environment. While the mattress industry slowness may remain for some period, we still expect to improve our performance through new programs and improved operations.Our recovery in CHF is not fully dependent on the industry environment, and assuming our sales volumes in fiscal '24 do not materially fall below the prior year, we expect to see significant progress with steady sustainable improvement in CHF this year and beyond. The third important theme is the continued profitability of Culp Upholstery Fabrics. I've detailed just now a lot of excitement about CHF, but it is equally as important to note the steady performance of CUF. Division President Boyd Chumbley and a strong leadership team have managed effectively in the most -- in the midst of abnormal tumultuous times. CUF has maintained profitability with a focus on improving operational efficiencies and proactively taking strategic actions to reduce our cost structure to align with demand levels while also always supporting our customers with our flexible global platform.I believe CUF has best-in-class in servicing our customers in our design and product excellence, combined with an effective global platform has led the way. Our improved operating cost within CUF began with the restructuring of our cut and sew upholstery kit platform in China during the second quarter of last fiscal year and then continued with the rationalization of our upholstery cut and sew platform in Haiti near the end of last fiscal year. We took further action in Haiti this quarter to discontinue production of cut and sew upholstery kits at this location based on demand softness. This step further reduces CUF cost structure and avoids losses that would have otherwise been incurred while allowing this business to continue to support customers through its strong Asian supply chain.Notably through these actions and other improvements in operational efficiencies, CUF has been effective in lowering its overall cost levels to remain profitable in the face of reduced demand. Just one quick aside. I do want to again reiterate that while we have discontinued production of upholstery, cut and sew kits in Haiti, our Haiti cut and sew platform for mattress covers remains an integral part of our strategic plan. Now turning back to CUF, we are also adjusting our global platform for the fabrics portion of our upholstery fabrics business as we look to provide options within our supply chain in China, Vietnam and multiple other new countries. Customer service is a hallmark for Culp and a diversified platform provides improved risk management and a more stable supply base.Of note, our hospitality contract business accounted for 33% of segment sales for the first quarter. While this percentage is higher than normal due to lower residential sales it does reflect the ongoing solid performance of our hospitality contract business as well as its importance to our overall strategy of product diversification for this segment. While the tough demand environment may continue for some time, upholstery fabrics remains well positioned for the long term with a scalable global platform and innovative product offerings, including our popular portfolio of LiveSmart performance products and our new product technologies. We are also beginning to see increases in newly written fabric orders, and we believe we will see the benefit from this in the second half of fiscal '24.Similar to the first quarter, we also expect the upholstery fabric segment will continue to benefit Culp through the remainder of fiscal '24 with improved inventory management, a solid hospitality contract fabric business improvement in our Read Window business and a rationalized cut and sew platform. And lastly, I'll shift to the fourth theme, which is constant focus on prudent financial management including maintaining a strong balance sheet and ensuring a strategic level of working capital. I am very pleased with the management team for its continued effort in maintaining our cash and total liquidity position. We ended the quarter with $16.8 million in cash and no outstanding borrowings, and we had total liquidity of $42.3 million, consisting of cash and borrowing availability under our domestic credit facility.We are continuing to carefully manage inventory against current demand levels, and we are strategically investing in our business. I have repeatedly, through my remarks, mentioned the softness within our industries, and that has been most evident to us by several recent closures within the furniture industry. And remember, this is on the heels of several bankruptcies we witnessed in the last year as well. We are seeing some suppliers, competitors and customers endure financial difficulty and it gives us more appreciation for our financial stability and it's important to our future. We are managing accounts receivable effectively, and we do not have any material exposure with respect to the recent closures. I am grateful to our credit teams and divisional management for how we conduct Culp's business with a lens towards the future and careful partner selection.We fully recognize that the management of Culp's strong balance sheet is a critical initiative, and we believe we are well positioned to focus on investing and optimizing our global manufacturing platform and growing profitable sales. I'll now turn the call over to Ken, who will review the financial results for the quarter, and then I'll briefly review the outlook for the second quarter of this fiscal year. Ken?Ken Bowling: Thanks, Iv. Here are the financial highlights for the first quarter. Starting with consolidated results, net sales were $56.7 million, down 9.5% and compared with the prior year period, driven almost entirely by a decline in upholstery fabrics sales. The company reported a loss of operations of $3.1 million, which included $517,000 in mostly noncash restructuring-related charges associated with the discontinued production of cut and sewn upholstery kits in Haiti during the quarter, as I have discussed earlier. Excluding this $517,000, adjusted loss from operations for the quarter was $2.6 million, a better-than-expected improvement as compared with a loss of operations of $4.7 million for the prior year period and a loss from operations of $4 million for the fourth quarter of last fiscal year.Net loss for the first quarter was $3.3 million or $0.27 per diluted share compared with a net loss of $5.7 million or $0.47 per diluted share for the prior year period. Net loss for the quarter included the $517,000 restructuring-related charges I just mentioned. Our overall operating performance for the first quarter as compared to the prior year period was positively affected by improved margins on new products improvement in operating efficiencies and lower overhead costs in both segments, a higher contribution from hospitality fabrics in the Read Window business and a more favorable foreign exchange rate associated with China. This year-over-year improvement in operating performance was partially offset by margin pressures due to lower sales and higher SG&A expense.SG&A expense was higher than last year due to increased compensation expense mostly related to wage inflation and higher incentive compensation pools, higher professional fees and increased sampling expense driven by new product rollouts in both businesses. Importantly, with regard to SG&A expense, as business conditions improve and demand for new products rise, we believe that we'll get significant leverage from the increased sales. Adjusted EBITDA for the period was close to breakeven at negative $416,000 as compared to adjusted EBITDA of negative $2.7 million for the prior year period. The effective income tax rate for the first quarter of this fiscal year was a negative 26.5% compared with a negative 18.7% for the same period a year ago.Our effective income tax rate for the quarter was impacted by the company's mix of earnings between our U.S. and foreign subsidiaries with an operating loss in the U.S. while China and Canada generated income that was packed at higher rate as compared to the U.S. Our cash income tax payments totaled $1.1 million for the first quarter of this fiscal year. And based on current expectations, we currently plan for cash income tax payments of approximately $3.2 million for the entire fiscal '24 year. Importantly, our estimated cash income tax payments for fiscal '24 or management's current projections only and can be affected by a variety of factors over the course of the year. Now let's take a look at our business segments. For the Mattress Fabrics segment, sales for the first quarter were $29.2 million, down 0.5% compared to last year's first quarter, outperforming overall industry trends.Operating loss for the quarter was $1.4 million, a 52% improvement compared to an operating loss of $2.9 million a year ago. This operating improvement was driven by new placements, price in line with current cost improvements in operating efficiencies and lower costs resulting from the restructuring and rationalization of this segment's mattress cover platform initiated last fiscal year, offset somewhat by higher SG&A expense. For the Upholstery Fabrics segment, sales for this first quarter were $27.4 million, down 17.4% over the prior year period, which was a strong quarter due to a lift in sales following pandemic-related shutdowns in China. Sales for our residential fabric business for the quarter were affected by ongoing softness in the residential home furnishings industry.However, demand remains solid in our upholstery -- in our hospitality contract business during the first quarter with sales for this business accounted for approximately 33% of the upholstery fabric segment's total sales. Operating income and operating margin for the quarter were $1.3 million and 4.8%, 145% and 320 basis point improvement, respectively, compared with the prior year period. This operating performance was positively affected by a higher contribution from hospitality fabrics and Read Window business, lower costs resulting from the restructuring of this segment's cut and sew platforms during earlier periods, and a more favorable foreign exchange rate associated with the segment's operations in China as well as other operational improvements.These factors were partially offset by lower residential fabric sales and higher SG&A during the period. Now I'll turn to the balance sheet. We reported $16.8 million in total cash and no outstanding debt as of the end of the first quarter. Cash flow from operations and free cash flow were negative $4.4 million and negative $4.2 million, respectively, for the first three months of this fiscal year. Our cash flow from operations and free cash flow during the period were affected by an operating loss and investments in working capital and capital expenditures mostly related to the mattress fabrics transformation plan. Capital expenditures for the first three months of this fiscal year were $513,000. Based on current expectations, capital spending for this fiscal year is projected to be in the range of $5 million to $6 million and will center mostly on maintenance CapEx and quick payback projects focused on improving quality and efficiency in our mattress fabrics business.Based on current expectations, depreciation for this fiscal year is expected to be approximately $7 million. With respect to liquidity, as of the end of the first quarter, we had $42.3 million consisting of $16.8 million in total cash and $25.5 million in borrowing availability under our asset-based domestic credit facility. Borrowing availability under this facility is based on a calculation using certain of the company's accounts receivable inventory determined on a monthly basis. The company did not repurchase any shares during the first quarter of this fiscal year, leaving $3.2 million available under our current share repurchase program. Despite the current share repurchase authorization, we do not expect any activity during the second quarter this fiscal year as we remain focused on preserving liquidity and being positioned to support future growth opportunities.With that, I'll turn the call over to Iv to discuss the general outlook for the second quarter of this fiscal year, and then we'll take your questions. Iv?Robert Culp: Thank you, Ken. Due to the continued volatility in the macro environment, we are providing only limited financial guidance for the second quarter of fiscal '24. We expect consolidated net sales for the second quarter to be comparable to the second quarter of fiscal '23 driven by further improvement in the Mattress Fabrics segment, but offset by lower residential upholstery fabrics sales. We expect consolidated operating loss for the second quarter of fiscal '24, that is in the range of $2.2 million to $2.6 million, a significant improvement compared to the $11.9 million operating loss for the prior year period, which did include approximately $6 million relating to certain inventory impairment charges, losses on inventory closeout sales and greater-than-normal inventory markdowns.Again, I will comment that we believe we are poised for a considerably better second half performance with a return to operating profitability this fiscal year. Finally, we will continue to be laser-focused on prudent financial management with the goal of always maintaining a strong balance sheet especially with regard to ensuring a strategic balance in our working capital. We are optimistic about Culp's future, and we know that financial stability is paramount to our success. So with that, we will now take questions.See also 16 Best High Volume Stocks To Buy Today and 12 Best High Risk High Reward Stocks To Buy Now.Q&A SessionOperator: [Operator Instructions] Our first question comes from Anthony Lebiedzinski with Sidoti & Company.Anthony Lebiedzinski : So first, just a quick comment. Overall, a perfect job of maintaining a strong balance sheet and certainly nice to see a solid gross profit gains here in the quarter. So it's first question here for CHF, so you mentioned that new placements are in line with current costs and that's great to hear. So I guess for the quarter, can you give us just kind of a rough breakdown between pricing and unit volumes? I would love to hear your thoughts on that.Robert Culp : Ken, can you?Ken Bowling: Yes. Yes. Anthony, I mean, we -- I think we've mentioned this before. I mean we price new products to capture the cost and that pricing flows throughout the year. I mean, obviously, we were right in line with sales and units were close as well. So really, it wasn't a big difference at all, pretty consistent on both.Robert Culp : We were building in the mattress fabrics business, Anthony, and you hopefully hear our excitement as we talk about the business. It's such a strong turnaround that's underway, and we're growing dollars in units. I mean we're a unit-driven company. So we're not going to have success without also growing the units. So we're doing both.Anthony Lebiedzinski : So I mean -- so before COVID, I mean, the gross margin at CHF was in the mid-teens and even higher in prior years. So given the transformation underway, do you think it's reasonable that you could get back to at least double-digit segment margin sometime this fiscal year?Robert Culp : Well, Anthony, we -- I'll let Tommy make some comments to what he's seeing. The problem won't be as bold to tell you exactly when that's going to happen. But in our -- all the investor information that we're putting out through our new deck, sort of a minimum standard for our expectation in the CHF business is double-digit operating income percent. And we certainly have every intention of being at that in our intermediate future. Now whether we can get all the way to double-digit profitability in this fiscal year, TBD, but we are expecting to return to profitability both in the division and consolidated in this year. Tommy, anything you would add as you're just going through the process?Tommy Bruno: No, I think that's a good representation of the improvement. I think, Anthony, we expect it to be sequentially higher quarter-over-quarter and with the objective of getting back to historical profitability rates.Anthony Lebiedzinski : Okay. That sounds good. And then for CUF, the residential, obviously, as you called out, is softer but are you seeing any notable customers moving away from Culp? Or is it just -- is that just seeing that customers are just ordering less across the board now?Robert Culp : I'll let Boyd speak to that question, Anthony.Boyd Chumbley: Yes, Anthony. No, we're really not seeing any dramatic changes in our customer base. I think this was more just an overall industry demand situation that we're being impacted with. And of course, we have to remember, too, that for this quarter, we were comparing to an abnormally high first quarter of last year due to the pandemic. So the extreme pandemic-induced swings in demand over the last several years have made year-over-year comparisons difficult. So -- but no, to answer your question, don't see that we're having any changes in our customer mix in any significant way. This is more just industry-wide demand depression at the moment.Robert Culp : And Anthony, as Boyd has worked here with Culp from 40 years and we have seen our shares of ups and downs in the residential furniture business over many times. And we always think and it has typically beared itself out we gain market position in times like this. And typically, when these times pass, we find ourselves in a better position. And this is no different. We believe on our side, we are actually gaining market position now and we think it's fully driven by just the slowest in the current industry. If supply chains are adjusting, new products are being rolled out on the floor. Remember, we skipped about a year of new intros in that business for a little bit as no one needed to relaunch retail. So as that starts to happen, we're pretty optimistic about where it's going to go.And we noted in our script that we are now starting to see new written orders gradually increase. So we are seeing optimism as we look past -- probably looking past second quarter, but we do see those sales levels starting to pick back up.Anthony Lebiedzinski : That's great to hear. And then last question before I turn the call over to others. I guess probably a question for Ken. So inventory management that has certainly been a nice source of cash, so a nice job with that. So do you think you can further reduce inventories? How about cash flow? So how should we think about that?Ken Bowling: Yes, Anthony, that's -- I mean, as we look to grow the business on both sides, I mean, we -- both teams have done -- if you look over the last six quarters, they've done a remarkable job of getting inventory down and really meeting demand. And so as we proceed ahead into the next quarters, our focus is going to be on growing the business, and as we said in the prepared remarks, balancing inventory with sales, and that's -- that we preach that every day. So is there some opportunity to continue to maximize efficiencies in inventory? Probably some but right now, the -- we've got to make sure we've got the right amount of inventory on hand to support growth. And so -- but that said, we're going to be very careful about balancing both as we grow the business.Operator: Our next question comes from Budd Bugatch with Water Tower Research.Budd Bugatch: First, I just want to make a comment that I know it's been a very tumultuous time for everybody. Congratulations on keeping the financial condition of Culp up pretty strong, making it through these times. I guess the first question is, you talk about the improvements in CHF. And I guess I would love to get some color on that, maybe anecdotally what you've done, what -- you talked about some of the operational cost efficiencies. Do you have some examples of what that was or maybe put some color to numbers on that?Robert Culp : Yes. And I'll let Tommy speak to that, Budd, because he's living it. He's living it. We're happy to have him here with us in the office and not on the plant floor. We got him. We had to pry him out from that. But Tommy, why don't you touch on anything from your standpoint?Tommy Bruno: Yes, sure. Budd, it's really, for us, improving our gross profit is really a combination of working on our mix, working on improving previous programs that weren't costed in line with the market conditions through COVID. As it related to operational efficiencies, we continue to really push our supply chain for best cost position on raw materials as well as continuous improvement, quality and manufacturing efficiency initiatives in Stokesdale and in Canada. Other initiatives we're doing is making sure that we're really leveraging our global platform for efficiency and profitability and balancing those together with our manufacturing assets.Budd Bugatch : And Tommy, can you kind of maybe characterize the importance of that? Was pricing more important than the operational efficiencies? How do you -- what's the relative mix between the two?Tommy Bruno: Yes. That's a really -- I don't want to take the easy way out of this question. I would say that they're equally important Budd, because we had some programs that weren't profitable that we had to reshift away. But we also have opportunities through a challenging COVID environment to really engage and drive operational improvement as the macro environment and raw materials opportunities have come along. So we're focused equally on both of them.Budd Bugatch : And so do we think about them as 50-50 kind of improvement? You get 50% of the improved gross margin from pricing and 50% from pricing that you can finally get a hold of or get either through new programs or realigning previously unprofitably priced programs and 50% through operational efficiencies?Tommy Bruno: Yes, sir. I would characterize it as 50-50.Robert Culp : And what I get excited about Budd from what Tommy is working on, I agree. It's both half and half, better pricing and better cost improvement. What makes me excited watching it is the business is gradually picking up. We are -- and we're doing that internally by gaining market position. We've been around this mattress business for some time, and we know our position is strong, and we're going to have periods where demand is going to be really high. We just hope that will start to turn a little bit to our favor. And having all these operational improvements in place will benefit so much more when that happens. And I think something he said is really important to realize we always want to leverage our strong global options.That's going to always be important, and if we get the right product priced and manufacturing them in the right places, so the right things for U.S., right things for Canada, we write things for Asia, right things for Haiti, that's where we really have the ability when the cylinders start firing to generate strong profit. So really good work being done and being prepared for the turnaround.Budd Bugatch : Okay. Turning to CUF, Read is embedded within CUF and that’s -- and you said that Read for this quarter looks like about 1/3 of the revenue, so somewhere around $9 million for Read. How did that compare to last year for Read in the first quarter. What was that comparison like?Boyd Chumbley: Yes, Budd, this is Boyd. And last year, first quarter, we were around 25% for that -- that's the total hospitality business as a percentage of our total sales, which is the way we characterize that. So 25% last year versus 33% this year and that exchange was gaining throughout the year last fiscal year.Budd Bugatch : I see. And so then on that basis and Read's gross margin, how would you characterize that versus the fleet margin, the average margin in CUF?Ken Bowling: Yes, Budd, this is Ken. As we -- the critical point that we made was Reed had dramatic improvement year-over-year from last year. In fact, we were at a loss last year. Now we're making money. The margin is comparable to the overall margin right now for CUF, Obviously, we want to continue to grow both as we make progress over the coming quarters. But we're just excited that, that business has really improved and really contributing this year.Budd Bugatch : Okay. That’s great. And turning a little bit to the future now, and I know that the guidance for the second quarter in the midst of a very uncertain macro environment has been tough, and we appreciate what you did give. But if you also did say you're looking to make operating profitability for the second half of the year. And I'm trying to make sure I understand, is that -- do you think you'll be operating profitable for all of the second half of the year? Or you think you'll be operating profitable for the entire year based upon the improvements that you're seeing in the second half of the year? How do we think about that?Robert Culp : Yes. Thank you, Budd. Good question. And the way we're talking about that is certainly, we aren't -- because we're coming from the first couple of quarters, we aren't forecasting operating profitability for the entire year. But we do believe somewhere in that back half of our year will have months and a quarter that will turn to consolidated operating profitability. We don't know if it's going to be the end of third, going to fourth, but somewhere in the second half. And a lot of that, we aren't dependent to keep sequentially improving on the macro demand. But if that happens faster, we'll turn faster. But even without -- if demand at current levels, we will have a quarter in the back half that turns profitable, most likely towards the end of the year, Budd.Budd Bugatch : And so even if it does not sufficiently to make the second half overall profitable, but just in the particular quarter in which you reach operating profitability? Is that what you're saying?Robert Culp : Yes, that's what -- that's -- now we hope your first statement is right. But that's what today we're saying. We're not saying for the whole second half. We're saying we'll turn to profitability in the second half.Budd Bugatch : In the second half. Okay. And looking further down the road, so now going from the near term, intermediate term to a little bit longer term, you continue to exude confidence and comfort longer term. And I think that if I got your message even stronger now than it might have been even in some of the past calls, can you kind of give us a framing of what that looks like? Tell us what we should think about success when you get to success in the longer term.Robert Culp : Yes, certainly, Budd, thank you for picking up on that. We are -- we certainly understand that we're in a tough period. We're recovering from an even tougher period, but there's a lot of confidence in all of us its executive management that we see brighter times for the business. We see where we're positioned. We see our innovative products and the platform we have to service customers and we know that our industry is, generally over our history, been a stable slow growing industry. We haven't been used to these ups and downs that we've had in the last two, three years. That's been -- that's taken a toll on our results. But as we get to some stability and the teams that we have in place operating in both divisions are really confidence inspiring.So when we look out into beyond '24 and to '25, '26, I mean we're back to double-digit operating incomes in mattress fabrics and high single-digit operating income percentages in upholstery fabrics. And we'd like to go past that. But that's our first target to recover to and I guess it depends on your horizon of medium to long term, but we would see that happening in our medium term as we look out forward.Budd Bugatch : Okay. So that gets us to the margin side of that. And then in terms of the top line, you think you can match the industry's slow growing low to mid-single-digit kind of growth over time top line?Robert Culp : Yes, sir. Yes, sir. I mean we are ideally in our best days and we hope we can grow faster than the industry grows. That's always our goal. And I don't see why we can, but we certainly will stay with industry pace and see that steady growth.Budd Bugatch : All right. And last for me, the other thing that I noticed in the quarter was SG&A was a little bit heavier than what we were looking for and operating expenses a little bit heavier. Maybe you can give us some color as to what we -- why that might have been and what we should expect as we go down the road.Ken Bowling: Yes, Budd, this is Ken. We listed some of the reasons for the hire. Obviously, wage inflation was a part of it. We did have some higher incentive compensation accrual. Keep in mind, we're coming off of a very, very tough year, and our -- the way we're looking at this year is significant improvement. So we've got some opportunity there. We also have some professional fees that -- just various professional fees. And also -- and this is something that both divisions had to contend with was sampling expense and people forget about that. But this time last year, we didn't have hardly any new programs, and now both teams are dealing with new great opportunities and new rollouts, and so the sampling expense was higher.So all of those reasons kind of impacted all three, the corporate account, our corporate expense and divisionals. What we're excited about is that we've talked about this in the prepared remarks, as we grow the business, we've got -- our SG&A level right now is supporting our activities in our business models. As we grow sales, we're going to have significant leverage opportunity to bank a lot of that profitability, and so both SG&A and fixed costs. So we've got everything ready to go, we just need that lift in sales to get that leverage.Budd Bugatch : And is there an order of magnitude on the sampling cost that you're willing to share? And doesn't that go into gross margin? I mean, sampling costs will be fabric you create? Or do you take out those -- that sample cost that you can isolate and then make sure that's showing up in SG&A and operating expense?Ken Bowling: Hey, Budd. The way that we characterize our sampling cost is really as a part of our launches, so it's really a part of our commercial process of sampling, creating, doing all the development and design work relative to new programs.Budd Bugatch : Okay. So it's not just the cost of the fabric you produce for the samples, you produce or maybe send out to your clients, but it's the wages and the cost inside of there for the team to develop those? There's no....Ken Bowling: It's all the cost from sampling, design and launch preparations.Budd Bugatch : And that winds up in operating expense. Is that right?Ken Bowling: Yes, sir. Yes.Budd Bugatch : Okay. Again, congratulations on navigating through a challenging period. There are some in the industry that -- well, they're not there anymore to do that.Robert Culp : Thank you, Bud. Have a good weekend.Operator: This concludes the question-and-answer session. I would like to turn the call back over to Iv Culp for any closing remarks.Robert Culp : Thank you, operator. And again, thank you to everyone for your participation and your interest in Culp. We look forward to updating you on our progress next quarter.Operator: The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.

Insider Monkey

Culp, Inc. (NYSE:CULP) Q1 2024 Earnings Call Transcript

https://finance.yahoo.com/news/culp-inc-nyse-culp-q1-125351671.html

4f7f9ac4-8d4c-3a8e-91c6-3c3fbb891ce3

CVLG

Covenant Logistics Group, Inc.Quest for Quality AwardQuality 2023CHATTANOOGA, Tenn., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Covenant Logistics Group, Inc. a leading provider of transportation and logistics services in the U.S., has been awarded the Quest for Quality Award from Logistics Management.The Quest for Quality Awards are the gold standard for customer satisfaction and performance excellence for carriers, ports, and logistics providers worldwide. Logistics Management's (LM) Annual Quest for Quality Awards is the culmination of a six-month research project conducted by Peerless Research Group (PRG). For nearly four decades, LM's Quest for Quality Awards has been regarded in the transportation and logistics industry as the most critical measure of customer satisfaction and performance excellence. Learn more.Quality 2023"Receiving the Quest for Quality Award is a testament to our commitment to providing reliable and efficient logistics solutions. I want to express my gratitude to our customers for their trust and support, and to our dedicated team for their hard work and unwavering dedication to excellence," states Covenant President Paul Bunn."We will continue to strive for excellence, innovate, and adapt to the evolving needs of our customers. This recognition fuels our motivation to push boundaries and set new benchmarks in the transportation and logistics industry," states Bunn."Now in its 40th year, the Quest for Quality Awards program continues to stand out in the industry for the simple fact that it's not a popularity contest," said Michael Levans, group editorial director of Peerless Media's Supply Chain Group. "Instead, this annual survey of LM readers is by invitation only, ensuring that all participants are qualified shippers that use the services of these carriers and service providers on a regular basis around the clock and around the world.""Indeed, here in 2023, we're seeing some of the well-publicized supply chain congestion ease," added Levans. "However, as our latest Quest for Quality results show, the improved collaboration between shippers and their carrier and services partners over the past year have only helped them to prepare for whatever supply chain disruption may be around the bend—an indication that more resilient logistics operations have been created to meet future challenges."Story continuesAbout Covenant Logistics Covenant Logistics Group, Inc., through its subsidiaries, offers a portfolio of transportation and logistics services to customers throughout the United States. Primary services include asset-based expedited and dedicated truckload capacity, asset-light warehousing, transportation management, and freight brokerage capability. In addition, Transport Enterprise Leasing is an affiliated company providing revenue equipment sales and leasing services to the trucking industry. Covenant's Class A common stock is traded on the NASDAQ Global Select Market under the symbol "CVLG."About the Quest for Quality Awards To determine the "best of the best," LM readers—logistics, transportation, and supply chain decision makers—rate carriers, third-party logistics (3PL) service providers, and U.S. port operators strictly based on service quality. One of the most notable elements of the Quest for Quality Awards is that it calls these shippers to vote in the genre of services in which they are customers; therefore, they vote for the providers they believe have the best-delivered quality service in specific niches. This year, LM had 3,512 ballots cast from logistics and supply chain decision-makers, resulting in 142 transportation and logistics services providers that earned Quest for Quality gold.Media Contact:Angie Harrison423-463-3291A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2ef645fd-37ae-40d6-82f6-2214fa6cf307

GlobeNewswire

Covenant Receives Quest for Quality Award from Logistics Management

https://finance.yahoo.com/news/covenant-receives-quest-quality-award-125000695.html

0637271b-5aaa-31c7-b283-570678b70f85

CVLG

Covenant Logistics Group, Inc. (NASDAQ:CVLG), might not be a large cap stock, but it saw a significant share price rise of over 20% in the past couple of months on the NASDAQGS. Less-covered, small caps tend to present more of an opportunity for mispricing due to the lack of information available to the public, which can be a good thing. So, could the stock still be trading at a low price relative to its actual value? Let’s examine Covenant Logistics Group’s valuation and outlook in more detail to determine if there’s still a bargain opportunity. Check out our latest analysis for Covenant Logistics Group What Is Covenant Logistics Group Worth?Good news, investors! Covenant Logistics Group is still a bargain right now according to my price multiple model, which compares the company's price-to-earnings ratio to the industry average. I’ve used the price-to-earnings ratio in this instance because there’s not enough visibility to forecast its cash flows. The stock’s ratio of 7.24x is currently well-below the industry average of 14.76x, meaning that it is trading at a cheaper price relative to its peers. What’s more interesting is that, Covenant Logistics Group’s share price is quite volatile, which gives us more chances to buy since the share price could sink lower (or rise higher) in the future. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.Can we expect growth from Covenant Logistics Group?earnings-and-revenue-growthInvestors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Though in the case of Covenant Logistics Group, it is expected to deliver a negative earnings growth of -14%, which doesn’t help build up its investment thesis. It appears that risk of future uncertainty is high, at least in the near term.Story continuesWhat This Means For YouAre you a shareholder? Although CVLG is currently trading below the industry PE ratio, the negative profit outlook does bring on some uncertainty, which equates to higher risk. I recommend you think about whether you want to increase your portfolio exposure to CVLG, or whether diversifying into another stock may be a better move for your total risk and return.Are you a potential investor? If you’ve been keeping an eye on CVLG for a while, but hesitant on making the leap, I recommend you research further into the stock. Given its current price multiple, now is a great time to make a decision. But keep in mind the risks that come with negative growth prospects in the future.So while earnings quality is important, it's equally important to consider the risks facing Covenant Logistics Group at this point in time. Case in point: We've spotted 2 warning signs for Covenant Logistics Group you should be mindful of and 1 of these shouldn't be ignored.If you are no longer interested in Covenant Logistics Group, you can use our free platform to see our list of over 50 other stocks with a high growth potential.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

Why Covenant Logistics Group, Inc. (NASDAQ:CVLG) Could Be Worth Watching

https://finance.yahoo.com/news/why-covenant-logistics-group-inc-185642720.html

4c8848f9-e137-36c3-9adc-f4288c33065f

CVM

By John Vandermosten, CFANYSE:CVMREAD THE FULL CVM RESEARCH REPORTCEL-SCI Corporation (NYSE:CVM) provided several updates in recent weeks. This includes details from its pre-submission meeting with the FDA, a poster presentation related to Multikine performance in subjects with low PD-L1 expression and the announcement of a small capital raise. We update our model to reflect the need for additional studies to support either conditional for full approval in the United States, and modify our probability adjusted conditional or full approval in other geographies including Canada, the United Kingdom and Europe.Capital RaiseCEL-SCI announced that it intended to raise additional capital to support continued funding of Multikine development and general corporate purposes in a July 17th press release. Pricing was subsequently determined and 2.5 million shares were offered at $2.00 per share yielding gross proceeds of $5.0 million. ThinkEquity is acting as sole book-running manager for the offering. The deal was closed on July 20th.FDA MeetingCEL-SCI updated investors on its interactions with the FDA in a July 14th, 2023 press release. While the FDA suggested that the company submit a biologic license application (BLA) based on available data, it also requested additional information which will be provided in a subsequent meeting with the agency. Few details were provided regarding the next steps; however, we anticipate another study will be required before the company may successfully file a BLA with the FDA.Pursuing Conditional Approval from Health CanadaIn an April 19th press release CEL-SCI announced its intent to pursue a conditional approval pathway for Multikine in advanced primary head and neck cancer. Conditional pathways are justified by limiting eligibility to drugs intended for serious and life-threatening diseases or where there is unmet need. It is an appropriate pathway for an indication that is considered a rare disease that lacks effective treatment.Story continuesConditional approval is a regulatory mechanism used by Health Canada to provide approval for marketing in Canada and is based on a less rigorous submission than is required for a full approval. It is intended for serious conditions that have few if any other treatments available and allows patients earlier access. If Health Canada grants conditional approval it is usually for a limited period while additional studies are conducted to support the product’s safety and effectiveness.CEL-SCI reported that it held a productive pre-submission meeting with Health Canada. The conversation with the agency explored how patients at lower risk for recurrence could be targeted for treatment and which post-market commitments could help ensure that only the most suitable patients would be treated with Multikine.Poster Presentation for Boston Biostatistics Research Foundation, Inc.CEL-SCI’s statistical consultant, Philip Lavin, PhD, presented new data examining the survival advantage of Multikine in the IT-MATTERS study. The July 10th presentation was announced in a press release and held at the American Head and Neck Cancer Society’s (AHNS) 11th Annual International Conference on Head and Neck Cancer on July 10, 2023 in Montreal, Canada. The presentation, which was entitled “Tumor cell PD-L1 biomarker confirms Leukocyte Interleukin Injection (LI) treatment (Tx) survival outcome advantage in naïve locally advanced primary head & neck squamous cell carcinoma (SCCHN), the IT-MATTERS Study” highlighted the performance of Multikine in patients with low levels of PD-L1 expression.The data demonstrated a relationship between low PD-L1 expression and efficacy of Multikine. The proportion of responders in the low PD-L1 group was 91.7%; this compares with low PD-L1 expression in the non-responders group which was 73.8%. High PD-L1 expressers had a lower level of responders in the Multikine group (8.3%) compared with the non-responder group (17.7%).Conclusions from the presentation are that Multikine is more effective in patients with low levels of tumor cell PD-L1. This contrasts with the effectiveness of PD-L1 and PD-1 inhibitors that work well in patients with high levels of this marker. This is a positive for patients with tumors that have low levels of PD-L1 expression, offering them an alternative when PD-L1/PD-1 inhibitors have a low likelihood of working.Valuation We update our valuation based on CEL-SCI’s anticipated strategy for the United States and other geographies. In the United States, we model costs for an additional study and extend anticipated approval to 2028. We adjust our penetration estimate to be able to address a third of low risk SCCHN patients in the United State by the fifth year of commercialization. This is just over 5,000 treatments by 2032 and 2033. We anticipate that new competition will arise in 2034, and individuals treated will slowly decline in the following years. Based on the positive statements from CEL-SCI management, we anticipate an application for conditional approval in Canada. While timing was not provided, we expect that a submission could take place in the next twelve months, followed by approval in 2025 and first sales in 2026. Canada has about 1,800 cases of SCCHN per year that fall into the low risk category and we see penetration into this addressable market to rise to 30% in the fifth year of commercialization. In 2032 and beyond, we see competition reducing the market share of Multikine. The EU is one of the more attractive markets given its size. We believe that CEL-SCI is in contact with EMA regulators and is strategizing on a plan to make a submission. An additional study may or may not be required and we elect to take a more conservative route and forecast a submission in the next twelve months, followed by approval in 2025, then a period of pricing negotiations and eventually sales in 2026. Similar to other regions, penetration into the near 22,000 low risk SCCHN cases is expected to start at 3% and rise to 30% by year six then market share stabilization and declines in 2033 and 2034. The final geography that we include in our DCF model is the UK. According to Cancer Research UK, there are about 12,400 head and neck cancers. As we work down to the addressable market for Multikine, we have a population of about 3,000 that are appropriate for treatment. Similar to other regions, we anticipate a regulatory submission and approval with first sales in 2026. By year six, we see Multikine providing treatments to about 30% of the addressable market which is about 928 individuals in 2031.Pricing for immunotherapy, especially immuno-oncology products is strong. The United States has the most favorable pricing that is in the mid-$100,000 range. With anticipated inflation of 3% per annum, we expect revenues per treatment of $162 thousand in the US by the first year of sales in 2028. Other regions are forecasted with inflation rates at 2%. We continue to anticipate that an approved product will be commercialized by a partner and that upfronts, milestones and royalties will be paid to CEL-SCI or that an acquisition will take place recognizing a similar valuation approach. In our model, for simplicity, we incorporate all economic value received by CEL-SCI in our royalty. Royalty rates will range from 25% to 30% which in the early years reflect a proportion passed through to ERGOMED related to the co-development agreement.We estimate research and development costs running at about $20 million per year over the 2024 to 2026 period, when they fall to $15 million and $8 million as final regulatory submissions are made. By 2029, R&D will fall to zero as Multikine is commercialized. In all, R&D estimates include an additional $81 million in expense for future studies required to obtain full approval in Canada and to receive consideration in the United States. General and administrative costs are forecasted at $10 million per year then rising at a 3% rate in 2026 and beyond. Cash taxes are calculated at 29.7%.Our discounted cash flow (DCF) model uses a net present value (NPV) of future cash flows to determine our valuation. The discount rate used is 15%, terminal growth after year 20 is -10%. We also apply a probability of success factor based on historical precedent and CEL-SCI specific factors of 60%.The product of our forecasts and estimates produces a valuation of approximately $7.00 per share.SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.

Zacks Small Cap Research

CVM: Model Revisions

https://finance.yahoo.com/news/cvm-model-revisions-094900023.html

3192ea59-055e-3af8-bb64-3abde8656c44

CVM

VIENNA, Va., August 11, 2023--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2023, as well as key clinical and corporate developments.Clinical and Corporate Developments this quarter include:CEL-SCI had a productive pre-submission meeting with Canada’s regulator, Health Canada, to determine the best regulatory path toward market approval. Health Canada advised CEL-SCI to request advance consideration for approval under a Notice of Compliance with Conditions (NOCC) policy which facilitates earlier access for physicians and patients to promising new drugs for patients suffering from serious, life-threatening, or severely debilitating diseases. CEL-SCI is preparing an application for the NOCC approval as suggested and plans to file it by early next year. If Health Canada grants the NOCC, then it is possible that CEL-SCI could begin commercialization in 2024.Europe is a priority market for CEL-SCI, as Europe has more than twice the number of head and neck cancer cases diagnosed each year as compared to the United States (US). CEL-SCI is seeking conditional marketing authorization for Multikine in Europe. Based on the published guidelines, the Company believes it meets the requirements for conditional approval of Multikine and has plans for meetings with regulators in the fall.CEL-SCI had a collaborative and positive meeting with the U.S. Food and Drug Administration (FDA). The FDA acknowledged the great need for improved treatments for head and neck cancer, particularly the locally advanced oral cavity that CEL-SCI is targeting and is open to close collaboration with CEL-SCI to help demonstrate that Multikine could fill this need. Preliminary feedback from the FDA included that the selection criteria developed by CEL-SCI from its Phase 3 data could be used to determine which locally advanced oral cavity cancer patients might benefit from Multikine treatment. CEL-SCI is preparing additional information about its Multikine development plan for a follow-up meeting with the FDA based on this feedback. A confirmatory clinical trial will be conducted based on the agreed upon selection criteria for patients that will be treated with Multikine as assessed by methods including PET-CT/MRI screening. CEL-SCI will collaborate closely with the FDA on the design of a clinical protocol that will allow the Company to generate, as expeditiously as possible, the confirmatory data they will require for approval of Multikine in the US. Importantly, this study is also expected to have intermediate endpoints during study enrollment for potential accelerated approval based on interim results.Potentially quite impactful PD-L1 biomarker data from CEL-SCI’s Phase 3 study was presented at the American Head and Neck Cancer Society’s 11th Annual International Conference on Head and Neck Cancer titled "Tumor cell PD-L1 biomarker confirms Leukocyte Interleukin Injection (LI) treatment (Tx) survival outcome advantage in naïve locally advanced primary head & neck squamous cell carcinoma (SCCHN), the IT-MATTERS Study". The data demonstrated that the tumors of patients who responded best to Multikine in the Phase 3 study had low levels of the PD-L1 biomarker. Currently approved checkpoint inhibitors (Keytruda and Opdivo) which are indicated for treatment of unresectable or recurrent or metastatic head and neck cancer are known to work best in patients whose tumors express high PD-L1 levels and are less likely to work in patients whose tumors express low PD-L1. These contrasting PD-L1 data observed in patients responsive to Multikine vs those observed in patients treated with checkpoint inhibitors are very significant.Story continuesThe data are expected to be helpful in key ways:Supporting marketing approval by using PD-L1 as a marker to select patients who are most likely to benefit from MultikinePositioning Multikine as a combination therapy with checkpoint inhibitorsCombination studies may be conducted in partnership with a larger pharma company that has an approved PD-L1 checkpoint inhibitorShould combination studies with checkpoint inhibitors be successful not only would patients benefit substantially, but the financial benefits to CEL-SCI could be very largeThe global PD-L1/PD-1 therapeutics market was valued at $34.8 billion in 2022Data presented at the European Society for Radiotherapy and Oncology (ESTRO) 2023 Congress in May confirmed that Multikine significantly prolonged overall survival in head and neck cancer. The presentation titled "Histopathology population (HPP) confirms Multikine* [Leukocyte Interleukin Injection (LI)] treatment (Tx) outcome in naïve locally advanced primary head & neck squamous cell carcinoma SCCHN)" provided findings from a histopathology and tumor biomarker analysis of its Phase 3 study that confirmed Multikine-treated subjects had improved 5-year survival, showed improved progression free survival and improved local regional control, and a significantly lowered death rate compared to control subjects who received standard of care alone."The growing body of data on the efficacy of Multikine presented at peer-reviewed conferences is highly encouraging as we move forward with regulatory meetings and submissions with the world’s most respected regulators in the world in addition to FDA. The data has also allowed us to define very well the population of patients who have the greatest benefit from Multikine treatment. This is a crucial part of our approval strategy in this unmet medical need as we are aiming for conditional/accelerated approval pathways with multiple regulators," stated CEL-SCI CEO, Geert Kersten. "We are also excited about the new prospect of developing Multikine in conjunction with a pharma partner as a combination therapy with a checkpoint inhibitor to boost patient outcomes.Financial ResultsCEL-SCI reported a loss per share for the quarter ending June 30, 2023 of $0.19 versus a loss of $0.23 for the quarter of June 30, 2022.About CEL-SCI CorporationCEL-SCI believes that boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in the Phase 3 study, CEL-SCI studied patients who were newly diagnosed with locally advanced primary squamous cell carcinoma of the head and neck (oral cavity and soft-palate) with the investigational product Multikine first, BEFORE they received surgery and radiotherapy or surgery plus concurrent radiotherapy and chemotherapy (the current standard of care for these patients). We believe this approach is unique. Most other cancer immunotherapies are administered only after conventional therapies have been tried and/or failed.Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. The Phase 3 study enrolled 928 patients.Multikine (Leukocyte Interleukin, Injection) received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such statements include, but are not limited to, statements about the terms, expected proceeds, use of proceeds and closing of the offering. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2022. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.CEL-SCI CORPORATIONCONDENSED STATEMENTS OF OPERATIONSNINE MONTHS ENDED JUNE 30, 2023 AND 2022(UNAUDITED)20232022Operating expenses:Research and development$17,203,823$18,893,857General and administrative6,804,7298,220,768Total operating expenses24,008,55227,114,625Operating loss(24,008,552)(27,114,625)Gain on derivative instruments-366,791Other non-operating losses-(30,793)Interest expense, net(493,522)(1,460,055)Other expense(61,525)-Net loss(24,563,599)(27,603,969)Modification of warrants(171,552)(294,409)Net loss available to common shareholders$(24,735,151)$(28,533,091)Net loss per common share – basic and diluted$(0.57)$(0.66)Weighted average common shares outstanding – basic and diluted43,761,39543,124,972CEL-SCI CORPORATIONCONDENSED STATEMENTS OF OPERATIONSTHREE MONTHS ENDED JUNE 30, 2023 AND 2022(UNAUDITED)20232022Operating expenses:Research and development$5,727,789$6,286,873General and administrative2,453,9682,432,518Total operating expenses8,181,7578,719,391Operating loss(8,181,757)(8,719,391)Interest expense, net(181,670)(913,193)Other expense(3,854)-Net loss(8,367,281)(8,997,871)Modification of Warrants-(294,409)Net loss available to common shareholders$(8,367,281)$(9,926,993)Net loss per common share – basic and diluted$(0.19)$(0.23)Weighted average common shares outstanding – basic and diluted44,254,36343,174,775View source version on businesswire.com: https://www.businesswire.com/news/home/20230811835404/en/ContactsGavin de WindtCEL-SCI Corporation(703) 506-9460

Business Wire

CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results

https://finance.yahoo.com/news/cel-sci-corporation-reports-third-120000172.html

50fe7204-cda0-3a4d-b68b-bab9ec0da997

CVNA

To say that Carvana (NYSE: CVNA) has hit a bit of a rough patch would be an understatement. This article will look at where Carvana's stock might be three years from now assuming the company doesn't run into any other financial troubles and once again starts achieving the growth it had before the pandemic. More than a decade ago when Carvana was founded, management saw that nearly every product category was starting to transition to online buying.Continue reading

Motley Fool

Where Will Carvana Stock Be in 3 Years?

https://finance.yahoo.com/m/e4fd27f5-260d-3490-b29b-c8ae8792a05e/where-will-carvana-stock-be.html

e4fd27f5-260d-3490-b29b-c8ae8792a05e

CVNA

After a gut-wrenching 98% drop in 2022, shares of Carvana (NYSE: CVNA) have bounced back tremendously this year, up over 900%. Boosting Carvana's stock was management's ability to restructure debt by extending maturities and substantially reducing interest payments this year and next.Continue reading

Motley Fool

A Bull Market Could Be Here: 2 Reasons to Buy Carvana Stock

https://finance.yahoo.com/m/6f3c3513-71bf-3dca-8854-de99820514a0/a-bull-market-could-be-here-.html

6f3c3513-71bf-3dca-8854-de99820514a0

CVS

CVS Health (CVS) closed the most recent trading day at $65.60, moving +0.14% from the previous trading session. This change outpaced the S&P 500's 0.32% loss on the day. At the same time, the Dow added 0.17%, and the tech-heavy Nasdaq lost 0.89%.Prior to today's trading, shares of the drugstore chain and pharmacy benefits manager had lost 12.19% over the past month. This has lagged the Retail-Wholesale sector's loss of 1.56% and the S&P 500's loss of 0.12% in that time.Wall Street will be looking for positivity from CVS Health as it approaches its next earnings report date. The company is expected to report EPS of $2.13, up 1.91% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $87.97 billion, up 8.39% from the prior-year quarter.For the full year, our Zacks Consensus Estimates are projecting earnings of $8.61 per share and revenue of $351.8 billion, which would represent changes of -0.92% and +9.1%, respectively, from the prior year.Any recent changes to analyst estimates for CVS Health should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.05% lower. CVS Health is holding a Zacks Rank of #3 (Hold) right now.Investors should also note CVS Health's current valuation metrics, including its Forward P/E ratio of 7.61. This valuation marks a premium compared to its industry's average Forward P/E of 6.42.Story continuesIt is also worth noting that CVS currently has a PEG ratio of 1.24. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Retail - Pharmacies and Drug Stores stocks are, on average, holding a PEG ratio of 1.21 based on yesterday's closing prices.The Retail - Pharmacies and Drug Stores industry is part of the Retail-Wholesale sector. This industry currently has a Zacks Industry Rank of 108, which puts it in the top 43% of all 250+ industries.The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportCVS Health Corporation (CVS) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Zacks

CVS Health (CVS) Gains As Market Dips: What You Should Know

https://finance.yahoo.com/news/cvs-health-cvs-gains-market-214518807.html

0e334b79-d080-3350-a216-1cfda16df9a4

CVS

Looking at CVS Health Corporation's (NYSE:CVS ) insider transactions over the last year, we can see that insiders were net sellers. That is, there were more number of shares sold by insiders than there were purchased.Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing. See our latest analysis for CVS Health The Last 12 Months Of Insider Transactions At CVS HealthThe Senior VP, James Clark, made the biggest insider sale in the last 12 months. That single transaction was for US$1.9m worth of shares at a price of US$74.94 each. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$65.84. So it is hard to draw any strong conclusion from it. James Clark was the only individual insider to sell shares in the last twelve months.You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!insider-trading-volumeFor those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.Insiders At CVS Health Have Sold Stock RecentlyOver the last three months, we've seen significant insider selling at CVS Health. Specifically, Senior VP James Clark ditched US$1.9m worth of shares in that time, and we didn't record any purchases whatsoever. This may suggest that some insiders think that the shares are not cheap.Does CVS Health Boast High Insider Ownership?I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. CVS Health insiders own 0.2% of the company, currently worth about US$207m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.Story continuesWhat Might The Insider Transactions At CVS Health Tell Us?An insider sold CVS Health shares recently, but they didn't buy any. Despite some insider buying, the longer term picture doesn't make us feel much more positive. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Case in point: We've spotted 5 warning signs for CVS Health you should be aware of.Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Simply Wall St.

This CVS Health Insider Reduced Their Stake By 85%

https://finance.yahoo.com/news/cvs-health-insider-reduced-stake-120042281.html

2d4da687-cda6-3802-92e3-b3284e22f677

CVX

Sept 11 (Reuters) - Chevron said on Monday it would ask Australia's industrial relations tribunal to intervene to halt strike action at its Gorgon and Wheatstone liquefied natural gas (LNG) plants.If an "intractable bargaining" declaration is approved by Australia's Fair Work Commission (FWC), the U.S. energy behemoth's unionised workers at the plants would be prohibited from legally taking any form of industrial action.Instead, the workers would need to wait for the FWC to impose a new agreement over the facilities that account for more than 5% of global LNG supply."Unfortunately, following numerous meetings and conciliation sessions with the Fair Work Commission, no agreement has been reached as the unions are asking for terms significantly above the market," a Chevron Australia spokesperson said.Workers at Chevron's Gorgon and Wheatstone LNG projects began hours-long work stoppages on Friday, with the industrial unrest leading to a spike in European gas prices.The LNG workers and Chevron are at loggerheads over issues including pay, job security, rosters, and rules around overtime and transfers between the company's facilities.The workers plan a total strike for two weeks from Sept. 14, a union alliance said last week, when Chevron had sought an enforced arbitration with labour unions.Chevron has already applied for FWC intervention at its Wheatstone platform facility, which has its first hearing scheduled for Tuesday. Chevron said it would ask the FWC to hear applications for the Gorgon and Wheatstone downstream facilities at the same hearing.Offshore Alliance, a coalition of two unions representing the Chevron workers, did not immediately respond to a request for comment.(Reporting by Roushni Nair in Bengaluru; Editing by Jamie Freed)

Reuters

Chevron appeals to workplace tribunal to halt Australia LNG strike action

https://finance.yahoo.com/news/chevron-appeals-workplace-tribunal-halt-235854434.html

92d59692-5bda-3a0e-bb49-8a6be8f8e828

CVX

(Adds details of Virgin Australia's use of these laws in paragraph 9)By Lewis Jackson and Roushni NairSept 11 (Reuters) - Chevron Australia no longer expects to reach a deal with unions and will instead pursue an untested legal strategy to stop industrial action at its Gorgon and Wheatstone liquefied natural gas days before it escalates into full strikes.Hundreds of workers at the facilities, which account for over 5% of global supply, started short strikes on Friday after five days of last-minute negotiations broke down without a deal. Unions have said they will escalate to two weeks of 24-hour strikes from Thursday.Chevron said on Monday it sees "no reasonable prospect of agreement" and will apply to Australia's industrial umpire, the Fair Work Commission, for an "intractable bargaining" declaration, which, if granted, would end strikes and allow the umpire to dictate an agreement.“Unfortunately, following numerous meetings and conciliation sessions with the Fair Work Commission, no agreement has been reached as the unions are asking for terms significantly above the market," a Chevron spokesperson said in a statement.The case will be a landmark test of the new laws, first introduced in June, which empower the umpire to force parties into an agreement they themselves are unable to make.However, with unions set to start full blown strikes on Thursday, it is unlikely the umpire will have time to hear arguments and decide beforehand. A first hearing scheduled for Tuesday at 3 p.m. (0500 GMT) in Melbourne will only handle administrative questions."Until we have some case law, until we get some Fair Work Commission decisions on how the laws work, we don't know (how long the process will take)," said Shae McCrystal, a professor of labour law at the University of Sydney Law School."There's no precedent for this particular section."A subsidiary of airline Virgin Australia made the only other application under these laws in June, local media reported. It took roughly three weeks to organise the first substantive hearings, but the parties reached an agreement the day they were due to start.Story continuesNo talks are scheduled between unions and Chevron, according to the FWC website.Offshore Alliance, a coalition of two unions, said on Saturday it was "bunkering down for a long dispute" and the U.S. oil and gas giant should prepare for "losing $billions of export revenue."An Offshore Alliance spokesperson did not immediately respond to a request for comment on Monday.(Reporting by Roushni Nair in Bengaluru and Lewis Jackson in Sydney; Editing by Jamie Freed and Michael Perry)

Reuters

UPDATE 2-Chevron gambles on untested laws to halt Australia LNG strike action

https://finance.yahoo.com/news/1-chevron-gambles-untested-laws-014808765.html

ac546863-fc71-3a68-9858-c4e6981db550